{"pages":[{"Nodular":{"CurationStatus":"uncurated","SuperCategory":"Structure","Id":"PATO_0002125","Definition":"A quality inhering in a bearer by virtue of the bearers's consisting a knot-like mass"}},{"Nodulus":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1165","Is part of":"Flocculonodular lobe"}},{"Nodulus (X) of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Nodulus (X)","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153003","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Vermal regions of ABA 2009","Organism":"mouse","Species":"Mouse"}},{"Noise Sensitivity":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001055","DefiningCitation":"ModelDB:122331","Definition":"Measure of the relative changes in a variable of interest as a function of noise."}},{"Nominal Beam Energy":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0114","SuperCategory":"DICOM term","Id":"nlx_150330","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Nominal Beam Energy at control point (MV/MeV)."}},{"Nominal Beam Energy Unit":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0015","SuperCategory":"DICOM term","Id":"nlx_150331","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Units used for Nominal Beam Energy (300A,0114). Required if Nominal Beam Energy (300A,0114) is sent. If Radiation Type (300A,00C6) isPHOTON, Nominal Beam Energy Unit (300A,0015) shall be MV."}},{"Nominal Interval":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1062","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150332","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Average R-R interval used for the scans in msec."}},{"Nominal Prior Dose":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_001A","SuperCategory":"DICOM term","Id":"nlx_150333","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Dose (in Gy) from prior treatment to this Dose Reference (e.g. from a previous course of treatment)."}},{"Nominal Scanned Pixel Spacing":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_2010","SuperCategory":"DICOM term","Id":"nlx_150334","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Physical distance on the media being digitized or scanned between the center of each pixel, specified by a numeric pair--adjacent row spacing (delimiter) adjacent column spacing in mm. Required if Conversion Type (0008,0064) is DF (Digitized Film). "}},{"Non-ABeta component":{"SuperCategory":"Alpha-Synuclein Protein","Id":"sao6503965574","Definition":"An alpha-Synuclein fragment found in amyloid plaques in Alzheimer's disease."}},{"Non-choice task to study expected value and uncertainty":{"Created":"2/11/2011 12:18","CurationStatus":"uncurated","Contributor":"Tom Schonberg","CAO_Id":"CAO_00895","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Non-choice_task_to_study_expected_value_and_uncertainty","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146119","Definition":"Each of 12 stimuli (circles of different colors, numbers and sizes) is associated with a different reward magnitude and probability. These include all combinations of (100 and 200) point rewards with (0, 0.25, 0.5, 0.75 and 1) probabilities, plus 300 and 400 rewards with 0.5 probability. Participants are first trained to learn the probabilities and outcomes associated with each stimulus. Next, on each trial, a stimulus appears in one of four quadrants of the screen, and participants indicate which quadrant using a button press"}},{"Non-commercial":{"Synonym":"Non commercial","CurationStatus":"uncurated","SuperCategory":"Unspecified license","Id":"nlx_152780","Definition":"Commercial usage is prohibited without specified permission, generally requiring written documentation."}},{"Non-contractile":{"SuperCategory":"Contractility","Id":"PATO_0001691","Definition":"A contractility quality inhering in a bearer by virtue of its inability of contracting or being contracted."}},{"Non-deciduous (any body part)":{"SuperCategory":"Disposition to shed","Id":"PATO_0001732","Definition":"Lacking disposition to shed any body part."}},{"Non-DICOM Output Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_4032","SuperCategory":"DICOM term","Id":"nlx_150335","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A Sequence that describes any non-DICOM output produced as results. Zero or more Items may be included in this sequence."}},{"Non-Familial Benign Neonatal Epilepsy":{"Synonym":"Non-Familial Benign Neonatal Convulsions","Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Benign Neonatal Epilepsy","Id":"birnlex_12736"}},{"Non-functional":{"Synonym":["functional failure"],"SuperCategory":"Disfunctional","Id":"PATO_0001511","Definition":"Disfunctional quality which is an inability to perform regular function(s)."}},{"Non-gated channel":{"RelatedTo":"Gating","Synonym":["Resting channel"],"CurationStatus":"uncurated","SuperCategory":"Ion Channel","Id":"oen_0001148","Has role":"Electrophysiology concept","Definition":"An ion channel that passively conducts ions across the cell membrane."}},{"Non-glutinous":{"SuperCategory":"Amylose composition","Id":"PATO_0001541","Definition":"Having a high amount of amylose content."}},{"Non-human primate":{"Created":"2007-08-20","Synonym":["Nonhuman primate"],"CurationStatus":"uncurated","Umlscui":"C0237798","SuperCategory":"Primate","Id":"birnlex_603","Definition":"A primate other than human"}},{"Non-human vertebrate":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","SuperCategory":"Vertebrata","Id":"birnlex_593"}},{"Non-ictal":{"SuperCategory":"Physiological state","Id":"PATO_0001914","Definition":"A physiological state which is characterized by normal electrical activity in neuronal tissue."}},{"Non-imaging hardware attribute":{"SuperCategory":"Attribute entity role","Id":"nlx_151701","Definition":"parameters related to hardware other than imaging devices, e.g., printers"}},{"Non-magnetic":{"SuperCategory":"Magnetism","Id":"PATO_0001686","Definition":"A magnetic quality inhering in a bearer by virtue of its inability to exert magnitism."}},{"Non-membrane bound organelle":{"Comment":"This class should be retired and all its children put under \"organelle\"","SuperCategory":"Organelle","Id":"sao1456184038","Definition":"Organized structure of distinctive morphology and function, not bounded by a lipid bilayer membrane. Includes ribosomes, the cytoskeleton and chromosomes (Gene Ontology)."}},{"Non-painful electrical stimulation":{"Created":"4/27/2011 14:11","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00759","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Non-painful_electrical_stimulation","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145981","Definition":"Subjects are electrically stimulated at a non-painful threshold."}},{"Non-painful thermal stimulation":{"Created":"4/27/2011 14:11","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00760","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Non-painful_thermal_stimulation","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145982","Definition":"Subjects experience thermal stimulation (heat) at a non-painful threshold."}},{"Non-progressive":{"SuperCategory":"Occurrence quality","Id":"PATO_0002026","Definition":"Not increasing over time."}},{"Non-realizable information entity":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Generically dependent continuant","Id":"birnlex_11000"}},{"Non-selective current":{"Created":"2007-10-10","SuperCategory":"Transmembrane ionic current","Id":"nifext_8059"}},{"Nonactivated":{"SuperCategory":"Functional Quality for Microglia","Id":"sao6363641087","Definition":"A microglia that is not activated."}},{"Nondeclarative memory":{"Created":"7/10/2009 14:06","CurationStatus":"uncurated","Contributor":"Agatha Lenartowicz","CAO_Id":"CAO_00419","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Nondeclarative_memory","SuperCategory":"Memory","Id":"nlx_145632","Has role":"Cognitive Atlas Concept","Definition":"Memory acquired through experience and which can not be consciously articulated (such as by recall or recognition). This type of memory includes priming, conditioning, skill-acquisition, and habits."}},{"Nonporous":{"SuperCategory":"Porosity","Id":"PATO_0000985"}},{"Nonprofit Organization":{"CurationStatus":"uncurated","SuperCategory":"Organization","Id":"nlx_152354"}},{"Nonrecursive digital filter":{"Synonym":"Nonrecursive filter","CurationStatus":"uncurated","SuperCategory":"Filter","Id":"oen_0001241","Definition":"Filtering output depends only on the input data. (adapted from the Axon Guide)"}},{"Nonsynaptic conduction":{"CurationStatus":"uncurated","SuperCategory":"Nerve conduction","Id":"oen_0001127","Has role":"Electrophysiology concept","Definition":"current flow through an area of postsynaptic membrane that surrounds a region containing synaptically activated ion channels."}},{"Nonword repetition task":{"Created":"4/15/2011 11:14","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00941","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Nonword_repetition_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146166","Definition":"No definition submitted yet."}},{"NOP receptor":{"Synonym":"NOP","Created":"2007-09-19","SuperCategory":"Opioid receptor","Id":"nifext_6407"}},{"Noradrenergic Receptor":{"Synonym":["NA receptor","NE receptor"],"CurationStatus":"uncurated","SuperCategory":"Neurotransmitter Receptor","Id":"nlx_mol_1006002","Is part of":"Noradrenergic system","Definition":"any receptor or receptor channel that preferentially binds norepinephrine."}},{"Noradrenergic system":{"CurationStatus":"uncurated","SuperCategory":"Catecholamine system","Id":"nlx_anat_1005027","Definition":"any molecule, protein, cell, tissue or organ that is related to norepinephrine (also known as noradrenaline)."}},{"Norepinephrine":{"RelatedTo":["Beta-1 adrenergic receptor","Alpha-2A adrenergic receptor","Alpha-2C adrenergic receptor","Sodium-dependent noradrenaline transporter","Alpha-1A adrenergic receptor","Alpha-2B adrenergic receptor","Alpha-1B adrenergic receptor","Beta-2 adrenergic receptor","Alpha-1D adrenergic receptor","Phenylalanine-4-hydroxylase"],"Synonym":["Arterenol","L-Norepinephrine","L-noradrenaline","Noradrenaline","Norepinephrine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00368","Has role":["Drug","Neurotransmitter"],"Is part of":["Catecholamine system","Adrenergic system"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00368","Abbrev":"NE","Definition":"Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic. (PubChem) Pharmacology: Noradrenaline acts on both alpha-1 and alpha-2 adrenergic receptors to cause vasoconstriction. Its effect in-vitro is often limited to the increasing of blood pressure through antagonising alpha-1 and alpha-2 receptors and causing a resultant increase in systemic vascular resistance. Mechanism of action: Norepinephrine functions as a peripheral vasoconstrictor (alpha-adrenergic action) and as an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). Drug type: Approved. Small Molecule. Drug category: Adrenergic alpha-Agonists. Sympathomimetics. Vasoconstrictor Agents"}},{"Norethindrone":{"RelatedTo":["Progesterone receptor"],"Synonym":[", Anhydrohydroxynorprogesterone","Anovulatorio","Anovule","Aygestin","Binovum","Brevicon","Brevinor","Brevinor 21","Brevinor 28","Brevinor-1 21","Brevinor-1 28","Camila","Ciclovulan","Conceplan","Conludaf","Conludag","Demulen","ENT","Errin","Estrinor","Ethinylnortestosterone","Ethynylmortestosterone","Ethynylnortestosterone","Gencept","Genora","Gestest","Jenest","Jenest-28","Loestrin","Menzol","Microneth","Micronett","Micronor","Micronovum","Milli","Mini-Pe","Mini-Pill","Minovlar","Modicon","N,E,E,","NET","Necon","Nelova","Neocon","Nodiol","Nor-Q,D,","Nor-Qd","Noraethisteronum","Noralutin","Norcept","Norcept-E","Norcolut","Noresthisterone","Norethadrone","Norethin","Norethin 1/35 E","Norethin 1/50 M","Norethindrone Acetate","Norethindrone Norethisterone","Norethisteron","Norethisterone","Norethisterone (Progestins)","Norethisteronum (INN-Latin)","Norethyndron","Norethynodron","Norethynodrone","Noretisterona (INN-Spanish)","Noretisterone (Dcit)","Norfor","Norgestin","Noriday","Noriday 28","Norimin","Norinyl","Norlestrin","Norlutate","Norluten","Norlutin","Norluton","Normapause","Norpregneninlone","Norpregneninolone","Norpregneninotone","Orlest","Ortho 1 35","Ortho 7 7 7","Ortho-Novum","Ortho-Novum 1 35","Ortho-Novum 1 50","Ortho-Novum 7 7 7","Ovcon","Ovysmen","Ovysmen 0,5 35","Ovysmen 1 35","Palonyl","Perovex","Primolut N","Primolut-N","Proluteasi","Synphase","Synphasic 28","Tri-Norinyl","Triella","Trinovum","Trinovum 21","Utovlan"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7627","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00717","Definition":"A synthetic progestational hormone with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception. (PubChem) Pharmacology: Norethindrone is a synthetic oral progestin. It is used for contraception or to treat such conditions as secondary amenorrhea, abnormal uterine bleeding, and endometriosis. As an oral contraceptive, norethindrone is available as either a single agent or in combination with an estrogen. Mechanism of action: Progestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge. Drug type: Approved. Small Molecule. Drug category: Contraceptives, Oral, Synthetic. Progestins"}},{"Norfloxacin":{"RelatedTo":["DNA gyrase subunit A","DNA topoisomerase 4 subunit A"],"Synonym":[", Chibroxin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01059","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01059","Definition":"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. (PubChem) Pharmacology: Norfloxacin is a quinolone/fluoroquinolone antibiotic. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Mechanism of action: The bactericidal action of Norfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Norfloxacin is a broad-spectrum antibiotic that is active against both gram-positive and gram-negative bacterias. The fluorine atom at the 6 position increases potency against gram-negative organisms, and the piperazine moiety at the 7 position is responsible for anti-pseudomonal activity Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Anti-Infectives. Enzyme Inhibitors. Nucleic Acid Synthesis Inhibitors. Quinolones"}},{"Norgestimate":{"RelatedTo":["Estrogen receptor","Progesterone receptor"],"Synonym":["Dexnorgestrel Acetime","Norgestimato (INN-Spanish)","Norgestimatum (INN-Latin)","Ortho Cyclen-21","Ortho Cyclen-28","Ortho Tri-Cyclen"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:50815","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00957","Definition":"Norgestimate is a form of progesterone, which is a female hormone important for the regulation of ovulation and menstruation. Norgestimate is used with estradiol to treat the symptoms of menopause. Pharmacology: Norgestimate is used as a female contraceptive. Norgestimate is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Norgestimate tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries. Mechanism of action: Norgestimate binds to androgen and progestogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Norgestimate will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Drug type: Approved. Small Molecule. Drug category: Contraceptives. Contraceptives, Oral, Synthetic"}},{"Norgestrel":{"RelatedTo":["Estrogen receptor","Alpha-1A adrenergic receptor"],"Synonym":[", Alesse","Alpha-Norgestrel","Component of Lo/Ovral","Component of Ovral","DL-Norgestrel","LD Norgestrel","Ld Norgestrel (French)","Lo/Ovral","Logynon","Methylnorethindrone","Microgynon","Microlut","Monovar","NOG","Neogest","Norgeston","Norgestrel (Progestins)","Norgestrel (Usan:Ban:Inn:Jan)","Norgestrelum (INN-Latin)","Ovral","Ovran","Postinor","Stediril","Tetragynon"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7630","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00506","Definition":"A synthetic progestational hormone with actions similar to those of progesterone and about twice as potent as its racemic or (+-)-isomer (norgestrel). It is used for contraception, control of menstrual disorders, and treatment of endometriosis. (PubChem) Pharmacology: Norgestrel is used as a female contraceptive. Norgestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Norgestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries. Mechanism of action: Norgestrel binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Norgestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Drug type: Approved. Small Molecule. Drug category: Contraceptive Agents, Female. Contraceptives. Contraceptives, Oral, Synthetic"}},{"Normal":{"Synonym":["average","healthy","control","typically developing","normal control"],"CurationStatus":"uncurated","SuperCategory":"Deviation(from normal)","Id":"PATO_0000461"}},{"Normalization Point":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3004_0008","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150336","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The Normalization Point (3004,0008) aids in the interpretation and subsequent use of the transmitted data. If used, it shall be a point receiving dose contributions from all referenced components of the dose summation. "}},{"North American Adult Reading Test":{"Created":"2008-03-14","CurationStatus":"uncurated","Umlscui":"C0451328","SuperCategory":"Assessment","Id":"birnlex_3034","Has role":"Neuropsychological assessment","DefiningCitation":["Nelson","H.E. (1982). National Adult Reading Test (NART): Test Manual","Windsor","U.K.: NFER nelson.","Nelson","H.E. & O'Connell","A. (1978). Denentia: The estimation of pre-morbid intelligence levels using the new adult reading test. Cortex","14"],"Abbrev":"NAART","Definition":"The North American Adult Reading Test (NAART) is an assessment of verbal intellectual ability. The NAART is a reliable and valid measure of verbal intelligence, comparable in psychometric properties to the WAIS-R Vocabulary test and with equal psychometric properties in young, middle-aged and older adults. Each incorrectly pronounced word is counted as one error, score range is from 0 to 60, with 0 indicating no pronunciation errors and 60 indicating pronunciation errors on all items."}},{"North American Biobank":{"CurationStatus":"uncurated","SuperCategory":"Biobank","Id":"nlx_143625","Abbrev":"North American Biobank","Definition":"A cryogenic storage facility located in North America used to archive biological samples for use in research and experiments or transplantation. Ranging in size from individual refrigerators to warehouses, North American biobanks are maintained by institutions such as hospitals, universities, nonprofit organizations, and pharmaceutical companies. (Adapted from Wikipedia)"}},{"North East Cyberinfrastructure Consortium":{"CurationStatus":"uncurated","SuperCategory":"University consortium","Id":"nlx_144352","Is part of":["University of Delaware; Delaware; USA","University of Vermont; Vermont; USA","University of Rhode Island; Rhode Island; USA","Brown University; Rhode Island; USA"],"DefiningCitation":"http://www.necyberconsortium.org/","Abbrev":"NECC","Definition":"A consortium of five states that are collaborating on building cyberinfrastructure in the NE region. The consortium is not formally affiliated with NSF EPSCoR or the NIH IDeA. "}},{"Northern Antibiotics":{"Synonym":["Northern Antibiotics Oy Ltd","Northern Antibiotics Ltd"],"CurationStatus":"curated","SuperCategory":"Commercial Organization","Id":"nlx_158545","Species":"Gram-negative bacteria","DefiningCitation":"http://www.northernantibiotics.com/","Definition":"Commercial organization headquartered in Helsinki, Finland, that engages in the discovery and development of antibiotics against multidrug-resistant gram-negative bacteria. It develops compounds, which are active against difficult-to-treat gram-negative bacteria, such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. (Adapted from Bloomberg Businessweek)"}},{"Northern clearwater crayfish":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1218308","SuperCategory":"Crockerinus","Id":"birnlex_359"}},{"Nortriptyline":{"RelatedTo":["Sodium-dependent noradrenaline transporter","Serum albumin"],"Synonym":[", AVENTYL HCL","Acetexa","Allegron","Altilev","Amitryptyline","Demethyl-","Ateben","Avantyl","Demethylamitriptylene","Demethylamitriptyline","Demethylamitryptyline","Desitriptilina","Desmethylamitriptyline","Lumbeck","Noramitriptyline","Noritren","Nortrilen","Nortriptyline Hcl","Nortryptiline","Norzepine","PAMELOR","Psychostyl","Sensaval","Sensival Ventyl","Sesaval"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7640","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00540","Definition":"A metabolite of amitriptyline that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions. (PubChem) Pharmacology: Similar to protriptyline, nortriptyline is a tricyclic antidepressant of the dibenzocycloheptene type and is the active metabolite of amitriptyline. Mechanism of action: It is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake. Drug type: Approved. Small Molecule. Drug category: Adrenergic Uptake Inhibitors. Antidepressants. Antidepressive Agents, Tricyclic. Norepinephrine-Reuptake Inhibitors"}},{"Notaspidea":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1028579","SuperCategory":"Opisthobranchia","Id":"birnlex_7259"}},{"Notch filter":{"CurationStatus":"uncurated","SuperCategory":"Filter","Id":"oen_0001239","Definition":"Filtering of signal within a small range, usually 60Hz.  Power lines emit 60Hz signals that interfere with signal measurement in this range."}},{"Notch Filter Bandwidth":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0223","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150337","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Nominal 3dB bandwidth of notch filter(s) in Hz."}},{"Notch Filter Frequency":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0222","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150338","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Center frequency of notch filter(s) in Hz."}},{"Notched":{"SuperCategory":"Concave","Id":"PATO_0001495","Definition":"Concave shape which is a V-shaped cut."}},{"Note":{"Synonym":"Notes","CurationStatus":"uncurated","SuperCategory":"Data or information resource","Id":"nlx_res_20090432","Definition":"A resource that provides notes that relate to neuroscience, such as from an introductory neurobiology course."}},{"Novartis":{"RelatedTo":["Resource:EFPIA"],"EditorialNote":"The website is down 11/24/14.","Synonym":["Novartis International AG","Novatris Pharma AG"],"CurationStatus":"curated","Address":["Basel","Basel-Stadt"],"SuperCategory":"Commercial Organization","Id":"nlx_158174","Keywords":["Drug","Pharmaceutical","Generic drug","Over-the-counter drug","Vaccine","Diagnostic","Contact lens"],"DefiningCitation":"http://www.novartis.com/","Abbrev":"Novartis","Definition":"A Swiss multinational pharmaceutical company dedicated to the research and development of new drugs. The businesses of Novartis are divided into six operating divisions: Pharmaceuticals, Alcon (eye care), Vaccines and Diagnostics, Sandoz (generics), Consumer (divided into two divisions: Over-the-Counter and Animal Health), and Corporate. (Adapted from Wikipedia)"}},{"Novelty suppressed feeding test.":{"CurationStatus":"uncurated","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_152192","Species":"Rodent"}},{"Novo Nordisk":{"tweets.background":"#F6F6F6","Synonym":"Novo Nordisk A/S ","count":"5","Related disease":["Diabetes"],"CurationStatus":"curated","tweets.links":"#013C41","tweets.color":"#605C4F","RelatedTo":"Resource:EFPIA","shell.background":"#013C41","Address":["Headquarters: Novo Nordisk A/S","Novo All√©","2880 Bagsvaerd"],"SuperCategory":"Commercial Organization","Id":"nlx_158501","Species":"Human","user":"{{#show: {{FULLPAGENAME ","DefiningCitation":"http://www.novonordisk.com/","Keywords":["Growth hormone therapy","Hormone replacement therapy","Pharmaceutical","Health care","Medicine","Device"],"Definition":"A Danish multinational pharmaceutical company that manufactures and markets pharmaceutical products and services. Key products include diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza. (Adapted from Wikipedia)"}},{"Novobiocin":{"RelatedTo":"DNA gyrase subunit B","Synonym":["Antibiotic Pa-93","Crystallinic Acid","NOV","Novobiocina (INN-Spanish)","Novobiocine (INN-French)","Novobiocinum (INN-Latin)","Albamix","Albamycin","Cardelmycin","Cathocin","Cathomycin","Inamycin","Novo-R","Robiocina","Sirbiocina","Spheromycin","Stilbiocina"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:28368","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01051","Definition":"An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity.  (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) (PubChem) Pharmacology: Novobiocin is an aminocoumarin antibiotic that was produced by the actinomycete Streptomyces niveus. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. Other antibiotics in the aminocoumarin class include coumermycin A1 and clorobiocin. Mechanism of action: Novobiocin is an aminocoumarin. Aminocoumarins are very potent inhibitors of bacterial DNA gyrase and work by targeting the GyrB subunit of the enzyme involved in energy tranduction. Novobiocin as well as the other aminocoumarin antibiotics act as competitive inhibitors of the ATPase reaction catalysed by GyrB. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Enzyme Inhibitors. Nucleic Acid Synthesis Inhibitors"}},{"NPBW1 receptor":{"Synonym":"NPBW1","Created":"2007-09-19","SuperCategory":"Neuropeptide W/neuropeptide B receptor","Id":"nifext_5634"}},{"NPBW2 receptor":{"Synonym":"NPBW2","Created":"2007-09-19","SuperCategory":"Neuropeptide W/neuropeptide B receptor","Id":"nifext_5297"}},{"NPFF1 receptor":{"Synonym":"NPFF1","Created":"2007-09-19","SuperCategory":"Neuropeptide FF/neuropeptide AF receptor","Id":"nifext_5777"}},{"NPFF2 receptor":{"Synonym":"NPFF2","Created":"2007-09-19","SuperCategory":"Neuropeptide FF/neuropeptide AF receptor","Id":"nifext_5856"}},{"NPS receptor":{"Created":"2007-09-19","Synonym":"NPS; G-protein coupled receptor 154; G-protein coupled receptor PGR14; G-protein coupled receptor for asthma susceptibility","CurationStatus":"uncurated","SuperCategory":"Neuropeptide S receptor","Id":"nifext_5576"}},{"NT-3":{"Synonym":"Neurotrophin-3","CurationStatus":"uncurated","SuperCategory":"Neurotrophin","Id":"nlx_443","Definition":"Neurotrophin-3, or NT-3, is a neurotrophic factor, in the NGF-family of neurotrophins. It is a protein growth factor which has activity on certain neurons of the peripheral and central nervous system; it helps to support the survival and differentiation of existing neurons, and encourages the growth and differentiation of new neurons and synapses. NT-3 was the third neurotrophic factor to be characterized, after NGF and BDNF.Although the vast majority of neurons in the mammalian brain are formed prenatally, parts of the adult brain retain the ability to grow new neurons from neural stem cells; a process known as neurogenesis. Neurotrophins are chemicals that help to stimulate and control neurogenesis. NT-3 is unique in the number of neurons it can potentially stimulate, given its ability to activate two of the receptor tyrosine kinase neurotrophin receptors (TrkC and TrkB - see below). Mice born without the ability to make NT-3 have loss of proprioceptive and subsets of mechanoreceptive sensory neurons."}},{"NT-proBNP":{"RelatedTo":["preproBNP","proBNP"],"Synonym":"N-terminal pro-B-type natriuretic peptide","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"414798009","Is part of":"NPPB","DefinitionPMID":"18243856","Definition":"Biologically inert 76-amino acid amino-terminal portion of proBNP"}},{"NTP Source Address":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1803","SuperCategory":"DICOM term","Id":"nlx_150339","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"IP Address of NTP time source. IPv4 addresses shall be in dotted decimal (e.g. 192.168.1.1). The IPv6 addresses shall be in colon separated hexadecimal (e.g. 12:34:56:78:9a:bc:de:f0). "}},{"NTS1 receptor":{"Synonym":"NTS1","Created":"2007-09-19","SuperCategory":"Neurotensin receptor","Id":"nifext_7003"}},{"NTS2 receptor":{"Created":"2007-09-19","Synonym":"NTS2; Levocabastine-sensitive neurotensin receptor; NT-R-2; NTR2 receptor\tNeurotensin receptor type 2","CurationStatus":"uncurated","SuperCategory":"Neurotensin receptor","Id":"nifext_6224"}},{"Nuclear Body":{"SuperCategory":"Nuclear Subcomponent","Id":"sao505137457","Definition":"Extra-nucleolar nuclear domains usually visualized by confocal microscopy and fluorescent antibodies to specific proteins (Gene Ontology)."}},{"Nuclear DNA":{"SuperCategory":"DNA","Id":"sao1785015039"}},{"Nuclear envelope":{"CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"GO:0005635","Is part of":"Nucleus","Definition":"The double lipid bilayer enclosing the nucleus and separating its contents from the rest of the cytoplasm; includes the intermembrane space, a gap of width 20-40 nm (also called the perinuclear space)."}},{"Nuclear inner membrane":{"CurationStatus":"uncurated","SuperCategory":"Nuclear Membrane","Id":"GO:0005637","Is part of":"Nuclear membrane","Definition":"The inner, i.e. lumen-facing, lipid bilayer of the nuclear envelope (Gene Ontology)."}},{"Nuclear Lamina":{"CurationStatus":"uncurated","SuperCategory":"Nuclear Subcomponent","Id":"GO:0005652","Is part of":"Nucleus","Definition":"Meshwork of extremely fine filaments composed of polypeptides called lamins that run parallel with the inner surface of the nuclear envelope (Peters, Palay and Webster, 1991)., The fibrous, electron-dense layer lying on the nucleoplasmic side of the inner membrane of a cell nucleus, composed of lamin filaments. The polypeptides of the lamina are thought to be concerned in the dissolution of the nuclear envelope and its re-formation during mitosis. The lamina is composed of lamin A and lamin C filaments cross-linked into an orthogonal lattice, which is attached via lamin B to the inner nuclear membrane through interactions with a lamin B receptor, an IFAP, in the membrane (Gene Ontology)."}},{"Nuclear magnetic resonance instrument":{"Synonym":"NMR instrument","Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Chemical compositional analysis instrument","Id":"birnlex_2419"}},{"Nuclear medicine imaging protocol":{"Created":"2007-11-20","Synonym":"NMR","CurationStatus":"uncurated","Umlscui":"C0024485","SuperCategory":"Image acquisition protocol","Id":"birnlex_2483"}},{"Nuclear Medicine Series Type":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0042","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150340","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Nuclear membrane":{"CurationStatus":"uncurated","SuperCategory":"Intracellular Membrane","Id":"GO:0031965","Is part of":"Nuclear envelope","Definition":"Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space (Gene Ontology)."}},{"Nuclear outer membrane":{"CurationStatus":"uncurated","SuperCategory":"Nuclear Membrane","Id":"GO:0005640","Is part of":"Nuclear membrane","Definition":"The outer, i.e. cytoplasm-facing, lipid bilayer of the nuclear envelope; continuous with the endoplasmic reticulum of the cell and sometimes studded with ribosomes (Gene Ontology)."}},{"Nuclear pore":{"CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"GO:0005643","Is part of":"Nuclear envelope","Definition":"Any of the numerous similar discrete openings in the nuclear envelope of a eukaryotic cell, where the inner and outer nuclear membranes are joined (Gene Ontology)."}},{"Nuclear Subcomponent":{"SuperCategory":"Cellular Subcomponent","Id":"sao1499850686"}},{"Nucleate quality":{"SuperCategory":"Cellular quality","Id":"PATO_0001404","Definition":"A cellular quality inhering in a bearer by virtue of its number of nuclei."}},{"Nuclei of the diagonal band":{"PMID":"61212,2416786,845280,8801249","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_23347","Is part of":"Diagonal band"}},{"Nuclei of the lateral lemniscus":{"PMID":"2229472,10440707,10982461,19034907,8867285,10213091,17912742","CurationStatus":"uncurated","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_69745","Is part of":"Pontine tegmentum","Definition":"Groups of cells situated largely within the fiber bundles of the lateral lemniscus.  Two nuclei are usually distinguished:  a ventral group and a dorsal group (Brodal, Neurological Anatomy, 3rd ed., 1981, pg. 619).  "}},{"Nuclei of the thalamus":{"PMID":"11413546,10722997","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_44488","Is part of":"Thalamus"}},{"Nucleic Acid":{"SuperCategory":"Biomolecule","Id":"sao83745184","Definition":"High molecular weight polymers containing a mixture of purine and pyrimidine nucleotides chained together by ribose or deoxyribose linkages (MSH)."}},{"Nucleic acid extraction":{"CurationStatus":"uncurated","Contributor":"PlanAndPlannedProcess Branch","SuperCategory":"Extraction","Id":"OBI_0666667","Has role":"Protocol","Definition":"A material separation to recover the nucleic acid fraction of an input material."}},{"Nucleic acid sequencing instrument":{"Synonym":"sequencer","Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Chemical compositional analysis instrument","Id":"birnlex_2408"}},{"Nucleolus":{"CurationStatus":"uncurated","SuperCategory":"Nuclear Subcomponent","Id":"GO:0005730","Is part of":"Nucleus","Definition":"A small, dense body one or more of which are present in the nucleus of eukaryotic cells. It is rich in RNA and protein, is not bounded by a limiting membrane, and is not seen during mitosis. Its prime function is the transcription of the nucleolar DNA into 45S ribosomal-precursor RNA, the processing of this RNA into 5.8S, 18S, and 28S components of ribosomal RNA, and the association of these components with 5S RNA and proteins synthesized outside the nucleolus. This association results in the formation of ribonucleoprotein precursors; these pass into the cytoplasm and mature into the 40S and 60S subunits of the ribosome (Gene Ontology)."}},{"Nucleolus-associated heterochromatin":{"CurationStatus":"uncurated","SuperCategory":"Nuclear Body","Id":"GO:0097424","Definition":"Dense particles of heterochromatin, consisting of a loosely twisted strang ~600 A thick,  found associated with the nucleolus (Palay and Chan-Palay, 1974)."}},{"Nucleoplasm":{"CurationStatus":"uncurated","SuperCategory":"Nuclear Subcomponent","Id":"GO:0005654","Is part of":"Nucleus","Definition":"That part of the nuclear content other than the chromosomes or the nucleolus (Gene Ontology)."}},{"Nucleoside":{"Created":"2007-09-19","SuperCategory":"Biomolecule","Id":"nifext_5008"}},{"Nucleotide":{"Created":"2007-09-19","SuperCategory":"Nucleoside","Id":"nifext_5193"}},{"Nucleus":{"Synonym":"cell nucleus","CurationStatus":"uncurated","SuperCategory":"Membrane bound organelle","Id":"GO:0005634","Definition":"A membrane-bounded organelle of eukaryotic cells that contains the chromosomes. It is the primary site of DNA replication and RNA synthesis in the cell (Gene Ontology)."}},{"Nucleus accumbens":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["nucleus accumbens septi"],"CurationStatus":"pending final vetting","EfferentProjections":"Ventral pallidum","Curator":["Maryann Martone"],"Abbrev":"Acb","AfferentProjections":["Ventral pallidum"],"Created":"2006-08-04","NeuronamesID":"259","SuperCategory":"Nucleus of CNS","Id":"birnlex_727","Is part of":["Basal ganglia","Ventral striatum","Striatum"],"Species":"Mammal,","Definition":"A region of the brain consisting of a collection of neurons located in the forebrain ventral to the caudate and putamen.  (caudoputamen in rodent) and continuous with these structures.  There is no distinct boundary between the nucleus accumbens and the caudate/putamen, but in rodents, it can be identified by its lack of traversing fiber bundles in comparison to the dorsal striatum.  Its principle neuron is the medium spiny neuron.  Together with the neostriatum (caudate nucleus and putamen), the nucleus accumbens forms the striatum."}},{"Nucleus accumbens of ABA 2009":{"PartiallyOverlapsWith":"Nucleus accumbens","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153193","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus ambiguus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","CurationStatus":"uncurated","NeuronamesID":"762","Umlscui":["C0152400"],"EfferentProjections":["Thyroarytenoid muscle"],"SuperCategory":"Regional part of brain","Id":"birnlex_2650","Has role":"Cranial nerve nucleus","Is part of":["Medulla oblongata"],"EfferentProjectionsPMID":"19426785","Abbrev":"Amb"}},{"Nucleus ambiguus dorsal division of ABA 2009":{"PartiallyOverlapsWith":"Nucleus ambiguus  dorsal division","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152958","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus ambiguus motor neuron":{"LocationOfAxonArborization":["thyroarytenoid muscle"],"Located in":"Nucleus ambiguus","CurationStatus":"uncurated","Neurotransmitter":"Acetylcholine,","LocationOfAxonArborizationPMID":"19426785","SuperCategory":"Neuron","Id":"nlx_53276","Species":"Vertebrata","Definition":"Motor neuron whose soma lies within the nucleus ambiguus and whose axons project through the glossopharyngeal or vagus nerve to innervate the striated muscules of the pharynx and larynx (Heimer, The human brain and spinal cord, 2nd ed, 1995, pg 258 and table 11-1, pg 266)."}},{"Nucleus ambiguus of ABA 2009":{"PartiallyOverlapsWith":"Nucleus ambiguus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153635","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus ambiguus ventral division of ABA 2009":{"PartiallyOverlapsWith":"Nucleus ambiguus  ventral division","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153174","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus centrobasalis":{"ConnDefiningCriteriaPMID":"266509","CurationStatus":"uncurated","EfferentProjections":"Cerebellum","ConnDefiningCriteria":["Following dorsal rhizotomy"],"MyeloDefiningCriteriaPMID":"266509","AfferentProjections":"Dorsal root ganglion","CytoDefiningCriteria":"The cells comprising this nucleus vary widely in size.  It was best identified in Nissl stain in sections 100-200 um thick","IsPartOfPMID":"266509","CytoDefiningCriteriaPMID":"266509","MyeloDefiningCriteria":"Weil or Weigert preparations reveal an abundantly myelinated neuropil in the basilar region of the dorsal horn.","SuperCategory":"Regional part of spinal cord","Id":"nlx_143588","Is part of":"Cervical spinal cord dorsal horn","Species":"Dog","Definition":"Nucleus located in the cervical and lumbosacral enlargements at base of the dorsal horn, bordered dorsally by the n. proprius cornus dorsalis, and ventrally by the zona intermedia.  Cells comprising this nucleus vary widely in size. Large cells appear to project ipsilaterally to the cerebellum.  The nucleus is a major site of termination for dorsal root fibers.  Petras and Cummings suggest that these cells give rise to the rostral spinocerebellar tract.","DefinitionPMID":"266509"}},{"Nucleus circularis of ABA 2009":{"PartiallyOverlapsWith":"Nucleus circularis","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153151","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus gigantocellularis":{"Synonym":["Gigantocellular nucleus","gigantocellular reticular nucleus"],"CurationStatus":"uncurated","SuperCategory":"Nucleus of CNS","Id":"nlx_anat_1005001","Is part of":"Medulla oblongata","Abbrev":"Gi"}},{"Nucleus incertus":{"RelatedTo":"theta rhythm","Synonym":["Central Gray pars 0","Central Gray part alpha","Central Gray pars beta (The rat brain in stereotaxic coordinates [electronic resource] / George Paxinos"],"CurationStatus":"uncurated","NeuronamesID":"1093","SuperCategory":"Regional part of brain","RelatedToPMID":"16817876","Id":"nlx_144477","Abbrev":["NI, CG0","CGalpha"],"DefinitionPMID":"11503154","Definition":"Distinct cell group in caudoventral regions of the pontine periventricular gray, adjacent to the ventromedial border of the caudal dorsal tegmental nucleus."}},{"Nucleus incertus of ABA 2009":{"PartiallyOverlapsWith":"Nucleus incertus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153231","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus intercalates of ABA 2009":{"PartiallyOverlapsWith":"Nucleus intercalates","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153094","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus intercalatus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["intercalated nucleus of medulla"],"CurationStatus":"uncurated","NeuronamesID":"756","Umlscui":["C0152398"],"SuperCategory":"Regional part of brain","Id":"birnlex_2654","Is part of":"Medulla oblongata","Abbrev":"In"}},{"Nucleus laminaris principal neuron":{"Located in":"Nucleus laminaris","AxonProjectionLateralityPMID":"20148439,","BranchingMetrics":"bipolar","Synonym":"Analogous to the Medial Superior Olive (MSO) in mammals","CurationStatus":"uncurated","CellSomaSize":"Medium soma","LocationOfAxonArborization":["superior olive","cell groups embedded in the lemniscus lateralis","and the nucleus mesencephalicus lateralis"],"SpineDensityOnDendrites":"Smooth","MolecularConstituentsPMID":"14755528; 19365819; 18440716","LocationOfLocalAxonArborization":"none","Neurotransmitter":"Glutamate,","SuperCategory":"Neuron","LocationOfAxonArborizationPMID":"3697720","CellSomaShape":"Oval","Species":["Vertebrata"],"AxonProjectionLaterality":"bilateral","DendriteLocation":"Chicken NL neurons are bipolar with segregated dorsal and ventral dendritic domains that are structurally and biochemically comparable in most aspects. The entire nucleus exhibits a unique three-layer organization with two dendritic layers separated by a single layer of cell bodies. The two dendritic domains receive segregated excitatory input from the ipsilateral and contralateral ears.","MolecularConstituents":["Voltage-gated potassium channel - type 1","Voltage-gated potassium channel - type 3","Sodium channel","High-molecular weight neurofilament","Plasma membrane ATPase","Microtubule-associated protein 2","Fragile x mental retardation protein"],"CellSomaShapeOther":"Round","AxonMyelinationPMID":"8313166,","NeurotransmitterReceptors":["Glutamate-gated channels"],"Has role":"Principal neuron role","OriginOfAxon":"soma and sometimes dendrite","Abbrev":"NL","Id":"nlx_151646","BranchingMetricsPMID":"7320232,","AxonMyelination":"myelinated","Definition":"The nucleus laminaris (NL) in birds is the third-order auditory neurons located in the brainstem, analogous to the medial superior olive (MSO) in mammals. Neurons in NL and MSO are structurally and biophysically specialized to compute interaural time differences (ITDs), time disparities in the arrival of signals between the two ears, using low-frequency sounds. ITDs are the primary binaural cues for sound localization and segregation in humans and other low-frequency hearing vertebrates. While commonly used laboratory mammals such as mice and rats are high-frequency listeners and have a poorly developed MSO circuit, the structurally and functionally similar circuit in the chicken brainstem provides a particularly useful vertebrate model for basic research of ITD computation, due to its simple anatomy, well-characterized development and cell biology, and importantly, as a genetic tractable system."}},{"Nucleus of anterior commissure":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-04","EditorialNote":"Neuronames has this nucleus as a part of the septal nuclear complex and so we have followed that convention.","AtlasImage":"Nucleus of AC Brainmaps.jpg,","Synonym":["bed nucleus of anterior commissure","bed nucleus of the anterior commissure"],"CurationStatus":"uncurated","NeuronamesID":"266","Umlscui":"C0262292","SuperCategory":"Nucleus of CNS","Id":"birnlex_712","OrganismPMID":"19129928","Is part of":"Septal nuclear complex","Species":"Mammal"}},{"Nucleus of CNS":{"Synonym":"nucleus","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_28443","Has role":"CUMBO term","Is part of":"Central nervous system","Definition":"A spatially aggregated collection of nerve cell bodies in the CNS, consisting of one or more subpopulations that share cell type, chemical phenotype, and connections, and including nearby cells that share the same cell type, chemical phenotype, and connections. (CUMBO)"}},{"Nucleus of Darkschewitsch":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"505","CurationStatus":"uncurated","Umlscui":"C0262291","SuperCategory":"Regional part of brain","Id":"birnlex_896","Is part of":"Midbrain tegmentum","Abbrev":"Dk"}},{"Nucleus of Darkschewitsch of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of Darkschewitsch","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153234","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of diagonal band":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-04","EditorialNote":"Neuronames has this nucleus listed as part of the septal nuclear complex and so we have followed that convention here;  however, it also may be considered part of the basal forebrain by some.  We will need to carefully review all of these structures.","Synonym":["diagonal band nucleus","nucleus of diagonal band","nucleus of the diagonal band of Broca"],"CurationStatus":"uncurated","NeuronamesID":"247","Umlscui":"C0175227","SuperCategory":"Nucleus of CNS","Id":"birnlex_719","Is part of":"Septal nuclear complex"}},{"Nucleus of field H of Forel":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_144081","Is part of":"Subthalamus","Species":"Mammal","DefinitionPMID":"ISBN:0471210056","Definition":"Nucleus of the subthalamus comprising cells lying scattered among fiber tracts, at the level of the mesodiencephalic junction, immediately rostral to the red nucleus and ventrolateral to the ventral tegmental area (Butler and Hodos, Comparative Vertebrate Anatomy, 2nd ed., 2005, p 478)"}},{"Nucleus of lateral olfactory tract":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":"Nucleus of the lateral olfactory tract","CurationStatus":"uncurated","NeuronamesID":"224","Umlscui":"C0175218","SuperCategory":"Nucleus of CNS","Is_part_of":"Corticomedial nuclear complex","Id":"birnlex_2702","Is part of":"Telencephalon","Species":"Mammal,","Abbrev":"LOT"}},{"Nucleus of medial eminence":{"Created":"2006-07-15","EditorialNote":"I am having trouble tracking down any reference to this nucleus other than Brain Info","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_870","Is part of":"Pontine reticular formation"}},{"Nucleus of optic tract":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","Synonym":["nucleus of the optic tract"],"SynonymPMID":"3676736","NeuronamesID":"453","CurationStatus":"uncurated","Umlscui":"C0175356","SuperCategory":"Regional part of brain","Id":"birnlex_868","Is part of":"Pretectum","AfferentProjections":"Retina","Definition":"Predominantly gray matter structure consisting of large multipoloar cells lying aong axons of the brachium of the superior colliculus, lyaing adjaent to the dorsal terminal nucleus of the accessory optic system.  In several species, cells of this nucleus receive inpu from the contralateral retina (Sefton and Dreher in Paxinos, G.  The rat nervous system, 1995, pg. 862)."}},{"Nucleus of posterior commissure":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"502","CurationStatus":"uncurated","Umlscui":"C0175386","SuperCategory":"Regional part of brain","Id":"birnlex_1470","Is part of":"Midbrain tegmentum","Abbrev":"PCom"}},{"Nucleus of pretectal area":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"451","CurationStatus":"uncurated","Umlscui":"C0175358","SuperCategory":"Regional part of brain","Id":"birnlex_864","Is part of":"Pretectal area"}},{"Nucleus of reunions of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of reunions","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153406","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of Roller of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of Roller","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153244","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the brachium of the inferior colliculus":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_144476"}},{"Nucleus of the brachium of the inferior colliculus of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the brachium of the inferior colliculus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153008","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral lemniscus dorsal part of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral lemniscus  dorsal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153562","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral lemniscus horizontal part of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral lemniscus  horizontal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153480","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral lemniscus of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral lemniscus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153280","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral lemniscus ventral part of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral lemniscus  ventral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153308","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral olfactory tract layer 3 of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral olfactory tract  layer 3","CurationStatus":"uncurated","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153808","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral olfactory tract layers 1-3 of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral olfactory tract  layers 1-3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153458","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral olfactory tract molecular layer of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral olfactory tract  molecular layer","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153372","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral olfactory tract of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral olfactory tract","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153549","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the lateral olfactory tract pyramidal layer of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the lateral olfactory tract  pyramidal layer","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153569","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the optic tract of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the optic tract","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153223","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the posterior commissure of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the posterior commissure","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153510","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the solitary tract central part of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the solitary tract  central part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153271","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the solitary tract commissural part of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the solitary tract  commissural part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153002","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the solitary tract gelatinous part of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the solitary tract  gelatinous part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153178","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the solitary tract lateral part of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the solitary tract  lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153785","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the solitary tract medial part of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the solitary tract  medial part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152920","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the solitary tract of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the solitary tract","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153263","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus of the stria medullaris":{"CytoDefiningCriteria":["Based on sagittal sections of Golgi material","Cajal reported that this cell group contains small multipolar neurons","as well as a dense plexus of collaterals","some of which are derived from the fornix"],"CytoDefiningCriteriaPMID":"8719273","EditorialNote":"According to Risold and Swanson (1995), this nucleus was likely first described by Cajal in newborn mice, but has been described by other authors as well.","DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_144458","Species":"Mouse","Definition":"Small nucleus in the thalamus lying between the fornix and the stria medullaris.  "}},{"Nucleus of the stria terminalis":{"PMID":"10340512,61212,19844991,10404250,412879","DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated","Comment":"This brain region was originally identified through text mining by French et al. 2012","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_11439"}},{"Nucleus of the trapezoid body of ABA 2009":{"PartiallyOverlapsWith":"Nucleus of the trapezoid body","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153475","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus paramedianus dorsalis":{"Synonym":"nucleus paramedianus dorsalis","CurationStatus":"uncurated","ChemoDefiningCriteriaPMID":"17869228","TomoDefiningCriteria":["located adjacent and medial to the nucleus prepositus in the dorsal medulla;  it begins at about the same A-P level as nucleus prepositus hypoglossi"],"PublicationLink":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2078602/figure/F2/","Abbrev":"PMD","CytoDefiningCriteria":"Cells in this region have large oval or polygonal cell bodies that stain darkly with a Nissl stain;  distinguishable with AChE staining","CytoDefiningCriteriaPMID":"17869228","TopoDefiningCriteriaPMID":"17869228","DefiningCriteria":["cyto-architecture","topography"],"PartiallyOverlapsWith":["nucleus paramedianus dorsalis of OB1954; Sadjadpour and Brodal","1968; Paxinos and Huang"],"ChemoDefiningCriteria":["It contains calretinin immunoreactive large cells with oval or polygonal cell bodies. Cells are not immunoreactive for either calbindin or parvalbumin","but a few fibers immunoreactive to each protein are found within its central region. Cells in PMD are also immunoreactive to nNOS"],"NeuronamesID":"735","SuperCategory":"Regional part of brain","Id":"nlx_143549","Is part of":"Medulla oblongata","Species":"Human","DefiningCitation":["Olszewski J"],"Definition":"Small nucleus in the brainstem of human, located adjacent and medial to the nucleus prepositus in the dorsal medulla, described in several atlases of human brain stem.  In transverse sections, it is oval with its long axis aligned with the dorsal border of the brainstem.  It begins at about the same A-P level as the nucleus prepositus, just rostral to the hypoglossal nucleus.  It includes calretinin immunoreactive large cells with oval or polygonal cell bodies. Cells are not immunoreactive for either calbindin or parvalbumin, but a few fibers immunoreactive to each protein are found within its central region. Cells in PMD are also immunoreactive to nNOS, and immunoreactivity to a neurofilament protein shows many labeled cells and fibers.  According to Baizer et al., no equivalent structure was observed in the cat, rat, mouse or monkey atlas although they did not look at the brains of the great apes.","DefinitionPMID":"17869228"}},{"Nucleus prepositus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["prepositus nucleus","prepositus hypoglossal nucleus","nucleus praepositus"],"CurationStatus":"uncurated","EfferentProjections":["Pedunculopontine tegmental nucleus"],"PublicationLink":"http://brainmaps.org/ajax-viewer.php?datid","Abbrev":["PrP"],"AfferentProjections":"Pedunculopontine tegmental nucleus","Created":"2007-08-28","AfferentProjectionsPMID":"1707725","NeuronamesID":"755","Umlscui":["C0152399"],"SuperCategory":"Regional part of brain","Id":"birnlex_2652","Is part of":"Medulla oblongata,","Species":"Mammal","EfferentProjectionsPMID":["1707725"]}},{"Nucleus prepositus of ABA 2009":{"PartiallyOverlapsWith":"Nucleus prepositus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153058","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus proprius":{"CurationStatus":"uncurated","SuperCategory":"Regional part of spinal cord","Id":"nlx_144478"}},{"Nucleus Quality":{"SuperCategory":"Morphological Quality","Id":"sao343486489","Definition":"The shape of the nucleus, e.g., round, lobulated, indented"}},{"Nucleus raphe magnus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-07","Synonym":"raphe magnus nucleus","CurationStatus":"uncurated","PartiallyOverlapsWith":"Nucleus raphe magnus of ABA 2009","NeuronamesID":"736","Umlscui":"C0175515","SuperCategory":"Regional part of brain","Id":"birnlex_1363","Is part of":["Raphe Nuclei"],"Abbrev":"RMg"}},{"Nucleus raphe magnus of ABA 2009":{"PartiallyOverlapsWith":"Nucleus raphe magnus","CurationStatus":"uncurated","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153328","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Medulla behavioral state related of ABA 2009","Organism":"mouse"}},{"Nucleus raphe obscurus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-07","Synonym":"raphe obscurus nucleus","CurationStatus":"uncurated","PartiallyOverlapsWith":["Raphe obscurus nucleus of PHT00"],"NeuronamesID":"737","Umlscui":"C0175516","SuperCategory":"Regional part of brain","Id":"birnlex_1369","Is part of":["Raphe Nuclei"],"Abbrev":"ROb"}},{"Nucleus raphe obscurus of ABA 2009":{"PartiallyOverlapsWith":"Nucleus raphe obscurus","CurationStatus":"uncurated","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153522","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Medulla behavioral state related of ABA 2009","Organism":"mouse"}},{"Nucleus raphe pallidus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-07","Synonym":"raphe pallidus nucleus","CurationStatus":"uncurated","PartiallyOverlapsWith":["raphe pallidus nucleus of PHT00"],"NeuronamesID":"738","Umlscui":"C0175517","SuperCategory":"Regional part of brain","Id":"birnlex_1375","Is part of":["Raphe Nuclei"],"Abbrev":"RPa"}},{"Nucleus raphe pallidus of ABA 2009":{"PartiallyOverlapsWith":"Nucleus raphe pallidus","CurationStatus":"uncurated","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153677","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Medulla behavioral state related of ABA 2009","Organism":"mouse"}},{"Nucleus raphe pontis of ABA 2009":{"PartiallyOverlapsWith":"Nucleus raphe pontis","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153196","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus retroambigualis":{"CurationStatus":"uncurated","NeuronamesID":"2319","SuperCategory":"Regional part of brain","Id":"nlx_144482","Definition":"a group of neurons in the medulla at the caudal end of the nucleus ambiguus, from which the cranial part of the accessory nerve originates (adapted from Brain Info)"}},{"Nucleus rotundus of thalamus":{"Synonym":"nucleus rotundus thalami","CurationStatus":"uncurated","NeuronamesID":"1254","SuperCategory":"Regional part of brain","Id":"nlx_144481","Is part of":"Midline nuclear group"}},{"Nucleus sagulum of ABA 2009":{"PartiallyOverlapsWith":"Nucleus sagulum","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153262","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus subceruleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"579","CurationStatus":"uncurated","Umlscui":"C0175441","SuperCategory":"Regional part of brain","Id":"birnlex_1088","Is part of":"Pontine tegmentum"}},{"Nucleus x of ABA 2009":{"PartiallyOverlapsWith":"Nucleus x","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153407","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus y of ABA 2009":{"PartiallyOverlapsWith":"Nucleus y","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153575","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nucleus z of ABA 2009":{"PartiallyOverlapsWith":"Nucleus z","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153633","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Nudibranchia":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1085158","SuperCategory":"Opisthobranchia","Id":"birnlex_7242"}},{"Number of Averages":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0083","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150341","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Number of times a given pulse sequence is repeated before any parameter is changed."}},{"Number of b NE 0 volumes":{"Created":"2008-03-14","CurationStatus":"graph_position_temporary","SuperCategory":"Cardinality value","Id":"birnlex_3053","Definition":"number of diffusion-weighted directions multiplied by the number of non-zero b-values"}},{"Number of b values":{"Created":"2008-03-14","CurationStatus":"graph_position_temporary","SuperCategory":"Cardinality value","Id":"birnlex_3050","Definition":"number of distinct b-values used"}},{"Number of Beams":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0080","SuperCategory":"DICOM term","Id":"nlx_150342","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of Beams in current Fraction Group. If Number of Beams is greater then zero, Number of Brachy Application Setups (300A,00A0) shall equal zero."}},{"Number of Blocks":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00F0","SuperCategory":"DICOM term","Id":"nlx_150343","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of shielding blocks associated with Beam. Required if Exposure Sequence (3002,0030) is sent."}},{"Number of Boli":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00ED","SuperCategory":"DICOM term","Id":"nlx_150344","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of boli associated with current Beam."}},{"Number of Brachy Application Setups":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00A0","SuperCategory":"DICOM term","Id":"nlx_150345","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of Brachy Application Setups in current Fraction Group. If Number of Brachy Application Setups is greater then zero, Number of Beams (300A,0080) shall equal zero."}},{"Number of Compensators":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00E0","SuperCategory":"DICOM term","Id":"nlx_150346","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of compensators associated with current Beam."}},{"Number of Contour Points":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0046","SuperCategory":"DICOM term","Id":"nlx_150347","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of points (triplets) in Contour Data (3006,0050). Required if Contour Sequence (3006,0040) is sent."}},{"Number of Control Points":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0110","SuperCategory":"DICOM term","Id":"nlx_150348","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of control points in Beam."}},{"Number of Detectors":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0021","SuperCategory":"DICOM term","Id":"nlx_150349","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of detectors."}},{"Number of diffusion-weighted directions":{"Created":"2008-03-14","CurationStatus":"graph_position_temporary","SuperCategory":"Cardinality value","Id":"birnlex_3051","Definition":"the number of gradient amplitude vectors used in each complete set of diffusion-weighted data"}},{"Number of Energy Windows":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0011","SuperCategory":"DICOM term","Id":"nlx_150350","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of energy window groupings."}},{"Number of Event Timers":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_2129","SuperCategory":"DICOM term","Id":"nlx_150351","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of event timers used at the time of acquisition of a Multi-frame image."}},{"Number of Fraction Pattern Digits Per Day":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0079","SuperCategory":"DICOM term","Id":"nlx_150352","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of digits in Fraction Pattern (300A,007B) used to represent one day."}},{"Number of Fractions Delivered":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_005A","SuperCategory":"DICOM term","Id":"nlx_150353","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of fractions delivered as of Treatment Summary Report. Required if Fraction Group Summary Sequence (3008,0220) is sent."}},{"Number of Fractions Planned":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0078","SuperCategory":"DICOM term","Id":"nlx_150354","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Total number of treatments (Fractions) prescribed for current Fraction Group."}},{"Number of Frames":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_0008","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150355","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of frames associated with the data volume."}},{"Number of Frames in Overlay":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0015","SuperCategory":"DICOM term","Id":"nlx_150356","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of Frames in Overlay. Required if Overlay data contains multiple frames."}},{"Number of Frames in Phase":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0033","SuperCategory":"DICOM term","Id":"nlx_150357","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of frames in this phase. Required if a sequence Item is present."}},{"Number of Frames in Rotation":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0053","SuperCategory":"DICOM term","Id":"nlx_150358","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of angular views in this rotation. Required if a sequence Item is present."}},{"Number of Graphic Points":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0021","SuperCategory":"DICOM term","Id":"nlx_150359","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of data points in this graphic."}},{"Number of k-Space Trajectories":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9093","SuperCategory":"DICOM term","Id":"nlx_150360","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of interleaves or shots. Required if Image Type (0008,0008) Value 1 is ORIGINAL or MIXED. May be present otherwise."}},{"Number of Patient Related Instances":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1204","SuperCategory":"DICOM term","Id":"nlx_150362","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of instances associated with this patient."}},{"Number of Patient Related Series":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1206","SuperCategory":"DICOM term","Id":"nlx_150363","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of series associated with this patient."}},{"Number of Patient Related Studies":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1200","SuperCategory":"DICOM term","Id":"nlx_150364","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of studies associated with this patient."}},{"Number of Phase Encoding Steps":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0089","SuperCategory":"DICOM term","Id":"nlx_150365","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Total number of lines in k-space in the \"y\" direction collected during acquisition."}},{"Number of Phases":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0031","SuperCategory":"DICOM term","Id":"nlx_150366","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of phases. Required if the value of the Frame Increment Pointer (0028,0009) includes the Tag for Phase Vector (0054,0030)."}},{"Number of Pulses":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_028A","SuperCategory":"DICOM term","Id":"nlx_150367","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of Pulses per fraction for current Channel. Required if Brachy Treatment Type (300A,0202) is PDR."}},{"Number of R-R Intervals":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0061","SuperCategory":"DICOM term","Id":"nlx_150368","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of R-R intervals. Required if the value of the Frame Increment Pointer (0028,0009) includes the Tag for R-R Interval Vector (0054,0060)."}},{"Number of Rotations":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0051","SuperCategory":"DICOM term","Id":"nlx_150369","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of rotations. Required if Image Type (0008,0008), Value 3 is TOMO, GATED TOMO, RECON TOMO, or RECON GATED TOMO."}},{"Number of Series Related Instances":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1209","SuperCategory":"DICOM term","Id":"nlx_150370","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of instances associated with this series."}},{"Number of Slices":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0081","SuperCategory":"DICOM term","Id":"nlx_150371","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of slices. Required if the value of the Frame Increment Pointer (0028,0009) includes the Tag for Slice Vector (0054,0080)."}},{"Number of Stages":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_2124","SuperCategory":"DICOM term","Id":"nlx_150372","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of Stages in this protocol. Required if image was acquired in a Staged protocol."}},{"Number of Study Related Instances":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1208","SuperCategory":"DICOM term","Id":"nlx_150373","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of instances associated with this study."}},{"Number of Study Related Series":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1206","SuperCategory":"DICOM term","Id":"nlx_150374","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of series associated with this study."}},{"Number of Table Break Points":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_6050","SuperCategory":"DICOM term","Id":"nlx_150375","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UL","Definition":"The number of break point coordinate pairs used to describe a piece wise linear curve. Required if Pixel Component Organization equals 0 or 1. Otherwise not used."}},{"Number of Table Entries":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_6056","SuperCategory":"DICOM term","Id":"nlx_150376","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UL","Definition":"The number of entries in the Table of Pixel Values. Required if the Pixel Component Organization equals 2."}},{"Number of Temporal Positions":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0105","SuperCategory":"DICOM term","Id":"nlx_150377","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Total number of temporal positions prescribed."}},{"Number of Time Slices":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0101","SuperCategory":"DICOM term","Id":"nlx_150378","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"The maximum number of Time Slices that may exist in this Series. Required if Series Type (0054,1000), Value 1 is DYNAMIC."}},{"Number of Time Slots":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0071","SuperCategory":"DICOM term","Id":"nlx_150379","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of time slots. Required if the value of the Frame Increment Pointer (0028,0009) includes the Tag for Time Slot Vector (0054,0070)."}},{"Number of Tomosynthesis Source Images":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1495","SuperCategory":"DICOM term","Id":"nlx_150380","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"The number of source images used to construct this tomosynthetic image. Only meaningful if Tomo Class (0018,1491) is OSYNTHESIS. These may be listed in Source Image Sequence (0008,2112) of the General Image Module."}},{"Number of Triggers in Phase":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0211","SuperCategory":"DICOM term","Id":"nlx_150381","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"The number of entries in the Trigger Vector (0054,0210) for this phase. Required if Trigger Vector  (0054,0210) is present."}},{"Number of Views in Stage":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_212A","SuperCategory":"DICOM term","Id":"nlx_150382","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of views in this Stage. Required if image was acquired in a Staged protocol."}},{"Number of Waveform Channels":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0005","SuperCategory":"DICOM term","Id":"nlx_150383","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of channels for this multiplex group."}},{"Number of Waveform Samples":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:003A_0010","SuperCategory":"DICOM term","Id":"nlx_150384","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UL","Definition":"Number of samples per channel in this multiplex group."}},{"Number of Wedges":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00D0","SuperCategory":"DICOM term","Id":"nlx_150385","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of wedges associated with current Beam."}},{"Number of Zero fills":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9066","SuperCategory":"DICOM term","Id":"nlx_150386","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of zero fills added to the time domain data before FT. Shall be 0 (zero) if no zero filling performed. Required if Image Type (0008,0008) Value 1 is ORIGINAL or MIXED. May be present otherwise."}},{"Numeric dataset":{"CurationStatus":"uncurated","SuperCategory":"Data set","Id":"nlx_158138","Keywords":"Resource:CINERGI","Definition":"Resources that are represented as large numerical file-based arrays, e.g. NetCDF or HDF."}},{"Numeric Value Qualifier Code Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A301","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150387","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Qualification of Numeric Value in Measured Value Sequence or reason for absence of Measured Value Sequence Item. Only a single Item shall be permitted in this sequence."}},{"Nursing":{"CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100656","Definition":"From BRO:  medical profession focused on patient care."}},{"Nutrition function":{"Created":"2007-03-06","CurationStatus":"uncurated","Umlscui":"C1442959","SuperCategory":"Behavioral system function","Id":"birnlex_1905"}},{"NWO - Netherlands Organization for Scientific Research":{"Synonym":"Netherlands Organization for Scientific Research","CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_151487","DefiningCitation":"http://www.nwo.nl/nwohome.nsf/pages/SPPD_5R2QE7_Eng","Abbrev":"NMO"}},{"Nyctalus":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1271423","SuperCategory":"Microchiroptera","Id":"birnlex_345"}},{"Nystatin":{"RelatedTo":"Cytochrome P450 51","Synonym":[", Barstatin 100","Candex","Korostatin","Myco-Triacet Ii","Mycolog-Ii","Mycostatin","Mykacet","Mykinac","Mytrex F","Nadostine","Nilstat","Nyaderm","Nysert","Nystaform","Nystatin sodium","Nystatin","sodium salt","Nystatin-Triamcinolone Acetonide","Nystex","Nystop","PMS Nystatin","Pedi-Dri","Sodium nystatin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00646","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00646","Definition":"Nystatin is a polyene antifungal drug to which many molds and yeasts are sensitive, including Candida spp. Nystatin has some toxicity associated with it when given intravenously, but it is not absorbed across intact skin or mucous membranes. It is considered a relatively safe drug for treating oral or gastrointestinal fungal infections. Pharmacology: Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses. Mechanism of action: Nystatin interacts with 14- demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Antifungal Agents. Ionophores"}},{"Obestatin":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5132"}},{"Obex":{"CurationStatus":"uncurated","NeuronamesID":"3123","SuperCategory":"Regional part of brain","Id":"nlx_151877","Has role":"Landmark","Is part of":"Medulla oblongata","Definition":"Small fold of tissue found at the caudal end of the 4th ventricle on the surface of the brain in the caudal medulla.  It also marks the location of the dorsal column nuclei (Adapted from Butler and Hodos, Comparative Vertebrate Neuroanatomy, 2nd ed., 2005, pg 135."}},{"Object":{"SuperCategory":"Material entity","Id":"Object","Definition":" An independent continuant (snap:IndependentContinuant) that is spatially extended, maximally self-connected and self-contained (the parts of a substance are not separated from each other by spatial gaps) and possesses an internal unity. The identity of substantial object (snap:Object) entities is independent of that of other entities and can be maintained through time., Synonyms: substance, Examples: an organism, a heart, a chair, a lung, an apple"}},{"Object aggregate":{"Comment":["Synonyms: substance aggregate","Examples: a heap of stones","a group of commuters on the subway","a collection of random bacteria","a flock of geese","the patients in a hospital"],"SuperCategory":"Material entity","Id":"ObjectAggregate"}},{"Object alternation task":{"Created":"4/15/2011 11:17","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00945","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Object_alternation_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146170","Definition":"No definition submitted yet."}},{"Object-discrimination task":{"Created":"6/13/2011 12:23","CurationStatus":"uncurated","Contributor":"Carinna Torgerson","CAO_Id":"CAO_00846","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Object-discrimination_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146069","Definition":"Participants are shown pairs or sets of objects. Experimenters then try to discern whether the participant is able to discriminate between the objects. This can be done by having subjects match identical objects to each other, having certain objects become associated with rewards and measuring accuracy, or measuring time spent observing novel objects compared to time spent observing previously seen objects."}},{"Objective specification":{"CurationStatus":"uncurated","Contributor":["Jennifer Fostel","Barry Smith","Bjoern Peters"],"SuperCategory":"Directive information entity","Id":"IAO_0000005","Has role":"Protocol","Definition":"A directive information entity that describes an intended process endpoint. "}},{"Oblate":{"Synonym":"Oblate Spheroid","SuperCategory":"Spheroid","Id":"PATO_0000409","Definition":"A spheroid in which the equatorial diameter is greater than the polar diameter."}},{"Oblique":{"SuperCategory":"Regional Part Of Dendrite","Id":"nlx_313"}},{"Oblique dendrite":{"CurationStatus":"uncurated","SuperCategory":"Dendrite","Id":"nlx_sub_1008001","Is part of":"Apical Dendrite","Definition":"Dendrite that arises from an apical dendrite"}},{"Oblong":{"SuperCategory":"2-D shape","Id":"PATO_0000946","Definition":"Having a somewhat elongated form with approximately parallel sides."}},{"Obovate":{"SuperCategory":"Ovate","Id":"PATO_0001936","Definition":"Egg-shaped and flat, with the narrow end attached to the base."}},{"Observation Date Time":{"DICOMID":"DICOM:0040_A032","SuperCategory":"DICOM term","Id":"nlx_152150 ","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DT","Definition":"The date time of the current observation."}},{"Observation DateTime":{"RelatedTo":"BIRN-INCF Derived Data Project","SuperCategory":"DICOM term","Id":"nlx_150388","Is part of":"Resource:DICOM standard","Definition":"TBD"}},{"Observation Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3006_0082","SuperCategory":"DICOM term","Id":"nlx_150389","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Identification number of the Observation. The value of Observation Number (3006,0082) shall be unique within the RT ROI Observations Sequence (3006,0080)."}},{"Obsessive-Compulsive Disorder":{"Created":"2007-10-05","Synonym":["Obsessive-Compulsive Neurosis"],"CurationStatus":"uncurated","SuperCategory":"Anxiety Disorder","Id":"birnlex_12674","Abbrev":"OCD","Definition":"An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension (MeSH)."}},{"Obstructed":{"SuperCategory":"Closed","Id":"PATO_0000648","Definition":"To block or fill (a passage) with obstacles or an obstacle."}},{"Obtectomera":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1048338","SuperCategory":"Ditrysia","Id":"birnlex_638"}},{"Obtuse":{"Synonym":"Roundish","SuperCategory":"Round","Id":"PATO_0001935","Definition":"Roundish, a little inclining to be oblong."}},{"Obtuse angle":{"SuperCategory":"Angular placement","Id":"PATO_0001052","Definition":"Angular placement that is at an angle which is more than 180 degrees."}},{"Occipital cortex":{"CurationStatus":"graph position temporary","Comment":["FMA lists the occipital lobe as synonymous with the occipital cortex.  I don't think that is technically true because if you cut off the lobe"],"SuperCategory":"Regional part of brain","Id":"nlx_94204","Is part of":["Occipital lobe"],"Species":"Mammal","Definition":"Gray matter of neocortex located in the occipital lobe in organisms that have distinct lobes, located in the occipital pole and continuous with the gray matter of the parietal cortex and temporal cortex"}},{"Occipital cortex of human":{"Synonym":"human occipital cortex","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"FMAID: 67325","Is part of":"Neocortex of human","Species":"Human","DefiningCitation":"http://sig.biostr.washington.edu/fma3.0#Occipital_lobe","Definition":"Gray matter located in the occipital lobe of humans which occupies the posterior-most portion of the hemisphere. Anteriorly, it shares an arbitrary border with the gray matter of the parietal lobe and temporal lobe. Medially, it is bounded by the longitudinal cerebral fissure (adapted from FMA)."}},{"Occipital gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"134","Umlscui":"C1110642","SuperCategory":"Regional part of brain","Id":"birnlex_747","Is part of":"Occipital lobe"}},{"Occipital lobe":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-04","CurationStatus":"uncurated","NeuronamesID":"122","Umlscui":"C0028785","SuperCategory":"Regional part of brain","Id":"birnlex_1136","Definition":"Posterior part of the cerebral hemisphere (MSH)"}},{"Occipital pole":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":"Polus occipitalis","NeuronamesID":"123","CurationStatus":"raw_import","Umlscui":"C0228217","SuperCategory":"Superficial feature part of occipital lobe","Id":"birnlex_4016","Abbrev":"ocp"}},{"Occipitotemporal sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":["occipito-temporal sulcus","inferior temporal sulcus (Szikla)","inferior temporal sulcus-2","inferior temporal sulcus (Roberts)","third temporal sulcus","inferior temporal fissure (Crosby)"],"CurationStatus":"uncurated","NeuronamesID":"36","Umlscui":"C0228245","SuperCategory":"Sulcus","Id":"birnlex_1422","Is part of":"Cerebral cortex","Species":"Human","Abbrev":"ots"}},{"Occupation":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_2180","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150390","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Occupation of the Patient."}},{"Occupation assessment":{"Synonym":"occupation","Created":"2008-03-14","CurationStatus":"graph_position_temporary","Umlscui":"C0028811","SuperCategory":"Familial member assessment","Id":"birnlex_3036","Definition":"An assessment of an individual's work specialties as defined by duties and required skills. Use a more specific term if possible. (PSY); An assessment of an individual's crafts, trades, professions, or other means of earning a living. (MSH); An assessment of the principal activity that a person does to earn money. (NCI)"}},{"Occurrence quality":{"Synonym":["incidence"],"SuperCategory":"Quality of a single process","Id":"PATO_0000057","Definition":"A monadic quality of occurrent inhering in a bearer by virtue of its occurence."}},{"Occurrent":{"Comment":["Synonyms: perdurant","Definition: An entity (bfo:Entity) that has temporal parts and that happens","unfolds or develops through time. Sometimes also called perdurants.","Examples: the life of an organism","a surgical operation as processual context for a nosocomical infection","the spatiotemporal context occupied by a process of cellular meiosis","the most interesting part of Van Gogh's life"],"SuperCategory":"Entity","Id":"Occurrent"}},{"Ocellus retinula cell":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Rhabdomeric photoreceptor cell","Id":"nlx_147816","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004242"}},{"Ochre":{"SuperCategory":"Yellow orange","Id":"PATO_0001945","Definition":"A moderate yellow-orange to orange color."}},{"Octave":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001231","Definition":"a range of frequencies where the largest frequency is double the lowest frequency (adapted from the Axon Guide)"}},{"Octopaminergic neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2009-07-13T03:01:02Z","Contributor":"djs93","SuperCategory":"Aminergic neuron","Id":"nlx_148080","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007364","Definition":"Any neuron (FBbt_00005106) that releases as a neurotransmitter, some octopamine (CHEBI:17134)."}},{"Octreotide":{"RelatedTo":["Somatostatin receptor type 1","Somatostatin receptor type 5"],"Synonym":["Octreotida (Spanish)","Octreotide acetate","Octreotidum (Latin)","Octrotide","Atrigel","Longastatin","Sandostatin","Sandostatin LAR"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7726","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00104","Definition":"Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Pharmacology: Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly. Mechanism of action: Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins. Drug type: Approved. Biotech. Investigational. Drug category: Anabolic Agents. Antineoplastic Agents, Hormonal. Gastrointestinal Agents. Hormone Replacement Agents"}},{"Oculocutaneous albinism":{"Synonym":"Yellow Mutant Albinism","CurationStatus":"uncurated","SuperCategory":"Multisystem disease","Id":"nlx_59269","Definition":"Heterogeneous group of autosomal recessive disorders comprising at least four recognized types, all having in common varying degrees of hypopigmentation of the skin, hair, and eyes. The two most common are the tyrosinase-positive and tyrosinase-negative types."}},{"Oculomotor delayed response":{"Created":"7/14/2010 12:07","CurationStatus":"uncurated","Contributor":"Russ Poldrack","CAO_Id":"CAO_00722","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Oculomotor_delayed_response","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145944","Definition":"a task that requires an eye movement to be made to a cued location after a delay"}},{"Oculomotor function":{"Created":"2007-08-22","Synonym":["Eye movement system"],"CurationStatus":"uncurated","Umlscui":["C0683208"],"SuperCategory":"Motor system function","Id":"birnlex_1839","Definition":"The oculomotor system consists of six extraocular muscles attached to the orbit and to the eyeball, extraocular motor neurons located in three different brainstem motor nuclei, and premotor centers and circuits involved in the generation and control of the different types of eye movement. Its exact functional design and robust biomechanics have allowed this motor system to survive, almost unchanged, across different trends in vertebrate evolution (http://www.els.net/WileyCDA/ElsArticle/refId-a0002968.html)."}},{"Oculomotor nerve fibers":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"520","CurationStatus":"uncurated","Umlscui":"C0175408","SuperCategory":"Regional part of brain","Id":"birnlex_1323","Is part of":["Midbrain tegmentum"],"Abbrev":"3nf"}},{"Oculomotor nuclear complex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","Synonym":"oculomotor nucleus","CurationStatus":"uncurated","NeuronamesID":"483","Umlscui":"C0228686","SuperCategory":"Regional part of brain","Id":"birnlex_1240","Has role":"Cranial nerve nucleus","Is part of":"Midbrain tegmentum","Abbrev":"3N","Definition":"Nuclear complex containing subnuclei that give rise to the axons of the occulomotor nerve, both motor and parasympathetic fibers, situated at the midline at the level of the superior colliculus in the midbrain tegmentum (Brodal, Neurological Anatomy, 3rd ed., 1981, pg 533-534)."}},{"Oculomotor nucleus motor neuron":{"Located in":"Oculomotor nuclear complex","Synonym":["oculomotor nucleus motor cell","3rd nerve motor neuron"],"CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_77027","Has role":["Principal neuron role"],"Species":"Vertebrata","Definition":"Motor neuron whose cell soma lies within the oculomotor nucleus"}},{"Oculomotor nucleus of ABA 2009":{"PartiallyOverlapsWith":"Oculomotor nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153700","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Oculomotor system":{"CurationStatus":"uncurated","SuperCategory":"Body system","Id":"nlx_137423"}},{"ODC Attribution License":{"Synonym":"Open Data Commons Attribution License","CurationStatus":"uncurated","SuperCategory":"Open Data Commons License","Id":"nlx_157713","DefiningCitation":"http://opendatacommons.org/licenses/by/","Abbrev":"ODC-By","Definition":"Open license requiring attribution for data/databases."}},{"ODC Database Contents License":{"RelatedTo":"ODC Open Database License","Synonym":["Database Contents License","Open Data Commons Database Contents License","Database Contents License (DbCL)"],"CurationStatus":"uncurated","SuperCategory":"Open Data Commons License","Id":"nlx_157715","DefiningCitation":"http://opendatacommons.org/licenses/dbcl/","Abbrev":"DbCL","Definition":"Waive all rights in the individual Contents of a Database licensed under the ODbL"}},{"ODC Open Database License":{"Synonym":["Open Data Commons Open Database License"],"CurationStatus":"uncurated","SuperCategory":"Open Data Commons License","Id":"nlx_157714","DefiningCitation":"http://opendatacommons.org/licenses/odbl/","Abbrev":"ODbL","Definition":"Open license requiring attribution and Share-Alike for Data/Databases."}},{"ODC Public Domain Dedication and License":{"Synonym":["Public Domain Dedication and License","Open Data Commons Public Domain Dedication and License","Open Data Commons Public Domain Dedication and License (PDDL)","Open Data Commons \u2013 Public Domain Dedication & Licence"],"CurationStatus":"uncurated","SuperCategory":"Open Data Commons License","Id":"nlx_157712","DefiningCitation":"http://opendatacommons.org/licenses/pddl/","Abbrev":"PDDL","Definition":"License that places the data(base) in the public domain (waiving all rights)."}},{"Oddball discrimination paradigm":{"Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Behavioral Experimental Paradigm","Id":"birnlex_2176","Definition":"A behavioral paradigm that assesses a  response to non-attended stimuli which are dissimilar to the majority of stimuli presented"}},{"Oddball task":{"Created":"7/10/2009 14:06","CurationStatus":"uncurated","Contributor":"Agatha Lenartowicz","CAO_Id":"CAO_00847","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Oddball_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146070","Definition":"A task in which stimuli are presented in a continuous stream and participants must detect the presence of an oddball stimulus. The oddball is a stimulus that occurs infrequently relative to all other stimuli, and has distinct characteristics (e.g., a different tone among auditory stimuli)."}},{"Odontoceti":{"Created":"2007-10-06","CurationStatus":"pending_final_vetting","Umlscui":"C0999564","SuperCategory":"Cetacea","Id":"birnlex_648"}},{"Odor":{"SuperCategory":"Quality of related physical entities","Id":"PATO_0000058","Definition":"A relational quality inhering in an object by virtue of the molecules being aerially dispersed and perceived by an odorant receptor."}},{"Odorless":{"SuperCategory":"Odor","Id":"PATO_0001208","Definition":"A quality of lacking odor."}},{"Odorous":{"SuperCategory":"Odor","Id":"PATO_0001331","Definition":"A quality of having odor."}},{"Offspring cardinality assessment":{"Synonym":"number of children","Created":"2008-03-14","CurationStatus":"graph_position_temporary","Umlscui":"C0008059","SuperCategory":"Familial member assessment","Id":"birnlex_3035","Definition":"An assessment of the number of sons or daughters of any age, including biological offspring and sometimes including unborn children, adopted children, stepchildren, foster children and children born outside of marriage; person under an age specified by law. (NCI)"}},{"Ofloxacin":{"RelatedTo":["DNA gyrase subunit A","DNA topoisomerase 4 subunit A"],"Synonym":[", Akilen","Baccidal","Bactocin","Danoflox","Effexin","Exocin","Exocine","Flobacin","Flodemex","Flotavid","Flovid","Floxal","Floxil","Floxin","Floxstat","Fugacin","Inoflox","Kinflocin","Kinoxacin","Liflox","Loxinter","Marfloxacin","Medofloxine","Mergexin","Novecin","Nufafloqo","O-Flox","Obide","Occidal","Ofcin","Oflin","Oflocee","Oflocet","Oflocin","Oflodal","Oflodex","Oflodura","Oflox","Ofloxin","Ofus","Onexacin","Operan","Orocin","Otonil","Pharflox","Praxin","Puiritol","Qinolon","Qipro","Quinolon","Quotavil","Rilox","Sinflo","Tabrin","Taravid","Tariflox","Tarivid","Telbit","Tructum","Uro Tarivid","Viotisone"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01165","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01165","Definition":"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. (PubChem) Pharmacology: Ofloxacin is a quinolone/fluoroquinolone antibiotic. Ofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. Mechanism of action: Ofloxacin acts on DNA gyrase, an enzyme which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Anti-Infective Agents, Urinary. Anti-Infectives. Nucleic Acid Synthesis Inhibitors. Quinolones"}},{"Ohms law":{"Synonym":"V","CurationStatus":"uncurated","SuperCategory":"Mathematical expression","Id":"oen_0001222","Definition":"states that voltage is proportional to current and resistance."}},{"Okinawa least horseshoe bat":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1194127","SuperCategory":"Rhinolophus","Id":"birnlex_404"}},{"Olanzapine":{"RelatedTo":["Cholinergic system","D(1A) dopamine receptor","Muscarinic acetylcholine receptor M3","Muscarinic acetylcholine receptor M1","Muscarinic acetylcholine receptor M5","D(4) dopamine receptor","Muscarinic acetylcholine receptor M4","Histamine H1 receptor","5-hydroxytryptamine 2A receptor","5-hydroxytryptamine 2C receptor","Muscarinic acetylcholine receptor M2","Alpha-1B adrenergic receptor","D(3) dopamine receptor"],"Synonym":["olanzapine","Olansek","Symbyax","Zydis","Zyprexa","Zyprexa Intramuscular"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7735","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00334","Definition":"Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011. Pharmacology: Olanzapine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, olanzapine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. Mechanism of action: Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine. Drug type: Approved. Investigational. Small Molecule. Drug category: Antiemetics. Antipsychotic Agents. Antipsychotics. Serotonin Uptake Inhibitors"}},{"Old":{"SuperCategory":"Age","Id":"PATO_0000308","Definition":"An age which is relatively high."}},{"Old mouse":{"Synonym":"Mouse old","CurationStatus":"uncurated","SuperCategory":"Mouse","Id":"nlx_organ_109099","Definition":"A mouse 18 months old or older."}},{"Oleoylethanolamide":{"Created":"2007-09-19","SuperCategory":"Fatty acid","Id":"nifext_5158"}},{"Olfactory bulb":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":"main olfactory bulb","CurationStatus":"uncurated","EfferentProjections":"Olfactory cortex","Abbrev":"Olb","AfferentProjections":"Olfactory cortex,","Created":"2006-10-05","NeuronamesID":"261","Umlscui":"C0028936","SuperCategory":"Regional part of brain","Id":"birnlex_1137","Is part of":"Telencephalon","Definition":"Structure of the vertebrate telencephalon involved in olfaction.","EfferentProjectionsPMID":"15714267"}},{"Olfactory bulb (accessory) external plexiform layer":{"Synonym":["external plexiform layer of the AOB"],"CurationStatus":"uncurated","SuperCategory":"Cell layer","Id":"nlx_152528","Is part of":"Olfactory bulb accessory nucleus"}},{"Olfactory bulb (accessory) glomerular layer cell":{"Located in":["Olfactory bulb","Olfactory bulb accessory nucleus"],"BranchingMetrics":"unipolar","AxonLength":"? 100-200 um","Synonym":["Glomerular layer cell"],"CurationStatus":"graph position temporary","FiringPatterns":"Regular firing and bursting","SpontaneousFiringPatterns":"Regular firing and bursting","CellSomaSize":"Small soma","SpineDensityOnDendrites":"spiny low density","Created":"2007-09-05","DefiningCriteria":"Morphology; Connectivity","LocationOfLocalAxonArborization":"Within extraglomerular regions","Neurotransmitter":["GABA"],"SuperCategory":"Neuron","CellSomaShape":"Oval","Species":"Mammal","DendriteThickness":"0.5-2 um at origin","AxonProjectionLaterality":"ipsilateral","DendriteLocation":"Olfactory bulb accessory glomerular neuropil","MolecularConstituents":"Calcium binding protein","Comment":["Information primarily from rat and mouse but expert indicated that it applies to all mammals"],"Curator":"Maryann Martone,","Has role":"Intrinsic neuron role","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"OriginOfAxon":"soma and sometimes dendrite","Abbrev":"PG cell","CellularSynapticTarget":"Other PG cells? initial trunks of mitral/tufted cell apical dendrites?","EditorialNote":"http://www.ricercaitaliana.it/prin/unita_op_en-2004057720_003.htmMoved PG cell to abbreviation;  changed \"glomerular layer\" etc to Olfactory bulb accessory glomerular layer etc","ExampleImage":"glomerular layer cell.jpg,","SubcellularSynapticTarget":"Cell bodies of other PG cells; initial trunks of primary apical dendrites of mitral/tufted cells","NumberOfPrimaryDendrites":"1","Id":"nifext_122","AxonMyelination":"unmyelinated","Polarity":"Single dendritic trunk","SpontaneousFiringRate":"Rapid firing","Definition":"Small intrinsic neuron in the glomerular layer of the accessory olfactory bulb, with cell bodies surrounding the olfactory glomerulus. Equivalent to the periglomerular cell of the main olfactory bulb, but the glomeruli are less clearly differentiated.  The cell body is 6-8 um in diameter, from which arises a short bushy dendrite that arborizes within a glomerulus, where it receives synaptic input from olfactory receptor cell axon terminals, and engages in dendrodendritic interactions with mitral/tufted cell dendrites. The axon distributes laterally within the extraglomerular region. Shepherd, Chen, Greer. Olfactory bulb. In The synaptic organization of the brain, ed 5 New York: Oxford University Press, 2004."}},{"Olfactory bulb (accessory) granule cell":{"Located in":["Olfactory bulb (accessory) granule cell layer"],"BranchingMetrics":"bipolar","AxonLength":"no axon","Synonym":["Accessory olfactory bulb granule neuron"],"CurationStatus":"graph position temporary","ISBN":"019515956X","FiringPatterns":"bursting","SpontaneousFiringPatterns":"Bursting","SynapticPhysiology":"Synaptic inhibition onto mitral and tufted cells","CellSomaSize":"Small soma","LocationOfAxonArborization":"This is an anaxonal cell; it lacks an axon","SpineDensityOnDendrites":"spiny high density","DefiningCriteria":["Radial apical dendrite","spiny branches"],"LocationOfLocalAxonArborization":"This is an anaxonal cell; it lacks an axon","Neurotransmitter":"GABA","SuperCategory":"Neuron","CellSomaShape":"Spherical","Species":"Mammal","DefiningCitation":"See The Synaptic Organization of the Brain.  ed 5.","DendriteThickness":"0.5-1 um","DendriteLocation":"Olfactory bulb (accessory) external plexiform layer","MolecularConstituents":"Parvalbumin","Comment":["Edited by GMS 8-10-09 Functinonally"],"Curator":"Maryann Martone,","Has role":"Intrinsic neuron role","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"OriginOfAxon":"no axon","Abbrev":"GC (AOB)","CellularSynapticTarget":["Olfactory bulb (accessory) mitral cell"],"EditorialNote":"Replaced Dendritic location  \"external plexiform layer of the AOB\" with preferred term \"Olfactory bulb (accessory) external plexiform layer\"As the curator noted that the cell is found generally in mammal, I replaced \"Rat, mouse(generally applies to mammals)\" with \"Mammal\".  Note that universality is not implied by this statement, that is, it need not be in all mammals, just some or most mammals.","SubcellularSynapticTarget":"Lateral dendrites of mitral and tufted cells","NumberOfPrimaryDendrites":"1","Id":"nlx_cell_20090401","Polarity":"Bipolar","SpontaneousFiringRate":"medium firing","Definition":"The main intrinsic neuron in the accessory olfactory bulb in the mammalian central nervous system.  It resembles the granule cell in the main olfactory bulb, including the lack of an axon.  Each cell gives rise to short central dendrites and a single long apical dendrite that traverses the granule cell layer, pierces the mitral cell body layer, and branches and terminates within the external plexiform layer among the lateral dendrites of mitral and tufted cells.  The dendrites receive synaptic input from mitral and tufted cell dendrites, and have synaptic outputs to those dendrites through reciprocal dendrodendritic synapses.  Shepherd, Chen, Greer.  Olfactory Bulb.  In The Synaptic Organization of the Brain, ed 5. New York: Oxford University Press, 2004.  The AOB granule cells are replaced in the adult through ongoing neurogenesis in the subventricular zone"}},{"Olfactory bulb (accessory) granule cell layer":{"Synonym":["granule cell layer of AOB"],"CurationStatus":"uncurated","SuperCategory":"Cell layer","Id":"nlx_152529","Is part of":"Olfactory bulb accessory nucleus"}},{"Olfactory bulb (accessory) mitral cell":{"DendriteLength":"Rat: 300-400 um","Located in":"Olfactory bulb (accessory) mitral cell body layer,","AxonLength":"Rat: 5-7 mm","BranchingMetrics":"multipolar","Synonym":["Mitral cell of the accessory olfactory bulb"],"CurationStatus":"uncurated","FiringPatterns":"Regular firing and bursting","SpontaneousFiringPatterns":"Regular firing and bursting","SynapticPhysiology":["Output synapses: GLU NMDA"],"CellSomaSize":"Medium soma","LocationOfAxonArborization":"amygdala cortico-medial nucleus","SpineDensityOnDendrites":"Smooth","DefiningCriteria":"Morphology;  Connectivity; Biochemical","LocationOfLocalAxonArborization":"olfactory bulb (accessory) external plexiform layer","Neurotransmitter":"Glutamate","SuperCategory":"Neuron","CellSomaShape":"Mitral","Species":["Mammal"],"DefiningCitation":["In: The Synaptic Organization of the Brain","ed 5.  New York: Oxford University Press"],"DendriteThickness":["Rat: Apical: 2-4 um maintained to the glomerular tuft; basal: 1-3 um at origin"],"AxonProjectionLaterality":"ipsilateral","DendriteLocation":"arborization within the glomerular neuropil and external plexiform layer","MolecularConstituents":["Tbr1","Tbr2"],"Comment":"Edited by GMS 8-10-9Output neuron of the accessory olfactory bulb","NeurotransmitterReceptors":"GABA","AxonDiameter":"1","OriginOfAxon":"soma and sometimes dendrite","Abbrev":"MC (AOB)","CellularSynapticTarget":["Intrinsic: granule cells in granule cell layer and external plexiform layer. Extrinsic: Pyramidal and short axon cells in the Nucleus of stria terminalis","Cortical amygdaloid nucleus","Medial amygdaloid nucleus","(medial anterior","medial posterior"],"SubcellularSynapticTarget":"Intrinsic: Dendrodendritic synapses on granule cell dendritic spines.  Extrinsic: Axon in olfactory cortical areas on apical dendritic spines of pyramidal cells and dendrites of superficial interneurons","NumberOfPrimaryDendrites":"1 (sometimes several)","Id":"nlx_cell_20090304","AxonMyelination":"myelinated","Polarity":"Apical (primary) and basal (lateral) dendrites","SpontaneousFiringRate":"medium firing","Definition":"A principal neuron of the mammalian accessory olfactory bulb.  Resembles the mitral cell of the main olfactory bulb, though somewhat smaller and less clearly differentiated.  The cell bodies are arranged in a thin layer between the granule cell layer and the external plexiform layer.  Each mitral cell is characterized by one (occasionally several) primary dendrite that traverses the external plexiform layer and terminates within an olfactory glomerulus in a tuft of branches where it receives input from the axons of sensory cells of the vomeronasal organ."}},{"Olfactory bulb (accessory) mitral cell body layer":{"CurationStatus":"uncurated","SuperCategory":"Cell layer","Id":"nlx_anat_1005002","Is part of":"Olfactory bulb accessory nucleus"}},{"Olfactory bulb (main) adult-born granule cell":{"Located in":"Olfactory bulb main granule cell layer,","BranchingMetrics":"apical/basal","DendriteLocation":"Dendrties arborize in the external plexiform layer where they contact the secondary/lateral dendrites of mitral cells via reciprocal dendrodendritic synapses.  The basal dendrite remains restricted to the granule cell layer.","CurationStatus":"graph position temporary","MolecularConstituents":"Parvalbumin","FiringPatterns":"bursting","Curator":"Maryann Martone,","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"Has role":"Intrinsic neuron role","SpontaneousFiringPatterns":"Bursting","OriginOfAxon":"no axon","Abbrev":"ABGC (MOB)","LocationOfAxonArborization":"Anaxonic - no axon","CellSomaSize":"Small soma","SpineDensityOnDendrites":"spiny high density","EditorialNote":"I'm wondering whether this is a subcategoy of olfactory bulb (main) granule cell or whether these represent a distinct class.  Needs review","SpineDensityOnDendritesPMID":"21602912","Neurotransmitter":"GABA","SuperCategory":"Neuron","Id":"nlx_144252","CellSomaShape":"Granule","SpontaneousFiringRate":"medium firing","Species":"Vertebrata","Definition":"The olfactory bulb adult-born granule cell is a cohort of cell that comprise a large fraction of the vertibrate olfactory bulb granule cell layer.  These neurons proliferate from from the subventricular zone, migrate through the rostral migratory stream and integrate into the olfactory bulb granule cell layer.  Upon arriving in the olfactory bulb granule cell layer they migrate radially outward and mature with morphologies similar to neonate olfactory bulb granule cells.  This process continues throughout the adult life of the vertibrate.  There is some decline in adult neurogenesis in aged vertebrates and the presence of the subventricular proliferative zone is controversial in humans","DefinitionPMID":"5361244"}},{"Olfactory bulb (main) Blanes cell":{"Located in":"Olfactory bulb main granule cell layer,","DendriteLength":"100-300 um","AxonLength":"100-300 um","BranchingMetrics":"stellate","Synonym":["Blanes Cell","Olfactory bulb (main) deep short axon cell"],"CurationStatus":"uncurated","FiringPatterns":"Regular spiking","CellSomaSize":"Large soma","LocationOfAxonArborization":"Olfactory bulb main granule cell layer,","SpineDensityOnDendrites":"spiny low density","Created":"2007-09-05","Neurotransmitter":"GABA","SuperCategory":"Neuron","HasRole":"Intrinsic neuron role","CellSomaShape":"Spherical","Species":"Rat","DefiningCitation":["Pressler","R. T. and Strowbridge","B. W. Blanes cells mediate persistent feedforward inhibition onto granule cells in the olfactory bulb.  Neuron 49 (6): 889-904"],"DendriteThickness":"1-3 um at origin","AxonProjectionLaterality":"ipsilateral","Comment":"Persistent firing (about 6.3 Hz) for up to 15-min after activation","Has role":"Intrinsic neuron role","OriginOfAxon":"soma","CellularSynapticTarget":"Olfactory bulb (main) granule cell","EditorialNote":"Preferred label:  Olfactory bulb main short axon cell deep","SubcellularSynapticTarget":"Dendritic spines of distal apical dendrites of granule cell","NumberOfPrimaryDendrites":"4-6","Id":"nifext_124","Polarity":"Multipolar","DefinitionPMID":"16543136","Definition":"Large, stellate-shaped short axon cell in the granule cell layer of the main olfactory bulb."}},{"Olfactory bulb (main) granule cell":{"Located in":["Olfactory bulb main granule cell layer"],"BranchingMetrics":"bipolar","AxonLength":"no axon","Synonym":["Granule cell of olfactory bulb"],"CurationStatus":"graph position temporary","FiringPatterns":"bursting","SpontaneousFiringPatterns":"Bursting","SynapticPhysiology":"Synaptic inhibition onto mitral and tufted cells","CellSomaSize":"Small soma","LocationOfAxonArborization":"This is an anaxonal cell; it lacks an axon","SpineDensityOnDendrites":"spiny high density","Created":"2007-09-05","DefiningCriteria":["Radial apical dendrite","spiny branches"],"Neurotransmitter":"GABA","SuperCategory":"Neuron","HasRole":"Self and lateral inhibition of mitral/tufted cells","CellSomaShape":"Granule","Species":["Rat","Mammal"],"DefiningCitation":["Shepherd","Chen & Greer.  Olfactory Bulb.  The Synaptic Organization of the Brain","ed 5. New York: Oxford University Press"],"DendriteThickness":"0.5-1 um","DendriteLocation":["Olfactory bulb main external plexiform layer"],"MolecularConstituents":"Parvalbumin","SenseLabId":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","Curator":["Maryann Martone"],"Has role":"Intrinsic neuron role","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"OriginOfAxon":"no axon","Abbrev":"GC (MOB)","CellularSynapticTarget":["Intrinsic: mitral cell"],"EditorialNote":"Changed \"Vertebrate\" to mammal, as the note indicated that \"generally applies to all mammals\". Moved the free text to notes.  Supplied regions for dendrites;  moved note on differential apical and basal dendrites to notes.","PassiveSubthresholdParameters":"R N ","ExampleImage":"Olfactory bulb (main) granule cell.gif,","SubcellularSynapticTarget":"Lateral dendrites of mitral and tufted cells","NumberOfPrimaryDendrites":"1","Id":"nifext_123","Polarity":"bipolar","SpontaneousFiringRate":"medium firing","Definition":"The main intrinsic neuron in the vertebrate olfactory bulb.  It lacks an axon.  Each cell gives rise to short central dendrites and a single long apical dendrite that traverses the granule cell layer, pierces the mitral cell body layer, and branches and terminates within the external plexiform layer among the lateral dendrites of mitral and tufted cells.  The dendrites receive synaptic input from mitral and tufted cell lateral dendrites, and have synaptic outputs on those dendrites through reciprocal dendrodendritic synapses.  Shepherd, Chen & Greer.  Olfactory Bulb.  The Synaptic Organization of the Brain, ed 5. New York: Oxford University Press, 2004."}},{"Olfactory bulb (main) internal plexiform layer":{"DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_63363","Is part of":"Olfactory bulb","Definition":"Lamina of the main olfactory bulb lying deep to the mitral cell layer and superficial to the granule cell layer. (in Shepherd, The Synaptic Organization of the Brain, ed 5, Fig. 5.2, page 167)"}},{"Olfactory bulb (main) internal plexiform layer outer part":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_152602","Is part of":"Olfactory bulb (main) internal plexiform layer"}},{"Olfactory bulb (main) mitral cell":{"Located in":"Olfactory bulb main mitral cell body layer","DendriteLength":"Rat: Apical trunk: 400-500 um; apical tuft: 70-150 um; basal: up to 1 mm","AxonLength":"several mm","Synonym":"Mitral neuron","CurationStatus":"graph position temporary","FiringPatterns":"Regular firing and bursting","SpontaneousFiringPatterns":"Regular firing and bursting","SynapticPhysiology":["Output synapses at both dendrodendritic and axodendritic synapses: GLU NMDA"],"CellSomaSize":"Large soma","LocationOfAxonArborization":"olfactory cortex","SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","DefiningCriteria":"Morphology;  Connectivity; Biochemical","LocationOfLocalAxonArborization":["Olfactory bulb main granule cell layer"],"Neurotransmitter":"Glutamate","SuperCategory":"Neuron","CellSomaShape":"Mitral","Species":"Mammal","DefiningCitation":["Shepherd","Chen and Greer (2004). Olfactory bulb.  In The Synaptic Organization of the Brain"],"DendriteThickness":["Rat: Apical trunk: 2-6; apical tuft: 1-2 um at origin; basal: 2-3 um at origin"],"AxonProjectionLaterality":"ipsilateral","MolecularConstituents":["T-box protein 21"],"LocationOfLocalDendriteArborization":"Olfactory bulb main external plexiform layer","SenseLabId":"267","Has role":"Principal neuron role","NeurotransmitterReceptors":["GABA_Receptor","AMPA-type glutamate-gated cationic channel","NMDA","GABA A-gated anionic channel"],"AxonDiameter":"Rat: 1 um","OriginOfAxon":"soma and sometimes dendrite","Abbrev":"MC","CellularSynapticTarget":["Olfactory bulb (main) granule cell","Intrinsic: granule cells in granule cell layer and external plexiform layer; possibly Blanes cells in granule cell layer; Extrinsic"],"EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","SpikingFeatures":"same","ExampleImage":"Olfactory bulb (main) mitral cell.gif,","SubcellularSynapticTarget":"Intrinsic: Dendrodendritic synapses on granule cell dendritic spines.  Extrinsic: Axon in olfactory cortical areas on apical dendritic spines of pyramidal cells and dendrites of superficial interneurons","NumberOfPrimaryDendrites":"1 (applies to most mammals)","Id":"nifext_120","AxonMyelination":"myelinated","Polarity":"Apical (primary) and basal (lateral) dendrites","SpontaneousFiringRate":"medium firing","Definition":"Principal neuron located in the olfactory bulb in the mammalian central nervous system. The cell bodies are arranged in a thin layer between the granule cell layer and the external plexiform layer.  Each mitral cell is usually characterized in the mammal by a single primary dendrite that traverses the external plexiform layer and terminates within an olfactory glomerulus in a tuft of branches which receives input from the axons of olfactory receptor neurons.  Axons of the mitral cells project to a number of areas in the brain, including the piriform cortex, entorhinal cortex, olfactory tubercle, and amygdala."}},{"Olfactory bulb (main) periglomerular cell":{"DendriteLength":"Rat: 50-70 um","Located in":"Olfactory bulb main glomerular layer","AxonLength":"Rat: up to 500 um","BranchingMetrics":"unipolar","Synonym":["Periglomerular neuron"],"CurationStatus":"pending final vetting","FiringPatterns":"bursting","SpontaneousFiringPatterns":"Bursting","SynapticPhysiology":"Postulated to mediate lateral inhibition at the glomerular level; also mediate gain control","CellSomaSize":"Small soma","SpineDensityOnDendrites":"spiny high density","DefiningCriteria":"Morphology;  Connectivity; Biochemical","LocationOfLocalAxonArborization":"Within extraglomerular regions","Neurotransmitter":["GABA"],"SuperCategory":"Neuron","CellSomaShape":"Spherical","Species":"Mammal","DefiningCitation":["Shepherd","Chen","Greer.  2004. Olfactory bulb. In The synaptic organization of the brain"],"DendriteThickness":"Rat: 0.5-2 um at origin","AxonProjectionLaterality":"ipsilateral","MolecularConstituents":"Calbindin 28K,","Comment":["Suggest that the name of this","here and in the neurolex wiki list","should be changed to \"olfactory bulb (main) periglomerular cell\"","to be consistent with the other olfactory bulb cells.Neurotransmitter: may be in separate cell populations","GABA","Or colocalized","Dopamine"],"Has role":"Intrinsic neuron role","AxonDiameter":"Rat: 1 um","OriginOfAxon":"soma","Abbrev":"PG cell: PGC","CellularSynapticTarget":"Other PG cells; initial trunks of mitral/tufted cell apical dendrites","EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","ExampleImage":"Olfactory bulb (main) periglomerular cell.gif,","SubcellularSynapticTarget":"Cell bodies of other PG cells; initial trunks of primary apical dendrites of mitral/tufted cells","NumberOfPrimaryDendrites":"1","Polarity":"single dendritic trunk","Id":"nlx_cell_091202","AxonMyelination":"unmyelinated","SpontaneousFiringRate":"Rapid firing","Definition":"Small intrinsic neuron in the glomerular layer of the olfactory bulb, with cell bodies surrounding the olfactory glomerulus.  The cell body is 6-8 um in diameter, from which arises a short bushy dendrite that arborizes within a glomerulus, where it receives synaptic input from olfactory receptor cell axon terminals, and engages in dendrodendritic interactions with mitral/tufted cell dendrites.  Occasionally, bitufted PG cells connected to two glomeruli are seen.  The axon distributes laterally within the extraglomerular region, extending as far as 5-10 glomeruli away.  Some PG cells appear to lack axons.  Subtypes may be identified based on their biochemical constituents."}},{"Olfactory bulb (main) tufted cell (middle)":{"Located in":["Olfactory bulb"],"BranchingMetrics":"apical/basal","AxonLength":"500 -5000 um?","Synonym":"Olfactory bulb (main) tufted cell (middle)","CurationStatus":"graph position temporary","FiringPatterns":"Regular firing and bursting","SpontaneousFiringPatterns":"Regular firing and bursting","LocationOfAxonArborization":"Olfactory cortex,","SpineDensityOnDendrites":"Smooth","DefiningCriteria":["Morphology; connetivity; biochemical.primary dendrite ending in tuft in a glomerulus"],"LocationOfLocalAxonArborization":"Olfactory bulb (main) internal plexiform layer","Neurotransmitter":"Glutamate","SuperCategory":"Neuron","CellSomaShape":"Spherical","Species":"Mammal,","DendriteThickness":"Apical: 2-3 um maintained to the glomerulus; Basal: 1-3 um at origin from cell body.","AxonProjectionLaterality":"ipsilateral","Comment":["Properties are primarily from rat but expert indicated they apply generally to all mammals"],"Curator":"Maryann Martone,","Has role":"Principal neuron role","NeurotransmitterReceptors":["Glutamate receptor"],"OriginOfAxon":"soma and sometimes dendrite","Abbrev":"TC","CellularSynapticTarget":"Intrinsic: unknown; Extrinsic: olfactory cortex pyramidal cell?","EditorialNote":"Would be nice to get the types of glutamate and GABA receptors","SubcellularSynapticTarget":"Dendritic spines of distal apical dendrites of olfactory cortex pyramidal cell","NumberOfPrimaryDendrites":["1-2"],"AxonMyelination":"myelinated","Id":"nifext_121","Polarity":"Apical and basal dendrites","SpontaneousFiringRate":"medium firing","Definition":"Principal neuron located in the outer third of the external plexiform layer of the olfactory bulb in the mammalian central nervous system. Each tufted cell is characterized by usually a single short primary dendrite that traverses the outer external plexiform layer and terminates within an olfactory glomerulus in a tuft of branches, where it receives the input from olfactory receptor neuron axon terminals. Differentiated from external tufted cells.  Axons of the tufted cells transfer information to a number of areas in the brain, including the piriform cortex, entorhinal cortex, olfactory tubercle, and amygdala. Shepherd, Shen, Greer.  Olfactory bulb.  In The synaptic organization of the brain, ed 5 New York: Oxford University Press, 2004."}},{"Olfactory bulb accessory nucleus":{"AfferentProjectionsPMID":"20607541","Synonym":"Accessory olfactory bulb","CurationStatus":"uncurated","EfferentProjections":["Bed nucleus of stria terminalis"],"SuperCategory":"Nucleus of CNS","Id":"nlx_53","Is part of":"Olfactory bulb","Species":"Rodent,","EfferentProjectionsPMID":"20607541","AfferentProjections":["Vomeronasal nerve","Vomeronasal organ"]}},{"Olfactory bulb main external plexiform layer":{"DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Is_part_of":"Plexiform layer","Id":"nlx_96","Is part of":"Olfactory bulb","Species":"Mammal,","Abbrev":"EPL","Definition":"Cytoarchitectural part of the olfactory bulb, lying superior to the mitral cell layer and inferior to the glomerular layer.  The EPL is mostly neuropil composed almost entirely of mitral and tulfted cell dendrites and granule cell dendrites and their synaptic inputs."}},{"Olfactory bulb main glomerular layer":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_anat_1005011","Is part of":"Olfactory bulb","Abbrev":"Gl","Definition":"The glomerular layer of the main olfactory bulb, lying deep to the olfactory nerve layer.  It contains the glomeruli, neuropil rich spheroid structures surrounded by a distinctive shell of small neuros and glial cells (Paxinos, the Rat Nervous System, 2nd ed., Academic Press, 1995)."}},{"Olfactory bulb main granule cell layer":{"Synonym":"Olfactory bulb granule cell layer","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_407","Is part of":"Olfactory bulb","Abbrev":"GrO"}},{"Olfactory bulb main mitral cell body layer":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_anat_100201","Is part of":"Olfactory bulb","Abbrev":"Mi"}},{"Olfactory bulb main of rodent":{"CurationStatus":"uncurated","SuperCategory":"Olfactory bulb","Id":"nlx_anat_1005019","Is part of":"Telencephalon of rodent"}},{"Olfactory bulb main olfactory nerve layer":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_anat_1005010","Is part of":"Olfactory bulb","Definition":"Superficial layer of the main olfactory bulb containing axons from the olfactory nerve and glial cells"}},{"Olfactory bulb main tufted cell external":{"Located in":"Olfactory bulb main glomerular layer,","AxonProjectionLaterality":"ipsilateral","BranchingMetrics":"unipolar","Synonym":["external tufted cell","olfactory bulb external tufted cell"],"CurationStatus":"uncurated","FiringPatterns":"Regular firing and bursting","NeurotransmitterReceptors":"Glutamate-gated cationic channel,","Has role":"Intrinsic neuron role","SpontaneousFiringPatterns":"Regular firing and bursting","OriginOfAxon":"soma and sometimes dendrite","LocationOfAxonArborization":"Olfactory bulb main glomerular layer,","SpineDensityOnDendrites":"Smooth","Neurotransmitter":"Cholecystokinin,","SuperCategory":"Neuron","Id":"nlx_82555","AxonMyelination":"unmyelinated","CellSomaShape":"Spherical","SpontaneousFiringRate":"medium firing","Species":"Vertebrata"}},{"Olfactory bulb of ABA 2009":{"PartiallyOverlapsWith":"Olfactory bulb","CurationStatus":"uncurated","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153163","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Cortical plate of ABA 2009","Organism":"mouse","Species":"Mouse"}},{"Olfactory bulb of WHS11":{"AtlasImage":"Olfactory bulb of WHS11.png,","PartiallyOverlapsWith":"Olfactory bulb","CurationStatus":"uncurated","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143703","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Telencephalon of WHS11","Species":"Mouse","Definition":"Delineation of olfactory bulb in Waxholm atlas as seen in T2* weighted volume.  Excludes portion of anterior commissure lying in the olfactory bulb.  As seen in sagittal section: apparent line at rostral cortex and tissue pattern differences"}},{"Olfactory cortex":{"Created":"2007-08-28","CurationStatus":"uncurated","PartiallyOverlapsWith":["prepyriform area","olfactory tubercle","olfactory entorhinal cortex"],"Umlscui":"C0162434","Comment":["Some authors have considered the anterior olfactory nucleus to be part of the olfactory cortex.  We have not added it here","as currently it is considered to be a nucleus"],"SuperCategory":"Regional part of brain","Id":"birnlex_2707","Definition":"Aggregate brain region defined as those areas of cerebral cortex receiving direct synaptic input from the olfactory bulb (Price, 1973).  The most recognized structure is the piriform cortex (prepyriform area), but other areas are often included, e.g., the olfactory tubercle."}},{"Olfactory cortex deep pyramidal cell":{"Located in":["piriform cortex layer 3"],"DendriteLength":"Rat: basal dendrites: 100-200 um; apical dendrite: 400-500 um","AxonLength":"Rat: several millimeters (association fibers extending to the olfactory bulb)","Synonym":["Small pyramidal neuron","Olfactory cortex pyramidal neuron"],"CurationStatus":"graph position temporary","FiringPatterns":"Regular firing and bursting","SpontaneousFiringPatterns":"Regular firing","CellSomaSize":"Large soma","LocationOfAxonArborization":["Olfactory bulb (main) granule cell","basolateral amygdala","lateral entorhinal cortex","orbitofrontal cortex"],"SpineDensityOnDendrites":"spiny high density","Created":"2007-09-05","DefiningCriteria":["pyramidal shaped soma in layer III"],"LocationOfLocalAxonArborization":["Olfactory cortex pyramidal neuron"],"Neurotransmitter":"Glutamate","SuperCategory":"Neuron","CellSomaShape":"Pyramidal","Species":"Vertebrata","DefiningCitation":["Neville and Haberly","The Synaptic Organization of the Brain"],"DendriteThickness":"Rat: basal: 1-2 um; apical: 3-6 um","AxonProjectionLaterality":"bilateral","Is_part_of":"olfactory cortex","SenseLabId":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","Curator":"Maryann Martone","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"OriginOfAxon":"soma","AxonDiameter":"2-3 um (thinly myelinated)","Abbrev":"PC","CellularSynapticTarget":"Local: inhibitory intrinsic neurons; association fibers: pyramidal neurons; centrifugal: granule cells","EditorialNote":"Changed olfactory cortex layer 3 to piriform cortex layer 3.  Is this OK?  Note that \"Location of axon arborization\" has been filled in with cell types and not brain regions.  Was this what was intended?  I think this should not be used for recording synaptic relationships.","LocatedInPMID":"21307252","ExampleImage":"Olfactory cortex pyramidal cell.gif,","SubcellularSynapticTarget":"Local: intrinsic cell dendrites; association: spines of apical dendrites of pyramidal neurons; centrifugal fibers: granule cell dendrites","NumberOfPrimaryDendrites":"5-7 basal dendrites; single apical dendrite","Id":"nlx_153868","Polarity":"pyramidal","Definition":"A cell with the classic pyramidal-shaped cell body and apical and basal dendritic trees, with cell body in layer III of the piriform (olfactory) cortex.  Its axon arises from the deeper aspect of the cell body and gives rise to collaterals which terminate within the layer III on local intrinsic cells, and also recur to layer III and II where they form association fibers that connect to the apical dendrites of pyramidal neurons and continue to become centrifugal fibers to the olfactory bulb."}},{"Olfactory cortex horizontal cell":{"Located in":["Piriform cortex layer 1"],"AxonProjectionLaterality":"ipsilateral","Synonym":["Horizontal cell (olfactory)"],"CurationStatus":"uncurated","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"Has role":"Intrinsic neuron role","OriginOfAxon":"soma and sometimes dendrite","Abbrev":"H","CellSomaSize":"Medium soma","SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","Neurotransmitter":"GABA","LocationOfLocalAxonArborization":"OLFACTORY CORTEX LAYER II","LocatedInPMID":"17714095","SuperCategory":"Neuron","AxonMyelination":"unmyelinated","Id":"nifext_118","CellSomaShape":"Oval","Species":"Vertebrata","Definition":"Medium-size interneuron in the superficial layer I of the olfactory cortex, with dendrites oriented parallel to the surface, and axon descending to layer II.  They presumably receive excitatory input from the LOT fibers and are inhibitory in layer II."}},{"Olfactory cortex layer 1":{"Synonym":["Olfactory cortex plexiform layer","layer 1 of olfactory cortex"],"CurationStatus":"uncurated{{PONS brain region","PartiallyOverlapsWith":"Piriform cortex layer 1","SuperCategory":"Cell layer","Id":"nlx_152609","Is part of":"Olfactory cortex","DefiningCitation":["Shepherd"],"Definition":"Surface layer of the olfactory cortex that contains dendrites, fiber systems and a small number of neurons.  It has been divided into a superficial part and a deep part."}},{"Olfactory cortex layer 1a":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Piriform cortex layer 1a","SuperCategory":"Cell layer","Id":"nlx_152612","Is part of":"Olfactory cortex layer 1","Definition":"Most superficial part of layer 1 of the olfactory cortex"}},{"Olfactory cortex layer 2":{"CytoDefiningCriteria":"Nissl stain","Synonym":"layer 2 of olfactory cortex","DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated{{PONS brain region","PartiallyOverlapsWith":"Piriform cortex layer 2","SuperCategory":"Cell layer","Id":"nlx_152610","Is part of":"Olfactory cortex","Definition":"Middle layer of olfactory cortex lying deep to layer 1 and superficial to layer 3, characterized by a compact layer of cell bodies.  It can be divided into a superficial part and a deep part."}},{"Olfactory cortex layer 3":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Piriform cortex layer 3","SuperCategory":"Cell layer","Id":"nlx_152611","Is part of":"Olfactory cortex","Definition":"Deepest layer of olfactory cortex"}},{"Olfactory cortex multipolar cell":{"Located in":["Olfactory cortex"],"AxonProjectionLaterality":"ipsilateral","Synonym":["Olfactory cortex large multipolar neuron"],"CurationStatus":"uncurated","OriginOfAxon":"soma","CellSomaSize":"Large soma","LocationOfAxonArborization":["Endopiriform nucleus"],"SpineDensityOnDendrites":"spiny low density","Neurotransmitter":"Glutamate","LocationOfLocalAxonArborization":"olfactory cortex layer III","SuperCategory":"Neuron","Polarity":"Multipolar","Id":"nlx_cell_091001","Species":"Vertebrata","DefiningCitation":["Neville and Haberly","Olfactory Bulb","in Shepherd"],"Definition":"A type of intrinsic neuron found in the deep part of layer III of the olfactory cortex and the subjacent endopiriform nucleus.   Several subpopulations of deep multipolar cells may be distinguished based on morphology and physiology.  The one described here has pyramidal cell-like spiny dendrites."}},{"Olfactory cortex semilunar cell":{"Located in":["Olfactory cortex layer 2a","Primary olfactory cortex"],"AxonProjectionLaterality":"ipsilateral","BranchingMetrics":"multipolar","Synonym":["semilunar cell"],"CurationStatus":"uncurated","MolecularConstituents":"Doublecortin","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"OriginOfAxon":"soma","LocationOfAxonArborization":"Other cortical areas","CellSomaSize":"Medium soma","SpineDensityOnDendrites":"spiny high density","MolecularConstituentsPMID":"18245040","Neurotransmitter":"Glutamate,","LocationOfLocalAxonArborization":["Olfactory cortex layer 2"],"LocatedInPMID":"21307252","SuperCategory":"Neuron","Id":"nlx_cell_091005","CellSomaShape":"Fusiform","Species":"Vertebrata","Definition":"Projection neuron found in the superficial border of layer II (IIa) of piriform cortex similar in characteristics to a pyramidal cell and also resembling the granule cell of the dentate gyrus.  It has an apical but no basilar dendrites.  They project to other cortical areas but, in contrast to pyramidal cells, they do not project back to the olfactory bulb."}},{"Olfactory cortex small globular cell":{"LocationOfAxonArborization":"Olfactory cortex layer 1","Located in":"Olfactory cortex,","Neurotransmitter":"GABA,","CurationStatus":"uncurated","SuperCategory":"Neuron","Polarity":"Multipolar","Id":"nlx_cell_091002","Has role":"Intrinsic neuron role","Species":"Vertebrata","DefiningCitation":["Neville and Haberly","Olfactory Cortex","in Shepherd"],"Definition":"A small stellate cell with globular somata found in all layers of the piriform cortex."}},{"Olfactory cortex superficial pyramidal cell":{"DendriteLength":"Rat: basal dendrites: 100-200 um; apical dendrite: 400-500 um","Located in":["Olfactory cortex layer IIb and superficial III","olfactory cortex"],"AxonProjectionLateralityPMID":"632378","AxonLength":"Rat: several millimeters (association fibers extending to the olfactory bulb)","BranchingMetrics":"apical/basal","Synonym":["Small pyramidal neuron"],"CurationStatus":"uncurated","FiringPatterns":"Regular firing and bursting","SpontaneousFiringPatterns":"Regular firing","CellSomaSize":"Large soma","LocationOfAxonArborization":"Olfactory bulb (main) granule cell","SpineDensityOnDendrites":"spiny high density","Created":"2007-09-05","DefiningCriteria":["pyramidal shaped soma in layer III"],"LocationOfLocalAxonArborization":["Olfactory cortex pyramidal neuron"],"Neurotransmitter":"Glutamate","SuperCategory":"Neuron","CellSomaShape":"Pyramidal","Species":"Vertebrata","DefiningCitation":["Neville and Haberly","The Synaptic Organization of the Brain"],"DendriteThickness":"Rat: basal: 1-2 um; apical: 3-6 um","AxonProjectionLaterality":"bilateral","Comment":"I notice that the location of axonal arborization field is filled with neuron types;  I believe these should be brain regions.","Is_part_of":"olfactory cortex","Has role":"Principal neuron role","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"AxonDiameter":"2-3 um (thinly myelinated)","OriginOfAxon":"soma","Abbrev":"PC","CellularSynapticTarget":"Local: inhibitory intrinsic neurons; association fibers: pyramidal neurons; centrifugal: granule cells","EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","LocatedInPMID":"21307252","ExampleImage":"Olfactory cortex pyramidal cell.gif,","SubcellularSynapticTarget":"Local: intrinsic cell dendrites; association: spines of apical dendrites of pyramidal neurons; centrifugal fibers: granule cell dendrites","NumberOfPrimaryDendrites":"5-7 basal dendrites; single apical dendrite","Id":"nlx_153867","Polarity":"pyramidal","Definition":"A cell with the classic pyramidal-shaped cell body and apical and basal dendritic trees, with cell body in layer IIb and superficial layer III of the piriform (olfactory) cortex.  Its axon arises from the deeper aspect of the cell body and gives rise to collaterals which terminate within the layer III on local intrinsic cells, and also recur to layer III, II and Ib where they form association fibers that connect to the apical dendrites of pyramidal neurons and continue to become centrifugal fibers to the olfactory bulb."}},{"Olfactory ensheathing cell":{"Created":"2008-10-21","CurationStatus":"uncurated","Comment":"This definition needs work","SuperCategory":"Glial Cell","Id":"nlx_cell_20081207","Definition":"Type of glial cell found in the peripheral olfactory nerve with properties of both astrocytes and Schwann cells"}},{"Olfactory entorhinal cortex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","CurationStatus":"uncurated","NeuronamesID":"436","SuperCategory":"Regional part of brain","Id":"birnlex_2705","Is part of":["Entorhinal cortex"],"Abbrev":"EOl","Definition":"A part of the entorhinal area defined on the basis of connectivity. It is the rostral portion, which receives a projection from the olfactory bulb (Price-90)-Adapted from Brain Info"}},{"Olfactory epithelium main sensory cell":{"Located in":"middle layer of pseudostratified olfactory epithelium,","AxonLength":"1-10 mm","BranchingMetrics":"bipolar","Synonym":["olfactory receptor cell"],"CurationStatus":"uncurated","FiringPatterns":"Regular firing and bursting","SpontaneousFiringPatterns":"Regular firing and bursting","CellSomaSize":"Small soma","LocationOfAxonArborization":"olfactory glomerulus","SpineDensityOnDendrites":"Smooth","RelatedTo":"Olfactory system","Created":"2007-09-05","DefiningCriteria":"bipolar cell with terminal dendritic knob giving rise to several cilia","LocationOfLocalAxonArborization":"none","Neurotransmitter":"Glutamate,","SuperCategory":"Neuron","HasRole":"sensory transduction","CellSomaShape":"Spherical","Species":"Vertebrata","DefiningCitation":["Shepherd","Chen & Greer.  Olfactory Bulb"],"DendriteThickness":"2-4 um","AxonProjectionLaterality":"ipsilateral","MolecularConstituents":"Olfactory receptors expressed in the cilia","Comment":"Sensory neuron stimulated by odor moleculesGMS 8-10-09","NeurotransmitterReceptors":"GABA-gated anionic channel,","OriginOfAxon":"soma","Abbrev":["ORN"],"CellularSynapticTarget":["Olfactory bulb (main) mitral cell","Olfactory bulb (main) tufted cell (middle)",""],"EditorialNote":"http://senselab.med.yale.edu/neurondb/NeuronProp.aspx?id","ExampleImage":"Olfactory epithelium (main) sensory cell.gif,","SubcellularSynapticTarget":"dendritic tufts","NumberOfPrimaryDendrites":"1","Polarity":"Bipolar","Id":"nifext_116","AxonMyelination":"unmyelinated","SpontaneousFiringRate":"slow firing","Definition":"This is the sensory neuron of the main olfactory epithelium in the nasal cavity that transduces odor molecules into receptor potentials, which give rise to the impulse trains that are sent further in the olfactory system..  It is a small bipolar cell in the pseudostratified olfactory epithelium, with cell body 8-15 um diameter giving rise to a single dendrite ending in a knob at the epithelial surface, from which arise several sensory cilia.  A single unmyelinated axon descends through the basal lamina and turns to project to the glomeruli of the olfactory bulb.  Shepherd, Chen & Greer.  Olfactory Bulb,  In The Synaptic Organization of the Brain. 5th ed. 2004."}},{"Olfactory epithelium main supporting cell":{"Located in":"Olfactory epithelium middle layer,","AxonProjectionLaterality":"ipsilateral","BranchingMetrics":"bipolar","Synonym":["sustentacular cell","supporting cell"],"CurationStatus":"uncurated","MolecularConstituents":"Olfactory receptors","FiringPatterns":"Regular firing and bursting","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel"],"Has role":"Intrinsic neuron role","SpontaneousFiringPatterns":"Regular firing and bursting","OriginOfAxon":"soma","LocationOfAxonArborization":"Olfactory bulb main glomerular layer,","CellSomaSize":"Medium soma","SpineDensityOnDendrites":"Smooth","Created":"2007-09-05","Neurotransmitter":"Glutamate,","SuperCategory":"Glial-like cell","Id":"nifext_119","CellSomaShape":"Fusiform","SpontaneousFiringRate":"slow firing","Species":"Vertebrata","Definition":"So called supporting or sustentacular cell, that spans the depth of the olfactory epithelium, with cell bodies in an approximate layer near the surface, and microvilli extending into the overlying mucus.  The cytoplasm contains large dense granules that are released into the mucus.  Their electrophysiological properties are similar to those of glial cells (high membrane potential, low input resistance).  They are coupled with each other through gap junctions."}},{"Olfactory Esthesioneuroblastoma":{"Synonym":["Paranasal Sinus-Nasal Cavity Esthesioneuroblastoma","Aesthesioneuroblastoma","Olfactory Neuroblastoma"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Neuroblastoma","Id":"birnlex_12632","DefiningCitation":["Holland et al.","Cancer Medicine","3rd ed"],"Definition":"A malignant olfactory neuroblastoma arising from the olfactory epithelium of the superior nasal cavity and cribriform plate. It is uncommon (3% of nasal tumors) and rarely is associated with the production of excess hormones (e.g., SIADH, Cushing Syndrome). It has a high propensity for multiple local recurrences and bony metastases (MeSH)."}},{"Olfactory modality":{"CurationStatus":"uncurated","SuperCategory":"Stimulus modality","Curator":"Jessica Turner","Id":"COGPO:00130","Definition":"The olfactory modality is the sensory modality pertaining to the sense of smell. It usually but not always arises from the stimulation of the olfactory system by chemicals."}},{"Olfactory monitor-discrimination":{"Created":"4/27/2011 14:10","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00761","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Olfactory_monitor-discrimination","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145983","Definition":"Subjects are presented with odors and are instructed to smell them passively or to discriminate according to some feature (pleasant-unpleasant, strong-weak, same-different, etc.)."}},{"Olfactory peduncle":{"DefiningCriteria":"topography","CurationStatus":"uncurated","NeuronamesID":"283","SuperCategory":"Regional part of brain","Id":"nlx_152599","Is part of":"Telencephalon","DefinitionPMID":"21618219","Definition":"The region connecting the olfactory bulb with the basal forebrain"}},{"Olfactory receptor neuron (FBbt Term)":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"ORN","SuperCategory":"Chemosensory neuron","Id":"nlx_147909","Is part of":"Peripheral nervous system (FBbt Term)","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00005926","Definition":"Any neuron (FBbt_00005106) that functions in (some) detection of chemical stimulus involved in sensory perception of smell (GO:0050911)."}},{"Olfactory receptor neuron of dorsal organ":{"Has_role":"Fly_Anatomy_Ontology","Created":"2008-09-08T12:42:14Z","Synonym":"DO ORN","Contributor":"david","SomaLocation":"dorsal organ ganglion","SuperCategory":"Embryonic / larval olfactory receptor neuron","Has_synaptic_terminal_in":"embryonic / larval antennal lobe glomerulus","Id":"nlx_148006","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007190","Fasciculates_with":"embryonic / larval antennal nerve","Definition":"Odorant receptor expressing bipolar neuron whose dendrite innervates the central dome sensillum of the dorsal organ, whose cell body is part of the dorsal organ ganglion and whose axon is carried by the antennal nerve to innervate a larval antennal lobe glomerulus."}},{"Olfactory sensation":{"Created":"2007-08-22","Synonym":["Olfactory perception"],"CurationStatus":"uncurated","Umlscui":"C0037361","SuperCategory":"Chemical sensation","Id":"birnlex_1844","Definition":"Smell; the faculty of smell, the sensation that results when olfactory receptors in the nose are stimulated by particular chemicals in gaseous form. (NCI) * The sensation or perception of scents or odors. (MSH) * The series of events required for an organism to receive an olfactory stimulus, convert it to a molecular signal, and recognize and characterize the signal. Olfaction involves the detection of chemical composition of an organism's ambient medium by chemoreceptors. (GO:ai, http://www.onelook.com/) (GO) * sensation or perception of scents or odors; sense of smell. (from UMLS)"}},{"Olfactory stimulus transduction":{"Synonym":["sensory detection of olfactory stimulus","smell stimulus transduction"],"Created":"2008-03-13","CurationStatus":"graph_position_temporary","Umlscui":"C1327496","SuperCategory":"Chemical stimulus transduction","Id":"birnlex_15007","Definition":"The series of events in which a sensory chemical stimulus is received and converted into a molecular signal. (GO:ai) (GO)"}},{"Olfactory Structures of CIVM postnatal rat brain atlas":{"AtlasImage":["olfactory p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151531","Is part of":"Pallium of CIVM postnatal rat brain atlas","Definition":"The olfactory structures (olfactory bulbs, olfactory tubercles, and piriform cortex) can be segmented in coronal T2-weighted or diffusion-weighted images. Rostrally, the olfactory bulbs are free-floating and therefore easily segmented. Further caudal, as the isocortex appears dorsally, the border between the two is defined by the thin rostral extent of the lateral olfactory tract, which is dark on T2 MRI. A horizontal line connecting the two rhinal fissures that is slightly convex towards the dorsal surface of brain approximates the dividing line between these two regions of cortex as far caudal as the mamillary bodies. Caudal to the mamillary bodies the dividing line between isocortex and piriform cortex can be defined based on the dorsal extent of layer 2 of the piriform cortex, which appears quite dark (high diffusivity) of diffusion-weighted images. At roughly the caudal extent of the amygdala (the posteromedial cortical amygdaloid nucleus) the piriform cortex disappears abruptly giving way to the entorhinal cortex, which we have included in the isocortex."}},{"Olfactory sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":["Sulcus olfactorius"],"CurationStatus":"uncurated","NeuronamesID":"78","Umlscui":["C1281082"],"SuperCategory":"Sulcus","Id":"birnlex_1655","Is part of":"Frontal lobe","Abbrev":"olfs"}},{"Olfactory system":{"RelatedTo":"Olfactory system function","Synonym":["Chemosensation"],"CurationStatus":"uncurated","SuperCategory":"Sensory system","Id":"nlx_anat_090806","Definition":"The sensory system used for olfaction, or the sense of smell. Most mammals and reptiles have two distinct parts to their olfactory system: a main olfactory system and an accessory olfactory system. The main olfactory system detects volatile, airborne substances, while the accessory olfactory system senses fluid-phase stimuli. Behavioral evidence indicates that most often, the stimuli detected by the accessory olfactory system are pheromones.The olfactory system is often spoken of along with the gustatory system as the chemosensory senses because both transduce chemical signals into perception. - definition adapted from Wikipedia"}},{"Olfactory system function":{"RelatedTo":"Olfactory system","CurationStatus":"uncurated","SuperCategory":"Sensory system function","Id":"nlx_152116","Definition":"The olfactory system in most vertebrate species consists of two distinct subsystems: the main olfactory system and the accessory olfactory system. The main olfactory system is generally considered to be important in the detection and processing of airborne chemicals whereas the accessory olfactory system is mainly used in the detection and processing of water-soluble chemicals (http://www.springerreference.com/docs/html/chapterdbid/332953.html)."}},{"Olfactory trigone":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2008-03-02","Synonym":"Trigonum olfactorium","CurationStatus":"uncurated","NeuronamesID":"15","Umlscui":"C0228279","SuperCategory":"Regional part of brain","Id":"birnlex_4042","Is part of":"Telencephalon","Abbrev":"olt","Definition":"A small triangular area in front of the anterior perforated substance. Its apex, directed forward, occupies the posterior part of the olfactory sulcus, and is brought into view by throwing back the olfactory tract (adapted from Wikipedia)"}},{"Olfactory tubercle":{"Synonym":["anterior perforated space","anterior perforated substance"],"CurationStatus":"graph position temporary","NeuronamesID":"282","Comment":"Brain Info has the olfactory tubercle synonymous with the anterior perforated substance.  I always considered that a surface feature rather than a nucleus (MM)","SuperCategory":"Regional part of brain","Curator":"Maryann Martone,","Id":"nlx_143578","Is part of":["Telencephalon","Olfactory system","Ventral striatum"],"Species":"Mammal","AfferentProjections":["Olfactory bulb"],"Definition":"Region in the ventral telencephalon, prominent in rodents, but present in all mammals, consisting of a laminated cortical part and the cap/hilus region.  It is traditionally viewed as part of the olfactory cortex but recognized by some as having a striatal character.  According to many authors, the structure of the OT transitions from cortical like to striatal like along the lateral medial axis.   (Maryann Martone)"}},{"Olfactory tubercle cap hilus region of Meyer et al 1989":{"CytoDefiningCriteria":["Part of olfactory tubercle chacterized by aggregations of small pyramidal neurons","dwarf cells and islands of granule cells and associated medium sized to large neurons"],"Synonym":["Olfactory tubercle cap/hilus"],"DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated","PartiallyOverlapsWith":"Olfactory tubercle","SuperCategory":"Parcellation scheme region","Id":"nlx_144075","ParcellationScheme":"Meyer et al 1989","Species":["Cat","Rat","Rabbit","Hedgehog","Monkey","Dolphin","Human"],"Definition":"Part of olfactory tubercle chacterized by aggregations of small pyramidal neurons, dwarf cells and islands of granule cells and associated medium sized to large neurons, all in varying proportions depending on location and species (Meyer et al., 1989)"}},{"Olfactory tubercle cortical region of Meyer et al 1989":{"Synonym":"olfactory tubercle cortical region","CurationStatus":"uncurated","Pages":"405-428","JournalVolume":"284","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/2474005","Authors":["Meyer G","Gonzalez-Hernandez T","Carrillo-Padilla F"],"Title":["Aggregations of granule cells in the basal forebrain (islands of Calleja): Golgi and cytoarchitectonic study in different mammals"],"PMID":"2474005","DefiningCriteria":"cyto-architecture","PartiallyOverlapsWith":"olfactory tubercle","NeuronamesID":"mammal","PublicationDate":"1989","SuperCategory":"Parcellation scheme parcel","PublicationName":"Journal of Comparative Neurology","Id":"nlx_144082","JournalNumber":"3","ParcellationScheme":"Meyer et al 1989","Is part of":"Olfactory tubercle","Species":"Mammal","DefiningCitation":"Meyer et al 1989","Definition":"Part of olfactory tubercle characterized by a laminar appearance with three layers (molecular, pyramidal and polymorph).","DefinitionPMID":"2474005"}},{"Olfactory tubercle Islets of Calleja DA cell":{"Located in":"Olfactory tubercle","Created":"2007-09-05","EditorialNote":"I can't find any evidence that this cell type exists; there are dopamine receptor expressing cells in this region, but I haven't found any reference to a dopamine containing cell.","Synonym":["Islands of Calleja dopamine cell","Islets of Calleja dopamine cell"],"CurationStatus":"uncurated","Neurotransmitter":"Dopamine","SuperCategory":"Neuron","Id":"nifext_155","Species":"Vertebrata"}},{"Olfactory tubercle Islets of Calleja dwarf neuron":{"Located in":"Islands of Calleja,","AxonProjectionLaterality":"ipsilateral","BranchingMetrics":"multipolar","CurationStatus":"uncurated","NeurotransmitterReceptors":["Dopamine D3R"],"Has role":"Intrinsic neuron role","OriginOfAxon":"soma and sometimes dendrite","CellSomaSize":"Small soma","SpineDensityOnDendrites":"spiny low density","LocationOfLocalAxonArborization":"Olfactory tubercle","SuperCategory":"Neuron","AxonMyelination":"unmyelinated","Id":"nlx_96825","CellSomaShape":"Spherical","Species":"Mammal,","DefiningCitation":["Calleja (1893); Cajal (1911); Millhouse","1987; Meyer et al"],"Definition":"The olfactory tubercle (anterior perforated substance in primates) contains clusters of cells appearing as caps made up of small cells surrounded by pyramidal cells, identified originally as \"islets of Calleja\" by Calleja (1893) and summarized by Cajal (1911)."}},{"Olfactory tubercle Islets of Calleja GABA cell":{"Located in":"Olfactory tubercle,","Created":"2007-09-05","Synonym":["Islands of Calleja Gaba interneuron","Islets of Calleja Gaba interneuron"],"Neurotransmitter":"GABA","CurationStatus":"uncurated","Comment":["I'm not sure that I would concatenate the Olfactory tubercle with the Islands of Calleja.  I'm waiting for clarification on this. Also"],"SuperCategory":"Neuron","Id":"nifext_154","Species":"Vertebrata"}},{"Olfactory tubercle Islets of Calleja granule neuron":{"Located in":"Islands of Calleja,","DendriteLocation":"Islands of Calleja,","Synonym":["Island of Calleja granule neuron"],"CurationStatus":"uncurated","Pages":"1-24","Comment":"Note that the nomenclature for the olfactory tubercle and islands of Calleja is not entirely consistent","JournalVolume":"265","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/3693600","Authors":["Millhouse"],"RetrievedOn":"Pub Med","Title":"Granule cells of the olfactory tubercle and the question of the islands of Calleja","LocationOfAxonArborization":"Islands of Calleja,","PMID":"3693600","PublicationDate":"1987","SuperCategory":"Neuron","PublicationName":"Journal of Comparative Neurology","NumberOfPrimaryDendrites":"1-2","Id":"nlx_68936","Polarity":["monopolar"],"JournalNumber":"1","Species":"Mammal,","Definition":"Neuron located in the granule cell clusters in the olfactory tubercle  characterized by a small soma with one to two small sparsely spiny varicose dendrites.  The axon has not been observed to exit the clusters in Golgi preparations.  Ultrastructurally, it is characterized by scant cytoplasm and a round nucleus (Meyer et al., 1989)","DefinitionPMID":"3693600"}},{"Olfactory tubercle Islets of Calleja large hilar cell":{"Located in":"Islands of Calleja,","Synonym":"Olfactory tubercle large hilar neuron","CurationStatus":"uncurated","JournalVolume":"265","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/3693600","Authors":["Millhouse"],"Figure":"12","PMID":"3693600","SpineDensityOnDendrites":"spiny low density","DefiningCriteria":"Morphology in Golgi stained preparations","PublicationDate":"1987","SuperCategory":"Neuron","Species":"Rat","DefiningCitation":["Millhouse J. Comp. Neurol 265:1-24"],"DendriteThickness":"3-5 um","DendriteLocation":"Islands of Calleja","Pages":"1-24","Comment":"We are using the term \"Islands of Calleja\" to be synonymous with the granule cell clusters of the olfactory tubercle.  Note that this usage may not be correct.","OriginOfAxon":"dendrite","Title":"Granule cells of the olfactory tubercle and the question of the islands of Calleja","RetrievedOn":"Pub Med","NumberOfPrimaryDendrites":"2","PublicationName":"Journal of Comparative Neurology","Id":"nlx_84634","JournalNumber":"1","Definition":"Large neuron associated with the hilar region of the granule cell clusters (Islands of Calleja) in the olfactory tubercle in the hilar region .  It has two thick primary dendrites, 40-90 um long, that branch near the periphery of the granule cell cluster with several dendritic branches coming off of the main shaft close together in a bushlike manner (Millhouse, 1987)."}},{"Olfactory tubercle Islets of Calleja large Type 2 hilar cell":{"Located in":"Islands of Calleja,","CurationStatus":"uncurated","JournalVolume":"265","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/3693600","Authors":["Millhouse"],"Figure":"13","CellSomaSize":"Rat: 15-17 um X 18-22 um","PMID":"3693600","SpineDensityOnDendrites":"Sparsely Spiny Dendrite Quality","DefiningCriteria":"Morphology in Golgi stained preparations","PublicationDate":"1987","SuperCategory":"Neuron","CellSomaShape":"Oval Soma Quality","Species":"Rat,","DefiningCitation":["Millhouse J. Comp. Neurol 265:1-24"],"DendriteThickness":"5-7 um","DendriteLocation":"Islands of Calleja,","Pages":"1-24","Curator":"Maryann Martone,","OriginOfAxon":"soma","Title":"Granule cells of the olfactory tubercle and the question of the islands of Calleja","RetrievedOn":"Pub Med","EditorialNote":"Millhouse did not give a name to this cell but described it as the \"second type of large hilar neuron\", hence the name Type 2","NumberOfPrimaryDendrites":"2","PublicationName":"Journal of Comparative Neurology","Id":"nlx_19563","JournalNumber":"1","Definition":"Type of large hilar neuron located in the hilar region of the granule cell clusters (Islands of Calleja) or the olfactory tubercle that can be differentiated morphologically from other types of hilar neurons:  it has several primary dendrites that branch relatively close to the soma but without forming bushlike or other special dendritic complexes;  the dendrites do not go along the border of the granule cell clusters but approach them at right angles; the axon also arises from the cell soma (Millhouse, 1987)."}},{"Olfactory tubercle Islets of Calleja spiny granule neuron":{"Located in":"Islands of Calleja,","Synonym":"Island of Calleja spiny granule neuron","CurationStatus":"uncurated","Pages":"1-24","JournalVolume":"265","PublicationLink":"http://www.ncbi.nlm.nih.gov/pubmed/3693600","Authors":["Millhouse"],"RetrievedOn":"Pub Med","Title":"Granule cells of the olfactory tubercle and the question of the islands of Calleja","LocationOfAxonArborization":"Islands of Calleja,","PMID":"3693600","DefiningCriteria":"Morphology:  spine covered dendrites","PublicationDate":"1987","SuperCategory":"Neuron","PublicationName":"Journal of Comparative Neurology","NumberOfPrimaryDendrites":"1-2","Id":"nlx_29378","JournalNumber":"1","Species":"Rat","DefiningCitation":["Millhouse J. Comp. Neurol 265:1-24"],"Definition":"Granule cell found in the granule cell clusters (Islands of Calleja) in the olfactory tubercle characterized by a high density of dendritic spines (Millhouse, 1987)"}},{"Olfactory tubercle layers 1-3 of ABA 2009":{"PartiallyOverlapsWith":"Olfactory tubercle  layers 1-3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153140","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Olfactory tubercle molecular layer of ABA 2009":{"PartiallyOverlapsWith":"Olfactory tubercle  molecular layer","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153352","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Olfactory tubercle of ABA 2009":{"PartiallyOverlapsWith":"Olfactory tubercle","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153031","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Olfactory tubercle polymorph layer of ABA 2009":{"PartiallyOverlapsWith":"Olfactory tubercle  polymorph layer","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153285","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Olfactory tubercle pyramidal layer of ABA 2009":{"PartiallyOverlapsWith":"Olfactory tubercle  pyramidal layer","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153326","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Olig2":{"SuperCategory":"Protein","Id":"sao1701066619"}},{"Oligo-glomerular lLN":{"Has_role":"Fly_Anatomy_Ontology","Created":"2009-12-14T04:44:27Z","Contributor":"djs93","SuperCategory":"LLN","Has_synaptic_terminal_in":"adult antennal lobe","Id":"nlx_148105","Is part of":"Adult antennal lobe","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007404","hasDBXref":"VFB:FBbt_00007404","Definition":"Local interneuron of the adult antennal lobe that is derived from the lateral AL neuroblast lineage and that innervates only some of the adult antennal lobe glomeruli."}},{"Oligodendrocyte":{"Synonym":"oligodendroglia","SuperCategory":"Macroglial Cell","Id":"sao844118448","Definition":"A class of large neuroglial (macroglial) cells in the central nervous system. Oligodendroglia may be called interfascicular, perivascular, or perineuronal (not the same as satellite cells, perineuronal of ganglia) according to their location. They form the insulating myelin sheath of axons in the central nervous system (MSH)."}},{"Oligodendrocyte Compact Myelin":{"SuperCategory":"Oligodendrocyte Myelin Sheath","Id":"sao1186642361","Definition":"The portion of the myelin sheath in which layers of cell membrane are tightly juxtaposed, completely excluding cytoplasm. The juxtaposed cytoplasmic surfaces form the major dense line, while the juxtaposed extracellular surfaces form the interperiod line visible in electron micrographs (Gene Ontology)."}},{"Oligodendrocyte Myelin Sheath":{"SuperCategory":"Regional Part Of Cell","Id":"sao1279474730","Definition":"An electrically insulating fatty layer that surrounds the axons of many neurons. It is an outgrowth of glial cells: Schwann cells supply the myelin for peripheral neurons while oligodendrocytes supply it to those of the central nervous system (Gene Ontology)."}},{"Oligodendrocyte Paranodal Termination":{"Synonym":"Paranodal loop","SuperCategory":"Oligodendrocyte Myelin Sheath","Id":"sao1354781919","Definition":"Cytoplasmic pockets, or as they appear in thin sections \"loops\" formed by the Schwann cell in the paranodal region.  These pockets are actually part of a continuous helical structure providing cytoplasmic continuity from the inntermost to the outermost layers of the myelin sheath through the cytoplasmic channel formed by the loop.  Most are directly apposed to the paranodal axonal membrane"}},{"Oligodendrocyte precursor cell":{"RelatedTo":"Polydendrocyte","Synonym":"oligodendrocyte progenitor cell","CurationStatus":"uncurated","SuperCategory":"Precursor Cell","Id":"sao1213292244","Abbrev":"OPC"}},{"Oligodendroglioma":{"Synonym":["Mixed Oligodendroglioma-Ependymoma","Oligodendroblastoma"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Glioma","Id":"birnlex_12627","DefiningCitation":["DeVita et al.","Cancer: Principles and Practice of Oncology","5th edOncology","p2052; Adams et al.","Principles of Neurology","6th ed"],"Definition":"A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms (MeSH)."}},{"Oligopotent":{"Comment":["Less potent than multipotent"],"SuperCategory":"Cellular potency","Id":"PATO_0001401","Definition":"Cellular potency that is the capacity to form multiple differentiated cell types of a specific lineage and lack self-renewing capacity"}},{"Olivary pretectal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","CurationStatus":"uncurated","EfferentProjections":"Parvocellular oculomotor nucleus","MyeloDefiningCriteriaPMID":"2865761","AfferentProjections":"Retina","Abbrev":"OPT","MyeloDefiningCriteria":["Anterior dorsal part of the nucleus is characterized by an almost complete lack of myelinated fibers"],"Created":"2006-07-15","AfferentProjectionsPMID":"2865761","DefiningCriteria":"myelo-architecture","NeuronamesID":"455","Umlscui":"C0175359","SuperCategory":"Regional part of brain","Id":"birnlex_1037","Is part of":"Pretectum","Species":"Mammal","DefiningCitation":["Scalia"],"EfferentProjectionsPMID":"2865761","Definition":"Small distinct nucleus in the pretectum of mammals involved in the pupillary light reflect.  In rats, it is an olive shaped (anterior) nucleus lying ventral to the brachium of the superior colliculus (Paxinos, The rat nervous system, 2nd ed, 1995, pg. 862).  Physiologically, it is identified by neurons sensitive to luminance changes.","DefinitionPMID":"8542320"}},{"Olivary pretectal nucleus of ABA 2009":{"PartiallyOverlapsWith":"Olivary pretectal nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153149","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Olivocerebellar tract":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"801","Umlscui":"C0175557","SuperCategory":"Nerve tract","Id":"birnlex_1579","Is part of":["Medulla oblongata"]}},{"Olivopontocerebellar Atrophy":{"Synonym":["Olivo-Ponto-Cerebellar Degeneration","Presenile Ataxia","Pontoolivocerebellar Atrophy","Olivopontocerebellar Atrophy","Dejerine-Thomas Syndrome","Olivopontocerebellar Degeneration","Olivopontocerebellar Atrophies"],"Created":"2007-10-05","CurationStatus":"uncurated","Umlscui":"C0028968","SuperCategory":"Multiple System Atrophy","Id":"birnlex_12574","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A group of inherited and sporadic disorders which share progressive ataxia in combination with atrophy of the CEREBELLUM; PONS; and inferior olivary nuclei. Additional clinical features may include MUSCLE RIGIDITY; NYSTAGMUS, PATHOLOGIC; RETINAL DEGENERATION; MUSCLE SPASTICITY; DEMENTIA; URINARY INCONTINENCE; and OPHTHALMOPLEGIA. The familial form has an earlier onset (second decade) and may feature spinal cord atrophy. The sporadic form tends to present in the fifth or sixth decade, and is considered a clinical subtype of MULTIPLE SYSTEM ATROPHY (MeSH)."}},{"Olmesartan":{"RelatedTo":"Type-1 angiotensin II receptor","Synonym":["DE-092","Olmesartan medoximil","Olmesartan medoxomil","olmesartan","Benicar","Olmetec"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:48416","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00275","Definition":"Olmesartan belongs to the class of medicines called angiotensin II receptor antagonists to treat high blood pressure. It is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and Forest Laboratories. Pharmacology: Olmesartan, a specific angiotensin II type 1 antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, olmesartan does not have an active metabolite or possess uricosuric effects. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II levels do not overcome the effect of olmesartan on blood pressure. Mechanism of action: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis. Olmesartan has more than a 12,500-fold greater affinity for the AT1 receptor than for the AT2 receptor. Drug type: Approved. Investigational. Small Molecule. Drug category: Angiotensin II Type 1 Receptor Blockers. Antihypertensive Agents"}},{"Olopatadine":{"RelatedTo":["Histamine H1 receptor"],"Synonym":[", Olopatadine Hydrochloride"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00768","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00768","Definition":"Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Pharmacology: Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Mechanism of action: Olopatadine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Drug type: Approved. Small Molecule. Drug category: Anti-Allergic Agents. Anti-Inflammatory Agents, Non-Steroidal. Antihistamines. Histamine H1 Antagonists. Histamine H1 Antagonists, Non-Sedating"}},{"Olsalazine":{"Synonym":["Olsalazine sodium"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01250","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01250","Definition":"Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines. Pharmacology: Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is that active site of disease in ulcerative colitis. Mechanism of action: Orally administered olsalazine is converted to mesalamine which is thought to be the therapeutically active agent in the treatment of ulcerative colitis. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes (LTs) and hydroxyelcosatetraenoic acids (HETEs) is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon. Drug type: Approved. Small Molecule. Drug category: Anti-Inflammatory Agents, Non-Steroidal. Gastrointestinal Agents"}},{"Omalizumab":{"RelatedTo":["High affinity immunoglobulin epsilon receptor subunit alpha"],"Synonym":["Ig gamma-1 chain C region"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00043","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00043","Definition":"A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin. Pharmacology: Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma. Mechanism of action: Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils. Drug type: Approved. Biotech. Investigational. Drug category: Anti-Asthmatic Agents. Immunomodulatory Agents"}},{"Omeprazole":{"RelatedTo":"Potassium-transporting ATPase alpha chain 1","Synonym":["OMEP","OMP","OMZ","Omeprazol (INN-Spanish)","Omeprazole magnesium","Omeprazolum (INN-Latin)","omeprazole","Antra","Audazol","Aulcer","Belmazol","Ceprandal","Danlox","Demeprazol","Desec","Dizprazol","Dudencer","Elgam","Emeproton","Epirazole","Erbolin","Exter","Gasec","Gastrimut","Gastroloc","Gibancer","Indurgan","Inhibitron","Inhipump","Lensor","Logastric","Lomac","Losec","Mepral","Miol","Miracid","Mopral","Morecon","Nilsec","Nopramin","Ocid","Olexin","Omapren","Omebeta 20","Omed","Omegast","Omepral","Omeprazon","Omeprol","Omesek","Omezol","Omezolan","Omid","Omisec","Omizac","Ompanyt","Ortanol","Osiren","Ozoken","Paprazol","Parizac","Pepticum","Pepticus","Peptilcer","Prazentol","Prazidec","Prazolit","Prilosec","Procelac","Proclor","Prysma","Ramezol","Regulacid","Result","Sanamidol","Secrepina","Tedec Ulceral","Ulceral","Ulcesep","Ulcometion","Ulcozol","Ulcsep","Ulsen","Ultop","Ulzol","Victrix","Zefxon","Zegerid","Zepral","Zimor"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7772","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00338","Definition":"A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. (PubChem) Pharmacology: Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Mechanism of action: Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Ulcer Agents. Enzyme Inhibitors. Proton-pump Inhibitors"}},{"Oncology":{"RelatedTo":"Nervous system neoplastic disease","CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100657","Definition":"is the branch of medicine dealing with tumors (cancer). A medical professional who practices oncology is an oncologist."}},{"Ondansetron":{"RelatedTo":["5-hydroxytryptamine 3 receptor"],"Synonym":[", Apo-ondansetron","Novo-ondansetron","PHL-ondansetron","PMS-ondansetron","Ratio-ondansetron","Sandoz ondansetron","Zofran","Zofran ODT","Zophren"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00904","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00904","Definition":"A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. (PubChem) Pharmacology: Ondansetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Ondansetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. Mechanism of action: Ondansetron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Ondansetron works by blocking the reception of serotonin at these 5-HT3 receptors. Drug type: Approved. Small Molecule. Drug category: Anti-anxiety Agents. Antiemetics. Antipruritics. Antipsychotic Agents. Antipsychotics. Serotonin Antagonists"}},{"One dimensional region":{"Comment":["Examples: the part of space that is a line stretching from one end of absolute space to the other","an edge of a cube-shaped part of space"],"SuperCategory":"Spatial region","Id":"OneDimensionalRegion"}},{"Ongur, Price, and Ferry (2003) area 10l":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4092","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-10l"}},{"Ongur, Price, and Ferry (2003) area 10o":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4069","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-10o"}},{"Ongur, Price, and Ferry (2003) area 10p":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4067","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-10p"}},{"Ongur, Price, and Ferry (2003) area 10r":{"CytoDefiningCriteria":"Granular layers II and IV; moderately developed layer III","MyeloDefiningCriteria":"Strong outer myelin band and radial bundles of fibers","Created":"2008-03-04","DefiningCriteria":"cyto-architecture","ChemoDefiningCriteria":["cholinesterase: Moderately stained plexus in layers I/II","III"],"CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4068","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","Species":"Human","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-10r"}},{"Ongur, Price, and Ferry (2003) area 11l":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4082","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-11l"}},{"Ongur, Price, and Ferry (2003) area 11m":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4071","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-11m"}},{"Ongur, Price, and Ferry (2003) area 13a":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4074","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-13a"}},{"Ongur, Price, and Ferry (2003) area 13b":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4073","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-13b"}},{"Ongur, Price, and Ferry (2003) area 13l":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4084","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-13l"}},{"Ongur, Price, and Ferry (2003) area 13m":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4083","ParcellationScheme":"Ongur Price and Ferry (2003) prefrontal cortical parcellation scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-13m"}},{"Ongur, Price, and Ferry (2003) area 14c":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4076","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-14c"}},{"Ongur, Price, and Ferry (2003) area 14r":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4075","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-14r"}},{"Ongur, Price, and Ferry (2003) area 24":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4077","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-24"}},{"Ongur, Price, and Ferry (2003) area 25":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4078","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-25"}},{"Ongur, Price, and Ferry (2003) area 32":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4079","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-32"}},{"Ongur, Price, and Ferry (2003) area 47l":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4085","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-47l"}},{"Ongur, Price, and Ferry (2003) area 47m":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4086","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-47m"}},{"Ongur, Price, and Ferry (2003) area 47r":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4087","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-47r"}},{"Ongur, Price, and Ferry (2003) area 47s":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4072","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-47s"}},{"Ongur, Price, and Ferry (2003) area 9":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4091","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-9"}},{"Ongur, Price, and Ferry (2003) area AON":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4095","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","Species":["Human"],"DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-AON"}},{"Ongur, Price, and Ferry (2003) area G":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4080","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-G"}},{"Ongur, Price, and Ferry (2003) area Iai":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4090","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-Iai"}},{"Ongur, Price, and Ferry (2003) area Ial":{"CytoDefiningCriteria":["Large cells in layer V"],"MyeloDefiningCriteria":"Sparse; strong layer I plexus","Created":"2008-03-04","ChemoDefiningCriteria":"cholinesterase: Moderate plexus in layers II-VISMI32 immunoreactivity: Many stained cells (++)Parvalbumin immunoreactivity: Band of stained neurons in layer V++","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4089","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","Species":"Human","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-Ial","Definition":"Insula agranular lateral area"}},{"Ongur, Price, and Ferry (2003) area Iam":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4088","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-Iam"}},{"Ongur, Price, and Ferry (2003) area Iapm":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4094","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","Species":["Human"],"DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-Iapm"}},{"Ongur, Price, and Ferry (2003) area PrCo":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4093","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","Species":["Human"],"DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-PrCo"}},{"Ongur, Price, and Ferry (2003) area PrCO (birnlex 4081)":{"Created":"2008-03-04","CurationStatus":"uncurated","SuperCategory":["Ongur","Price"],"Id":"birnlex_4081","ParcellationScheme":"Ongur,_Price,_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","Species":["Human"],"DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human       Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"],"Abbrev":"OFP03-PrCO"}},{"Ongur, Price, and Ferry (2003) prefrontal cortical partition scheme region":{"Created":"2008-03-04","Synonym":["Ongur","and Ferry (2003) prefrontal cortical parcellation scheme","and Ferry (2003) prefrontal cortical areas","and Ferry (2003) prefrontal cortical partition scheme"],"CurationStatus":"uncurated","SuperCategory":"Cortical parcel","Id":"birnlex_4064","Is part of":"Ongur_Price_and_Ferry_(2003)_prefrontal_cortical_parcellation_scheme","Species":"Human","DefiningCitation":["Dost Ongur","Amon T. Ferrry","AND Joseph L. Price (2003) Architectonic Subdivision of the Human Orbital and Medial Prefrontal Cortex. J. Comp. Neurol.","v460"]}},{"Online course":{"Synonym":"On-line course","CurationStatus":"uncurated","SuperCategory":"Training resource","Id":"nlx_151773","Definition":"Resource that provides online training and educational resources. (BRO)"}},{"Ontario Ministry of Agriculture Food and Rural Affairs":{"Synonym":"Ontario Ministry of Agriculture and Food","CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_157744","DefiningCitation":"http://www.omafra.gov.on.ca/english/","Abbrev":["OMAF"],"Definition":"An Ontario government ministry responsible for the food, agriculture and rural sectors of the Canadian province of Ontario."}},{"Ontario Ministry of Economic Development Employment and Infrastructure":{"tweets.color":"#605C4F","tweets.background":"#F6F6F6","Synonym":["Ontario Ministry of Economic Development and Innovation","MEDI","Ministry of Economic Development and Innovation"],"count":"5","CurationStatus":"uncurated","shell.background":"#013C41","SuperCategory":"Government granting agency","Id":"nlx_158221","user":"{{#show: {{FULLPAGENAME ","DefiningCitation":"http://www.ontario.ca/ministry-economic-development-trade-employment","tweets.links":"#013C41","Abbrev":"MEDEI"}},{"Ontario Ministry of Research and Innovation":{"tweets.color":"#605C4F","tweets.background":"#F6F6F6","count":"5","CurationStatus":"uncurated","shell.background":"#013C41","SuperCategory":"Government granting agency","Id":"nlx_157929","user":"{{#show: {{FULLPAGENAME ","DefiningCitation":"https://www.ontario.ca/ministry-research-innovation","tweets.links":"#013C41","Definition":"Ministry that supports world-class research, commercialization and innovation taking place across Ontario through a range of programs and services like the Ontario Research Fund, Innovation Demonstration Fund and Ontario Venture Capital Fund."}},{"Ontology":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Controlled vocabulary","Id":"birnlex_2339","Definition":"In both computer science and information science, an ontology represents a set of concepts within a domain and the relationships between those concepts. It is used to reason about the objects within that domain.  Ontologies are used in artificial intelligence, the semantic web, software engineering, biomedical informatics and information architecture as a form of knowledge representation about the world or some part of it. Ontologies generally describe:      * Individuals: the basic or \"ground level\" objects     * Classes: sets, collections, or types of objects     * Attributes: properties, features, characteristics, or parameters that objects can have and share     * Relations: ways that objects can be related to one another     * Events: the changing of attributes or relationsNITRC definition: Controlled, standardized vocabulary that describes objects and the relations between them."}},{"Onuf's nucleus":{"NeuronamesID":"2701","CurationStatus":"uncurated","EfferentProjections":"Sphincter muscle","SuperCategory":"Regional part of spinal cord","Id":"nlx_86651","Is part of":"Sacral spinal cord ventral horn","Species":"Mammal","Definition":"A group of small somatic motor neurons located in the anterior gray column of the sacral spinal cord."}},{"Opacity":{"SuperCategory":"Optical quality","Id":"PATO_0000957","Definition":"An optical quality which obtains by virtue of the ability of the bearer to absorb visible light."}},{"Opaque":{"Synonym":["cloudy","clouding"],"SuperCategory":"Opacity","Id":"PATO_0000963","Definition":"Not clear; not transmitting or reflecting light or radiant energy."}},{"Open":{"SuperCategory":"Closure","Id":"PATO_0000610","Definition":"Affording unobstructed passage or view."}},{"Open course":{"Synonym":["OpenCourseWare","Open Course Ware"],"CurationStatus":"uncurated","Availability":"Open access","SuperCategory":"Online course","Id":"nlx_151771","Abbrev":"OCW","Definition":"University course content published gratis via the Internet that do not typically provide certification or access to faculty. (Adapted from Wikipedia)"}},{"Open Data Commons License":{"Synonym":"ODC License","CurationStatus":"uncurated","SuperCategory":"Open-source license","Id":"nlx_157711","DefiningCitation":"http://opendatacommons.org/licenses/","Abbrev":"ODC"}},{"Open field test":{"CurationStatus":"uncurated","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_152173","Species":"Rodent","Abbrev":"OFT","Definition":"A commonly used qualitative and quantitative measure of general locomotor activity and willingness to explore in rodents. Originally developed as a test of emotionality by Calvin Hall (1932). The open field is an arena with walls to prevent escape. Commonly, the field is marked with a grid, and square crossings, rearing, and time spent moving are used to assess the activity of the rodent. In the modern open field apparatus, infrared beams or video cameras with associated software can be used to automate the assessment process. The OFT is also often used to assess anxiety by including additional measures of defecation, time spent in the center of the field, and the first few minutes of activity. The relation between the OFT and other tests of exploratory activity (elevated plus maze and emergence) have been analyzed in two mouse strains. Changes in these measures are often used to assess the sedative or stimulant effects of pharmacological agents (adapted from Wikipedia:  http://en.wikipedia.org/wiki/Open_Field_(animal_test%))."}},{"Open Government Licence":{"RelatedTo":["Creative Commons Attribution License"],"Synonym":"Open Government License","CurationStatus":"uncurated","SuperCategory":"Open-source license","Id":"nlx_158451","Is part of":"National Archives","DefiningCitation":"http://www.nationalarchives.gov.uk/doc/open-government-licence/","Abbrev":"OGL","Definition":"A copyright licence for Crown Copyright works published by the UK government. It may also be applied to publications by other public sector bodies in the UK. It is compatible with the Creative Commons Attribution (CC-BY) licence, which covers copyright, and Open Data Commons Attribution License (ODC-By), which covers database rights and applicable copyrights. (Adapted from Wikipedia)"}},{"Open unspecified license":{"Synonym":["Open","Open source"],"CurationStatus":"uncurated","SuperCategory":"Unspecified license","Id":"nlx_152576","Definition":"No license has been specified but the resource is designated as \"Open\" or \"Open-source\""}},{"Open-source license":{"Created":"2007-10-11","Synonym":"Open source license","CurationStatus":"uncurated","SuperCategory":"License","Id":"birnlex_2343","Definition":"An open source license is a copyright license for computer software that makes the source code available under terms that allow for modification and redistribution without having to pay the original author. Such licenses may have additional restrictions such as a requirement to preserve the name of the authors and the copyright statement within the code. One popular (and sometimes considered normative) set of open source software licenses are those approved by the Open Source Initiative (OSI) based on their Open Source Definition (OSD)."}},{"Operating Mode":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9178","SuperCategory":"DICOM term","Id":"nlx_150391","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Operating mode applicable for the defined by the applicable standard."}},{"Operating Mode Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9176","Comment":"DICOM Specific term","SuperCategory":"DICOM term","Id":"nlx_150392","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence of operating mode information relating to the frame/SOP instance as required to adhere to the Applicable Safety Standard Agency (0018,9174) regulations. One or more Items may be included in this sequence. Required if required by law or regulation."}},{"Operating Mode Type":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9177","SuperCategory":"DICOM term","Id":"nlx_150393","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The type of operating mode used in this observation."}},{"Operation span task":{"Created":"7/16/2010 14:37","CurationStatus":"uncurated","Contributor":"Russ Poldrack","CAO_Id":"CAO_00723","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Operation_span_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145945","Definition":"A task in which subjects are asked to perform a simple mathematical verification (e.g., 4-2 +1 "}},{"Operator Identification Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_1072","SuperCategory":"DICOM term","Id":"nlx_150394","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Identification of the operator(s) supporting the Series. One or more items shall be included in this sequence. If more than one Item, the number and order shall correspond to the value of Operators Name (0008,1070), if present."}},{"Operators Name":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_1070","SuperCategory":"DICOM term","Id":"nlx_150395","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"PN","Definition":"Name(s) of the operator(s) who supporting this Series."}},{"Opercular part of inferior frontal gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":"pars opercularis gyri frontalis inferioris","NeuronamesID":"69","CurationStatus":"uncurated","Umlscui":"C0262296","SuperCategory":"Regional part of brain","Id":"birnlex_823","Is part of":"Inferior frontal gyrus","Definition":"Component of the inferior frontal gyrus.defined as the first gyrus from the precentral gyrus."}},{"Ophthalmology":{"CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100658","Definition":"Branch of medicine which deals with the diseases and surgery of the visual pathways, including the eye, brain, and areas surrounding the eye, such as the lacrimal system and eyelids. "}},{"Opioid peptide":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5094"}},{"Opioid receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5659"}},{"Opioid-Related Disorder":{"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Substance-Related Disorder","Id":"birnlex_12713","Definition":"Disorders related or resulting from abuse or mis-use of opioids (MeSH)."}},{"Opisthobranchia":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998096","SuperCategory":"Euthyneura","Id":"birnlex_560"}},{"Opium":{"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"nlx_chem_100309","Has role":["Drug of abuse role"]}},{"Opposite":{"CurationStatus":"uncurated","SuperCategory":"Relational spatial quality","Id":"PATO_0001933","Definition":"A positional quality inhering in a bearer by virtue of the bearer's being positioned on opposite sides on the same plane."}},{"Oprelvekin":{"RelatedTo":"Interleukin-11 receptor alpha chain","Synonym":["AGIF","Adipogenesis inhibitory factor","IL-11","Interleukin-11 precursor","oprelvekin","Neumega"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00038","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00038","Definition":"Oprelvekin, the active ingredient in Neumega is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.The primary hematopoietic activity of Neumega is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega improved platelet nadirs and accelerated platelet recoveries compared to controls.In animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines. Pharmacology: Oprelvekin is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. The primary hematopoietic activity of Oprelvekin is stimulation of megakaryocytopoiesis and thrombopoiesis. Oprelvekin has shown potent thrombopoietic activity in individuals with compromised hematopoiesis Mechanism of action: Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. Drug type: Approved. Biotech. Investigational. Drug category: Coagulants. Thrombotics"}},{"Opsin-like receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5536"}},{"Opsin-like receptor - unspecified 1":{"EditorialNote":"Probably a sensory receptor.","Created":"2007-09-19","SuperCategory":"Opsin-like receptor","Id":"nifext_5537"}},{"Opsoclonus-Myoclonus Syndrome":{"Synonym":["Dancing Eyes-Dancing Feet Syndrome","Kinsbourne Syndrome","Opsoclonus Myoclonus Ataxia"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Dyskinesia","Id":"birnlex_12660","Definition":"A neurological condition that is characterized by uncontrolled rapid irregular movements of the eye ( OPSOCLONUS) and the muscle ( MYOCLONUS) causing unsteady, trembling gait. It is also known as dancing eyes-dancing feet syndrome and is often associated with neoplasms, viral infections, or autoimmune disorders involving the nervous system (MeSH)."}},{"Optic chiasm":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","CurationStatus":"uncurated","TomoDefiningCriteria":"Located inferior to the thalamus.","EfferentProjections":"Lateral geniculate body","Has role":"Visual system function","ConnDefiningCriteria":["optic nerve"],"AfferentProjections":"Retina ganglion cell layer,","Abbrev":"ox","Created":"2007-03-03","DefiningCriteria":["connectivity"],"NeuronamesID":"442","Umlscui":"C0029126","SuperCategory":"Regional part of brain","Id":"birnlex_1416","Is part of":["Diencephalon","Optic nerve"],"OrganismPMID":"22103419","Species":"Mammal","EfferentProjectionsPMID":"22103419","Definition":"A location within the visual system of binocular animals where axons of retinal ganglion cells cross contralaterally or remain ipsilatterally towards termination zones in the lateral geniculate nucleus.","DefinitionPMID":"22103419"}},{"Optic lobe neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Neuron","Has_synaptic_terminal_in":"optic lobe","Id":"nlx_147433","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00003702","Definition":"Any neuron (FBbt_00005106) that has synaptic terminals in some optic lobe (FBbt_00003701)."}},{"Optic Nerve Glioma":{"Synonym":["Glioblastoma Multiforme","Optic Glioma"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Astrocytoma","Id":"birnlex_12621","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"Glial cell derived tumors arising from the optic nerve, usually presenting in childhood. Roughly 50% are associated with NEUROFIBROMATOSIS 1. Clinical manifestations include decreased visual acuity; EXOPHTHALMOS; NYSTAGMUS, PATHOLOGIC; STRABISMUS; pallor or swelling of the optic disc; and INTRACRANIAL HYPERTENSION. The tumor may extend into the optic chiasm and hypothalamus (MeSH)."}},{"Optic Pathways of CIVM postnatal rat brain atlas":{"AtlasImage":["optic p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151550","Is part of":"Major White Matter Structures of CIVM postnatal rat brain atlas","Definition":"The optic pathways are very easy to segment on coronal T2-weighted MRI. This pathway, comprised of optic nerves, optic chiasm, and optic tracts, is comprised largely of densely packed, myelinated axons, which appear quite dark on T2 MRI. The entire pathway can be segmented by simple seeded thresholding (magic wand) with a seed placed in the optic chiasm. The dorsal and caudal most extent of the optic tracts as the course lateral to the diencephalon can become quite thin, and may be difficult to distinguish depending on image resolution."}},{"Optic recess of third ventricle":{"Synonym":["preoptic recess","supraoptic recess","Recessus opticus","Recessus praeopticus"],"SynonymPMID":"Brain Info","CurationStatus":"uncurated","NeuronamesID":"457","SuperCategory":"Regional part of brain","Id":"nlx_144280","Is part of":"Third ventricle","DefinitionPMID":"ISBN: 978-0323041317","Definition":"Recess in third ventricle lying in front of the optic chiasm at the base of the lamina terminalis"}},{"Optic tract":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"443","Umlscui":"C0152405","SuperCategory":"Nerve tract","Is_part_of":"Diencephalon","Id":"birnlex_1684","Has role":"Visual System","Is part of":["Diencephalon","White matter"],"Definition":"Predominantly white matter structure found in diencephalon consisting of fibers originating in the retina.  The optic tract is considered to extend from the point of the optic chiasm and terminates largely, although not exclusively, in the lateral geniculate complex.  Other fibers end in the superior colliculus and other structures in the diencephalon, midbrain and brainstem (MM)."}},{"Optic tract of WHS11":{"AtlasImage":"Optic tract of WHS11.png,","EditorialNote":"Still needs defining criteria to be added.  Note that the current hierarchy within MBAT lists it as a type of cranial nerve/sensory nerve.  According to the CUMBO definitions of nerve, this is not correct.  Most hierarchies include it as part of the diencephalon, so I've put it there.  Currently does not delineate the optic tract all the way into the diencephalon.","PartiallyOverlapsWith":"Optic tract","CurationStatus":"graph position temporary","SuperCategory":"Waxholm 2011 parcellation scheme region","Curator":["Maryann Martone"],"Id":"nlx_143801","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Diencephalon of WHS11","Species":"Mouse","Definition":"TBA"}},{"Optical imaging protocol":{"Created":"2007-10-09","Synonym":["Light microscopy imaging protocol","Light microscopy","Light-microscopy"],"CurationStatus":"uncurated","SuperCategory":"Image acquisition protocol","Id":"birnlex_2252","Definition":"An imaging protocol that uses any form of optical microscopy assay to form an image, i.e., an assay that employs light waves as the source of electromagnetic radiation."}},{"Optical microscope":{"Created":"2006-05-15","CurationStatus":"uncurated","SuperCategory":"Microscope","Id":"birnlex_2112"}},{"Optical quality":{"SuperCategory":"Electromagnetic (EM) radiation quality","Id":"PATO_0001300","Definition":"An EM radiation quality in which the EM radiation is within the fiat range of the spectrum visible deemed to be light."}},{"Optogenetics":{"RelatedTo":"Channel rhodopsin","CurationStatus":"uncurated","SuperCategory":"Experimental paradigm","Id":"nlx_152558","Definition":"Aneuromodulation technique that uses a combination of techniques from optics and genetics to control the activity of individual neurons in living tissue\u2013even within freely-moving animals\u2013and to precisely measure the effects of those manipulations in real-time. It was developed by Karl Deisseroth and his colleagues at Stanford University in 2006 (Adapted from Wikipedia: http://en.wikipedia.org/wiki/Optogenetics)"}},{"Oral part of spinal trigeminal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"1015268157","CurationStatus":"uncurated","Umlscui":"C0175417","SuperCategory":"Regional part of brain","Id":"birnlex_1100","Is part of":"Spinal trigeminal nucleus","Abbrev":"Sp5O"}},{"Oral part of ventral lateral nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-03","EditorialNote":"Synonyms derived both from UMLS and from NN, with NN given precedence (BB: 2007-03-03).","Synonym":["ventral lateral nucleus","pars oralis","nucleus lateralis oralis situs principalis","ventral lateral thalamic nucleus","nucleus ventralis lateralis","oral part","nucleus ventrooralis externus","ventral lateral anterior nucleus","anterior part (Van Buren)"],"NeuronamesID":"321","CurationStatus":"uncurated","Umlscui":"C0175280","SuperCategory":"Regional part of brain","Id":"birnlex_817","Is part of":"Ventral lateral nucleus","Abbrev":"VLO,VAL(VO)"}},{"Oral part of ventral posterolateral nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-04","Synonym":["ventral posterolateral nucleus","nucleus ventrointermedius","nucleus ventralis posterior lateralis","nucleus lateralis intermedius lateralis","ventral posterolateral thalamic nucleus","nucleus ventralis intermedius thalami","pars oralis","nucleus ventralis intermedius (DeWulf)","oral part","nucleus ventralis intermedius (Walker)"],"NeuronamesID":"328","CurationStatus":"uncurated","Umlscui":"C0175286","SuperCategory":"Regional part of brain","Id":"birnlex_918","Is part of":"Ventral posterolateral nucleus","Abbrev":"VPLO"}},{"Oral pontine reticular nucleus":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_875","Is part of":"Pontine reticular formation","Abbrev":"PnO"}},{"Oral pulvinar nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["anterior pulvinar nucleus","oral part of pulvinar","oral portion of pulvinar","oral nuclear group of pulvinar","nucleus pulvinaris oralis"],"NeuronamesID":"312","CurationStatus":"uncurated","Umlscui":"C0262299","SuperCategory":"Regional part of brain","Id":"birnlex_1239","Is part of":"Pulvinar","Abbrev":"OPul,APul"}},{"Orange":{"SuperCategory":"Color","Id":"PATO_0000953","Definition":"A color hue with high-medium wavelength that of that portion of the visible spectrum lying between red and yellow, evoked in the human observer by radiant energy with wavelengths of approximately 585 to 620 nanometers."}},{"Orangutan":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2006-10-07","CurationStatus":"raw_import","Umlscui":"C0032638","SuperCategory":"Pongo","Id":"birnlex_204"}},{"Orbicular":{"SuperCategory":"Round","Id":"PATO_0001934","Definition":"Perfectly circular."}},{"Orbital area lateral part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  lateral part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153502","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area lateral part layer 2-3 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  lateral part  layer 2-3","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153616","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area lateral part layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  lateral part  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153455","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area lateral part layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  lateral part  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152915","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area lateral part layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  lateral part  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153171","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area lateral part of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153546","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153156","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153086","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153781","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153207","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area medial part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  medial part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153105","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area medial part layer 2 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  medial part  layer 2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153444","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area medial part layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  medial part  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153180","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area medial part layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  medial part  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153621","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area medial part of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  medial part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153600","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area of ABA 2009":{"PartiallyOverlapsWith":"Orbital frontal cortex","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153768","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area ventral part of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  ventral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153348","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area ventrolateral part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  ventrolateral part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153703","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area ventrolateral part layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  ventrolateral part  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153113","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area ventrolateral part layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  ventrolateral part  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153111","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area ventrolateral part layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  ventrolateral part  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153548","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital area ventrolateral part of ABA 2009":{"PartiallyOverlapsWith":"Orbital area  ventrolateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152990","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Orbital frontal cortex":{"Synonym":"orbitofrontal cortex","CurationStatus":"uncurated","EfferentProjections":["Medial OfC reciprocally connects with the hippocampus","Posterior parahippocampal cortex","Posterior cingulate and retrosplenial areas","And area prostriataLateral orbitofrontal sector reciprocally connects with sensory areas of the gustatory","somatic and visual modalities"],"ConnDefiningCriteria":["Defined as the part of the prefrontal cortex that receives projections from the magnocellular"],"Abbrev":"OFC","AfferentProjections":["Medial OfC reciprocally connects with the hippocampus","Posterior parahippocampal cortex","Posterior cingulate and retrosplenial areas","And area prostriataLateral orbitofrontal sector reciprocally connects with sensory areas of the gustatory","somatic and visual modalities"],"Created":"2006-10-08","EditorialNote":"UMLS clearly has obscured this distinction between cortex and gyri here, as they include the following under this CUI: orbital gyrus, orbital area, orbital cortex, gyri orbitales, orbitofrontal gyrus, orbitofrontal gyri, gyrus orbitofrontalis.  Clearly, this would equate this volumetric structure defined as Orbital Frontal Cortex and the \"volumetric\" structure defined in NN as \"Orbital gyrus\".","AfferentProjectionsPMID":"10731218","Umlscui":"C0152301","SuperCategory":"Regional part of brain","Id":"birnlex_1049","Is part of":"Frontal lobe","Species":"Human","Definition":"Component of the prefontal cortex, frontal lobe, inferior region (Christine Fennema-Notestine).","EfferentProjectionsPMID":"10731218"}},{"Orbital gyri complex":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":"Orgital_gyri","CurationStatus":"uncurated","NeuronamesID":"73","Umlscui":"C0152301","SuperCategory":"Regional part of brain","Id":"birnlex_1223","Is part of":"Frontal lobe"}},{"Orbital operculum":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":"orbitofrontal opercular area","CurationStatus":"uncurated","NeuronamesID":"40","Umlscui":"C0694580","SuperCategory":"Superficial feature of brain","Id":"birnlex_1102"}},{"Orbital part of inferior frontal gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":"pars orbitalis gyri frontalis inferioris","CurationStatus":"uncurated","NeuronamesID":"70","Umlscui":"C0262300","SuperCategory":"Regional part of brain","Id":"birnlex_1207","Is part of":"Inferior frontal gyrus","Definition":"Component of the inferior frontal gyrus.defined as the first gyrus from the precentral gyrus.the remainder of the inferior frontal gyrus once the pars opercularis and triangularis have been defined (Christine Fennema-Notestine)., NeuroNames"}},{"Orbital sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":["Cruciate sulcus of Campbell"],"CurationStatus":"uncurated","NeuronamesID":"61","Umlscui":"C0228206","SuperCategory":"Sulcus","Id":"birnlex_1112","Is part of":"Frontal lobe","Abbrev":"orbs"}},{"Orciprenaline":{"RelatedTo":"Beta-2 adrenergic receptor","Synonym":["Metaproterenol","Metaproterenol Sulfate","Orciprenalina (INN-Spanish)","Orciprenaline Sulfate","Orciprenalinum (INN-Latin)","Alotec","Alupent","Metaprel","Metaproterenol Polistirex","Novasmasol"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00816","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00816","Definition":"A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. (PubChem) Pharmacology: Orciprenaline (also known as metaproterenol), a synthetic amine, is structurally and pharmacologically similar to isoproterenol. Orciprenaline is used exclusively as a bronchodilator. The pharmacologic effects of beta adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Mechanism of action: Orciprenaline is a moderately selective beta(2)-adrenergic agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. Intracellularly, the actions of orciprenaline are mediated by cAMP, the production of which is augmented by beta stimulation. The drug is believed to work by activating adenylate cyclase, the enzyme responsible for producing the cellular mediator cAMP. Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Agonists. Bronchodilator Agents. Sympathomimetics. Tocolytic Agents"}},{"Orconectes":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":["C1644133"],"SuperCategory":"Cambarinae","Id":"birnlex_607"}},{"Order Callback Phone Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_2010","SuperCategory":"DICOM term","Id":"nlx_150396","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Telephone Number at which additional information can be retrieved."}},{"Order Entered By":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_2008","SuperCategory":"DICOM term","Id":"nlx_150397","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"PN","Definition":"The person who entered the Imaging Service Request into an Information System."}},{"Order Enterers Location":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_2009","SuperCategory":"DICOM term","Id":"nlx_150398","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"The location at which the Imaging Service Request was entered."}},{"Orexin":{"Created":"2007-09-19","Synonym":"hypocretin,","CurationStatus":"uncurated","SuperCategory":"Peptide","Id":"nifext_5101","Has role":"Neuropeptide,","Abbrev":["ORX"],"Definition":"A protein that is a translation product of the HCRT gene or a 1:1 ortholog thereof. (PRO:000008476)"}},{"Orexin (hypocretin) receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_7173"}},{"Orexin A":{"Created":"2007-09-19","Synonym":"hypocretin 1","CurationStatus":"uncurated","SuperCategory":"Orexin","Id":"nifext_5102","Has role":["Neuropeptide"]}},{"Orexin B":{"Created":"2007-09-19","Synonym":"hypocretin 2","CurationStatus":"uncurated","SuperCategory":"Orexin","Id":"nifext_5103","Has role":["Neuropeptide"]}},{"Organ":{"Created":"2006-09-07","SuperCategory":"Anatomical entity","Id":"birnlex_4"}},{"Organ at Risk Full-volume Dose":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_002A","SuperCategory":"DICOM term","Id":"nlx_150399","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Maximum dose (in Gy) to entire Dose Reference if Dose Reference Type (300A,0020) is ORGAN_AT_RISK and Dose Reference Structure Type (300A,0014) is VOLUME."}},{"Organ at Risk Limit Dose":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_002B","SuperCategory":"DICOM term","Id":"nlx_150400","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Maximum permitted dose (in Gy) to any part of Dose Reference if Dose Reference Type (300A,0020) is ORGAN_AT_RISK and Dose Reference Structure Type (300A,0014) is VOLUME."}},{"Organ at Risk Maximum Dose":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_002C","SuperCategory":"DICOM term","Id":"nlx_150401","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Maximum dose (in Gy) to non-overdosed part of Dose Reference if Dose Reference Type (300A,0020) is ORGAN_AT_RISK  and Dose Reference Structure Type (300A,0014) is VOLUME."}},{"Organ at Risk Overdose Volume Fraction":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_002D","SuperCategory":"DICOM term","Id":"nlx_150402","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Maximum permitted fraction (in percent) of the Organ at Risk to receive more than the Organ at Risk Maximum Dose if Dose Reference Type (300A,0020) is ORGAN_AT_RISK and Dose Reference Structure Type  (300A,0014) is VOLUME."}},{"Organ cavity":{"Created":"2006-07-15","CurationStatus":"graph_position_temporary","SuperCategory":"Anatomical cavity","Id":"birnlex_1019"}},{"Organ Dose":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_0316","SuperCategory":"DICOM term","Id":"nlx_150403","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Average organ dose value measured in dGy during the acquisition of this image. Note: This may be an estimated value."}},{"Organ Exposed":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_0318","SuperCategory":"DICOM term","Id":"nlx_150404","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Organ to which Organ Dose (0040,0316) applies."}},{"Organelle":{"CurationStatus":"uncurated","SuperCategory":"Cellular component","Id":"GO:0043226","Definition":"Organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton. Excludes the plasma membrane (Gene Ontology)."}},{"Organism":{"Created":"2006-09-07","CurationStatus":"uncurated","SuperCategory":"Material entity","Id":"birnlex_2","Definition":"A living thing"}},{"Organism role":{"CurationStatus":"uncurated","SuperCategory":"Role","Id":"nlx_15782","Definition":"Role of any organism, e.g., patient, model organism"}},{"Organism supplier":{" limit":"1000","Synonym":"organism repository","CurationStatus":"uncurated","SuperCategory":"Biomaterial supply resource"," format":"CSV","Id":"nlx_res_090901","Definition":"A resource that provides organisms such as transgenic mice; e.g., the Jackson Laboratory."}},{"Organism-related portal":{"CurationStatus":"uncurated","SuperCategory":"Topical portal","Id":"nlx_21567","Definition":"A topical portal that provides information and resources related primarily to one type of organism, e.g., worm, mouse, E coli"}},{"Organismal quality":{"SuperCategory":"Quality of a single physical entity","Id":"PATO_0001995","Definition":"A quality that inheres in an entire organism or part of an organism."}},{"Organization":{"CurationStatus":"uncurated","SuperCategory":"Object aggregate","Id":"nlx_152328","Has role":"CINERGI Resource Descriptor","Keywords":"Resource:CINERGI","DefiningCitation":"http://purl.obolibrary.org/obo/OBI_0000245","Xref":"OBI_0000245","Definition":"An entity that can bear roles, has members, and has a set of organization rules. Members of organizations are either organizations themselves or individual people. Members can bear specific organization member roles that are determined in the organization rules. The organization rules also determine how decisions are made on behalf of the organization by the organization members."}},{"Organization portal":{" limit":"1000","Created":"2007-10-11","Synonym":["Institution portal","Institutional portal"],"CurationStatus":"uncurated","SuperCategory":"Portal"," format":"CSV","Id":"birnlex_2368","Definition":"A resource that serves as a web-accessible source of information for a group of people unified by some formally defined purpose."}},{"Organized":{"SuperCategory":"Structure","Id":"PATO_0000938"}},{"Organum vasculosum lamina terminalis":{"Synonym":["supraoptic crest","vascular organ of the lamina terminalis","medial prechiasmatic gland"],"SynonymPMID":"ISBN:0-12-547635-3","CurationStatus":"uncurated","NeuronamesID":"383","SuperCategory":"Circumventricular organ","Id":"nlx_anat_100313","Is part of":["Anterior hypothalamic region"],"Species":"Mammal,","Abbrev":["OVLT"],"DefinitionPMID":"ISBN:0-12-547635-3","Definition":"circumventricular organ that forms the ventral part of the midline anterior wall of the third ventricle"}},{"Orientation":{"SuperCategory":"Anatomical Pattern","Id":"sao271899308","Definition":"Refers to the \"entities of reference\" (FMA).  Location may be defined by qualitative coodrinates or absolute coordinates."}},{"Oriented":{"SuperCategory":"Position","Id":"PATO_0000614","Definition":"Placement that is the location of an entity relative to an axis."}},{"Original Image Identification":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_5000","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150405","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"AT","Definition":"TBD (retired)."}},{"Original Image Identification Nomenclature":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_5002","SuperCategory":"DICOM term","Id":"nlx_150406","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"TBD (retired)."}},{"Original Image Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2130_00C0","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150407","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"TBD (retired)."}},{"Original Specialized SOP Class UID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_001B","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150408","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UI","Definition":"TBD."}},{"Originator":{"ValueRepresentation":"AE","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2100_0070","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150409","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"AE","Definition":"Application Entity Title that issued the print operation."}},{"Orlistat":{"RelatedTo":["Lipoprotein lipase","Pancreatic triacylglycerol lipase"],"Synonym":["(-)-Tetrahydrolipstatin","Orlipastat","Orlipastatum (INN-Latin)","Tetrahydrolipstatin","orlistat","Alli"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01083","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01083","Definition":"Orlistat is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. Pharmacology: Orlistat is a lipase inhibitor for obesity management that acts byinhibiting the absorption of dietary fats. At the recommendedtherapeutic dose of 120 mg three times a day, orlistat inhibitsdietary fat absorption by approximately 30%. It works by inhibitingpancreatic lipase, an enzyme that breaks down fat in theintestine. Without this enzyme, fat from the diet is excretedundigested, and not absorbed by the body. Because some vitamins arefat soluble, the effect of orlistat is to reduce their bodyabsorption. Therefore the drug should only be taken in conjuction withfatty meals, and a multivitamin tablet containing these vitamins (D EK and beta-carotene) should be taken once a day, at least 2 hoursbefore or after taking the drug. In the March 15, 2004 issue of CancerResearch, (1) Steven J. Kridel et al. state that orlistat may also inhibit growth of prostate cancer, and in theory may be useful in treating other cancers, by interfering with the metabolism of fats. Mechanism of action: Orlistat is a reversible inhibitor of lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Obesity Agents. Enzyme Inhibitors"}},{"Ornithorhynchus anatinus":{"Synonym":"platypus","CurationStatus":"uncurated","SuperCategory":"Monotreme","Id":"NCBITaxon: 9258"}},{"Orphan (Chemokine receptor-like)":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_6718"}},{"Orphan (Chemokine receptor-like) - unspecified 1":{"Created":"2007-09-19","SuperCategory":"Orphan (Chemokine receptor-like)","Id":"nifext_6719"}},{"Orphan (Mas-related) receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5338"}},{"Orphan (Mas-related) receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5339"}},{"Orphan (Mas-related) receptor - unspecified 10":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_7106"}},{"Orphan (Mas-related) receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5343"}},{"Orphan (Mas-related) receptor - unspecified 3":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5347"}},{"Orphan (Mas-related) receptor - unspecified 4":{"Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5351"}},{"Orphan (Mas-related) receptor - unspecified 5":{"Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5355"}},{"Orphan (Mas-related) receptor - unspecified 6":{"Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5478"}},{"Orphan (Mas-related) receptor - unspecified 7":{"Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5546"}},{"Orphan (Mas-related) receptor - unspecified 8":{"Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5622"}},{"Orphan (Mas-related) receptor - unspecified 9":{"EditorialNote":"Proposed ligand, single publication (aka GPR80)","Created":"2007-09-19","SuperCategory":"Orphan (Mas-related) receptor","Id":"nifext_5706"}},{"Orphan (melatonin-like) receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_6878"}},{"Orphan (melatonin-like) receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"Orphan (melatonin-like) receptor","Id":"nifext_6879"}},{"Orphan (P2Y-like) receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_7851"}},{"Orphan (P2Y-like) receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"Orphan (P2Y-like) receptor","Id":"nifext_7852"}},{"Orphan (trace amine-like) receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_6835"}},{"Orphan (trace amine-like) receptor - unspecified 1":{"EditorialNote":"Might be pseudogene.","Created":"2007-09-19","SuperCategory":"Orphan (trace amine-like) receptor","Id":"nifext_6836"}},{"Orphan (trace amine-like) receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"Orphan (trace amine-like) receptor","Id":"nifext_7989"}},{"Orphan (trace amine-like) receptor - unspecified 3":{"Created":"2007-09-19","SuperCategory":"Orphan (trace amine-like) receptor","Id":"nifext_8040"}},{"Orphan receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5670"}},{"Orphan receptor - unspecified 1":{"EditorialNote":"Proposed ligand, single publication (aka GPR80)","Created":"2007-09-19","SuperCategory":"Orphan receptor","Id":"nifext_5671"}},{"Orphan receptor - unspecified 2":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"Orphan receptor","Id":"nifext_6311"}},{"OrphanA1 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5868"}},{"OrphanA1 receptor - unspecified 1":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"OrphanA1 receptor","Id":"nifext_5869"}},{"OrphanA1 receptor - unspecified 2":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"OrphanA1 receptor","Id":"nifext_7424"}},{"OrphanA1 receptor - unspecified 3":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"OrphanA1 receptor","Id":"nifext_7692"}},{"OrphanA12 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5444"}},{"OrphanA12 receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanA12 receptor","Id":"nifext_5445"}},{"OrphanA12 receptor - unspecified 2":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"OrphanA12 receptor","Id":"nifext_7777"}},{"OrphanA13 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5326"}},{"OrphanA13 receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanA13 receptor","Id":"nifext_5327"}},{"OrphanA13 receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanA13 receptor","Id":"nifext_7305"}},{"OrphanA14 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_6890"}},{"OrphanA14 receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanA14 receptor","Id":"nifext_6891"}},{"OrphanA14 receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanA14 receptor","Id":"nifext_7295"}},{"OrphanA15 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5945"}},{"OrphanA15 receptor - unspecified 1":{"EditorialNote":"aka RDC1","Created":"2007-09-19","SuperCategory":"OrphanA15 receptor","Id":"nifext_5946"}},{"OrphanA15 receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanA15 receptor","Id":"nifext_6182"}},{"OrphanA2 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5316"}},{"OrphanA2 receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanA2 receptor","Id":"nifext_5317"}},{"OrphanA2 receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanA2 receptor","Id":"nifext_5519"}},{"OrphanA3 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5321"}},{"OrphanA3 receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanA3 receptor","Id":"nifext_5322"}},{"OrphanA3 receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanA3 receptor","Id":"nifext_5729"}},{"OrphanA4 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_6542"}},{"OrphanA4 receptor - unspecified 1":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"OrphanA4 receptor","Id":"nifext_6543"}},{"OrphanA4 receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanA4 receptor","Id":"nifext_6730"}},{"OrphanA6 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_6288"}},{"OrphanA6 receptor - unspecified 1":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"OrphanA6 receptor","Id":"nifext_6289"}},{"OrphanA6 receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanA6 receptor","Id":"nifext_7317"}},{"OrphanA7 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_7210"}},{"OrphanA7 receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanA7 receptor","Id":"nifext_7211"}},{"OrphanA9 receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5693"}},{"OrphanA9 receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanA9 receptor","Id":"nifext_5694"}},{"OrphanA9 receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanA9 receptor","Id":"nifext_5754"}},{"OrphanLGR receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5331"}},{"OrphanLGR receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanLGR receptor","Id":"nifext_5332"}},{"OrphanLGR receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanLGR receptor","Id":"nifext_5764"}},{"OrphanLGR receptor - unspecified 3":{"Created":"2007-09-19","SuperCategory":"OrphanLGR receptor","Id":"nifext_7231"}},{"OrphanSREB receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_6109"}},{"OrphanSREB receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"OrphanSREB receptor","Id":"nifext_6110"}},{"OrphanSREB receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"OrphanSREB receptor","Id":"nifext_6562"}},{"OrphanSREB receptor - unspecified 3":{"Created":"2007-09-19","SuperCategory":"OrphanSREB receptor","Id":"nifext_6582"}},{"Orphenadrine":{"RelatedTo":["Glutamate (NMDA) receptor subunit zeta-1","Glutamate (NMDA) receptor subunit epsilon-4","Histamine H1 receptor","Glutamate (NMDA) receptor subunit 3B","Glutamate (NMDA) receptor subunit 3A"],"Synonym":["Mephenamine","O-Methyldiphenhydramine","Orphenadine","Orphenadrin","Orphenadrine Citrate","Orphenate","Orphenedrine","Antiflex","Banflex","Biorphen","Brocadisipal","Brocasipal","Disipal","Flexoject","Mio-Rel","Myolin","Myotrol","Norflex"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01173","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01173","Definition":"A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. (PubChem) Pharmacology: Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia. Mechanism of action: Orphenadrine binds to both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect. Drug type: Approved. Small Molecule. Drug category: Antidyskinetics. Antiparkinson Agents. Muscarinic Antagonists. Muscle Relaxants, Central. Parasympatholytics. Skeletal Muscle Relaxants"}},{"Orthodox Mitochondrial Quality":{"SuperCategory":"Mitochondrial Quality","Id":"sao358853874","Definition":"Morphological state characterized by an expanded matrix space and contracted intracristal space;  observed experimentally when ADP is added (Mannella et al., 2001)."}},{"Orthogastropoda":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1228753","SuperCategory":"Gastropod","Id":"birnlex_444"}},{"Orthogonal Array":{"Synonym":"square array","SuperCategory":"Subcellular entity","Id":"sao1747012216","Definition":"Square arrays of closely spaced intramembrane particles, 4-6 nm in size seen in astrocyte processes, now known to contain aquaporins."}},{"Orthographic discrimination":{"Created":"4/27/2011 14:09","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00762","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Orthographic_discrimination","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145984","Definition":"Subjects view letters and discriminate according to some feature (uppercase-lowercase, alphabetic order, same-different spelling of words, vowel-consonant, font size, etc.)."}},{"Orthoptera":{"Synonym":"Saltatoria","Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0029361","SuperCategory":"Orthopteroidea","Id":"birnlex_434"}},{"Orthopteroidea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1004425","SuperCategory":"Neoptera","Id":"birnlex_114"}},{"Oryctolagus":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0999632","SuperCategory":"Leporidae","Id":"birnlex_230"}},{"Oscillation":{"RelatedTo":"Wave","Synonym":"vibration","CurationStatus":"uncurated","SuperCategory":"Physical_quality","Id":"nlx_41371","Has role":"Regulation of synaptic transmission","Definition":"A set of repeating waves or measurements."}},{"Oseltamivir":{"RelatedTo":["Neuraminidase"],"Synonym":["Oseltamivir phosphate"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7798","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00198","Definition":"An acetamido cyclohexene that is a structural homolog of sialic acid and inhibits neuraminidase. (PubChem) Pharmacology: Oseltamivir is an antiviral drug, a neuraminidase inhibitor used in the treatment and prophylaxis of both influenza A and influenza B. Oseltamivir is a prodrug (usually administered as phosphate), it is hydrolysed hepatically to the active metabolite, the free carboxylate of oseltamivir (GS4071). Like zanamivir, oseltamivir acts as a transition-state analogue inhibitor of influenza neuraminidase. Mechanism of action: Oseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. Drug type: Approved. Small Molecule. Drug category: Antiviral Agents. Enzyme Inhibitors"}},{"Osmolality":{"SuperCategory":"Concentration of","Id":"PATO_0002027","Definition":"Amount of osmoles of soluter per kg of solvent."}},{"Osmolarity":{"SuperCategory":"Concentration of","Id":"PATO_0001655","Definition":"Amount of osmoles of solute per liter of solution."}},{"Osmometer":{"CurationStatus":"uncurated","Comment":"http://en.wikipedia.org/wiki/Osmometer","SuperCategory":"Measurement device","Id":"nlx_137418","Has role":"Instrument role","Definition":"is a device for measuring the osmotic strength of a solution, colloid, or compound."}},{"OspA lipoprotein":{"RelatedTo":"B-cell receptor CD22","Synonym":["Outer surface protein A precursor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00045","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00045","Definition":"Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant. Pharmacology: OspA lipoprotein is a single polypeptide chain of 270 amino acids. It is a vaccination used to prevent Lyme Disease. Mechanism of action: OspA lipoprotein, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. B. burgdorferi. Therefore, it is used as a vaccination against Lyme Disease.s Drug type: Approved. Biotech. Drug category: Vaccines"}},{"Ossified":{"SuperCategory":"Calcified","Id":"PATO_0001448","Definition":"A structural quality inhering in a bearer by virtue of being hardened by the deposition of calcium into bone."}},{"Ostariophysi":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1004204","SuperCategory":"Otocephala","Id":"birnlex_443"}},{"Osteoglossomorpha":{"SuperCategory":"Teleostei","Id":"nlx_348"}},{"OT receptor":{"Created":"2007-09-19","Synonym":"OT; OT-R; Oxytocin receptor","CurationStatus":"uncurated","SuperCategory":"Vasopressin/oxytocin receptor","Id":"nifext_5797"}},{"Other Magnification Types Available":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2010_00A7","SuperCategory":"DICOM term","Id":"nlx_150410","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"A code string containing the other types of magnification available."}},{"Other Media Available Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2000_00A4","SuperCategory":"DICOM term","Id":"nlx_150411","Has role":"Non-imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A sequence of items representing the other types of media available."}},{"Other Orphan Gene receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5359"}},{"Other Orphan Gene receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5360"}},{"Other Orphan Gene receptor - unspecified 10":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5400"}},{"Other Orphan Gene receptor - unspecified 11":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5418"}},{"Other Orphan Gene receptor - unspecified 12":{"EditorialNote":"aka GPCR1","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5426"}},{"Other Orphan Gene receptor - unspecified 13":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5436"}},{"Other Orphan Gene receptor - unspecified 14":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5453"}},{"Other Orphan Gene receptor - unspecified 15":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5470"}},{"Other Orphan Gene receptor - unspecified 16":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5486"}},{"Other Orphan Gene receptor - unspecified 17":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5503"}},{"Other Orphan Gene receptor - unspecified 18":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5527"}},{"Other Orphan Gene receptor - unspecified 19":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5553"}},{"Other Orphan Gene receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5364"}},{"Other Orphan Gene receptor - unspecified 20":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5785"}},{"Other Orphan Gene receptor - unspecified 21":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5821"}},{"Other Orphan Gene receptor - unspecified 22":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5879"}},{"Other Orphan Gene receptor - unspecified 23":{"EditorialNote":"Proposed ligands, single publications","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5956"}},{"Other Orphan Gene receptor - unspecified 24":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5978"}},{"Other Orphan Gene receptor - unspecified 25":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5989"}},{"Other Orphan Gene receptor - unspecified 26":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_6141"}},{"Other Orphan Gene receptor - unspecified 27":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_6174"}},{"Other Orphan Gene receptor - unspecified 28":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_6450"}},{"Other Orphan Gene receptor - unspecified 29":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_6553"}},{"Other Orphan Gene receptor - unspecified 3":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5368"}},{"Other Orphan Gene receptor - unspecified 30":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_6643"}},{"Other Orphan Gene receptor - unspecified 30 (nifext 6647)":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor - unspecified 30","Id":"nifext_6647"}},{"Other Orphan Gene receptor - unspecified 31":{"EditorialNote":"aka PGR7","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_6674"}},{"Other Orphan Gene receptor - unspecified 32":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_6814"}},{"Other Orphan Gene receptor - unspecified 33":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7065"}},{"Other Orphan Gene receptor - unspecified 34":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7184"}},{"Other Orphan Gene receptor - unspecified 35":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7193"}},{"Other Orphan Gene receptor - unspecified 36":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7202"}},{"Other Orphan Gene receptor - unspecified 37":{"EditorialNote":"pseudogene in most individuals due to polymorphic premature stop codon","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7358"}},{"Other Orphan Gene receptor - unspecified 38":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7396"}},{"Other Orphan Gene receptor - unspecified 39":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7501"}},{"Other Orphan Gene receptor - unspecified 4":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5372"}},{"Other Orphan Gene receptor - unspecified 40":{"EditorialNote":"Proposed ligand, single publication","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7641"}},{"Other Orphan Gene receptor - unspecified 41":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7671"}},{"Other Orphan Gene receptor - unspecified 42":{"EditorialNote":"aka RE2","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7718"}},{"Other Orphan Gene receptor - unspecified 43":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_7798"}},{"Other Orphan Gene receptor - unspecified 5":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5377"}},{"Other Orphan Gene receptor - unspecified 6":{"EditorialNote":"probable pseudogene","Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5381"}},{"Other Orphan Gene receptor - unspecified 7":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5384"}},{"Other Orphan Gene receptor - unspecified 8":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5388"}},{"Other Orphan Gene receptor - unspecified 9":{"Created":"2007-09-19","SuperCategory":"Other Orphan Gene receptor","Id":"nifext_5392"}},{"Other Patient IDs":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_1000","SuperCategory":"DICOM term","Id":"nlx_150412","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Other identification numbers or codes used to identify the patient."}},{"Other Patient Names":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_1001","SuperCategory":"DICOM term","Id":"nlx_150413","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"PN","Definition":"Other names used to identify the patient."}},{"Other Smoothing Types Available":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2010_00A9","SuperCategory":"DICOM term","Id":"nlx_150414","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"A sequence of items representing the other smoothing available."}},{"Other Study Numbers":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1070","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_150415","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"TBD (retired)."}},{"OTKA Foundation":{"Synonym":["Hungarian Scientific Research Fund"],"CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_144434","DefiningCitation":"http://www.otka.hu/?set_lang","Abbrev":"OTKA","Definition":"The Hungarian Scientific Research Fund (Hungarian abbreviation: OTKA) has been the major funding agency of basic science and scholarship since 1986 when the transition to competitive research funding started in Hungary. Its \"founding fathers\" modelled the principles of operation on the practice of German (Deutsche Forschungsgemeinschaft) and American research funds (National Science Foundation, National Institutes of Health). Upon a government decree, OTKA has been operating as an independent non-profit organisation since 1991. Its legal status and rules of operation were established in an act in 1993 and reinforced in 1997 by the Hungarian parliament in order to provide independent support to scientific research activities and infrastructure, to promote scientific achievements of international standards, and to provide assistance to young researchers. As an independent institution, OTKA reports to the parliament and the government of Hungary. With regards to the funds provided within the annual budget of the Republic of Hungary, the appropriations of OTKA are administered via the budget of the Hungarian Academy of Sciences. The administrative and financial tasks related to its operation are performed by the OTKA Office in Budapest."}},{"Otocephala":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1210437","SuperCategory":"Clupeocephala","Id":"birnlex_522"}},{"Otophysi":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1210430","SuperCategory":"Ostariophysi","Id":"birnlex_449"}},{"Ouabain":{"RelatedTo":["Sodium/potassium-transporting ATPase alpha-1 chain","Kininogen-1"],"Synonym":["G-Strophanthin","Ouabagenin L-Rhamnoside","Ouabain Octahydrate","Ouabain","Octahydrate","Ouabaine","Strophanthin G","Strophanthin-G","Acocantherin","Astrobain","G-Strophicor","Gratibain","Gratus Strophanthin","Kombetin","Purostrophan","Rectobaina","Solufantina","Strodival","Strophalen","Strophoperm","Strophosan","Uabaina"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7805","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01092","Definition":"A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase. (PubChem) Pharmacology: Ouabain, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Mechanism of action: Ouabain inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Ouabain also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential. Drug type: Approved. Small Molecule. Drug category: Cardiotonic Agents. Enzyme Inhibitors"}},{"Outer ear":{"Synonym":"External ear","Created":"2007-08-20","CurationStatus":"uncurated","Umlscui":["C1269548"],"SuperCategory":"Regional part of ear","Id":"birnlex_1705"}},{"Outer granular layer of cerebellar cortex":{"Created":"2007-08-20","CurationStatus":"uncurated","Umlscui":["C0228473"],"SuperCategory":"Cell layer","Id":"birnlex_797","Is part of":"Granular layer of cerebellar cortex"}},{"Output Information Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_4033","SuperCategory":"DICOM term","Id":"nlx_150416","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A Sequence that provides reference to one or more Composite SOP instances, that identify the Structured Reports or other results created. Zero or more Items may be included in this sequence."}},{"Output Power":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_5000","SuperCategory":"DICOM term","Id":"nlx_150417","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"Manufacturer defined character string description of ultrasound output level(s) used in generating a given image. Data may be expressed in dB, %, W/cm2, etc."}},{"Oval":{"Synonym":"Oval Soma Quality","SuperCategory":"Soma Shape","Id":"sao1595237779","Definition":"Generally rounded shape, where the minimum and maximum dimensions produce a roughly egg-shape."}},{"Ovate":{"Synonym":["Ovoid","Egg-shaped"],"SuperCategory":"Spheroid","Id":"PATO_0001891","Definition":"Shape which is a continuous convex surface with an axis of symmetry and one axis longer than the other; egg-shaped."}},{"Overdeveloped":{"SuperCategory":"Structure","Id":"PATO_0000644"}},{"Overlap with":{"Synonym":"overlap","SuperCategory":"Relational structural quality","Id":"PATO_0001590","Definition":"Coincide spatially, partially, or wholly with another entity."}},{"Overlay Activation Layer":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1001","SuperCategory":"DICOM term","Id":"nlx_150418","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The layer (defined in Graphic Layer (0070,0002) of the Graphic Layer Module C.10.7) in which the Overlay described in group 60xx shall be displayed. If no layer is specified (zero length) then the overlay shall not be displayed. Required if Group 60xx is present."}},{"Overlay Bit Position":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0102","SuperCategory":"DICOM term","Id":"nlx_150419","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Bit in which Overlay is stored. See PS 3.5 for further explanation. If the overlay data are stored in the Overlay Data (60xx,3000) Attribute, the value of this Attribute shall be 0."}},{"Overlay Bits Allocated":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0100","SuperCategory":"DICOM term","Id":"nlx_150420","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of Bits Allocated in the Overlay. If the overlay data are embedded in the Image Pixel Data (7FE0,0010), the value of this Attribute shall be the same as Bits Allocated (0028,0100). "}},{"Overlay Columns":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0011","SuperCategory":"DICOM term","Id":"nlx_150421","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of Columns in Overlay."}},{"Overlay Data":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_3000","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150422","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"OB or OW","Definition":"Overlay pixel data. The order of pixels sent for each overlay is left to right, top to bottom, i.e., the upper left pixel is sent first followed by the remainder of the first row , followed by the first pixel of the 2nd row, then the remainder of the 2nd row, etc."}},{"Overlay Date":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0024","SuperCategory":"DICOM term","Id":"nlx_150423","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"The date the Overlay was created."}},{"Overlay Description":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0022","SuperCategory":"DICOM term","Id":"nlx_150424","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"User-defined comments about the overlay."}},{"Overlay Descriptor - Blue":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1103","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150425","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlay Descriptor - Gray":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1100","SuperCategory":"DICOM term","Id":"nlx_150426","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlay Descriptor - Green":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1102","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150427","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlay Descriptor - Red":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1101","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150428","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlay Format":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0110","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150429","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Overlay Label":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1500","SuperCategory":"DICOM term","Id":"nlx_150430","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"A user defined text string which may be used to label or name this overlay."}},{"Overlay Location":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0200","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150431","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlay Mode":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2040_0090","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150432","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Overlay Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0022","SuperCategory":"DICOM term","Id":"nlx_150433","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"A number that identifies this Overlay."}},{"Overlay Origin":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0050","SuperCategory":"DICOM term","Id":"nlx_150434","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SS","Definition":"Location of first overlay point with respect to pixels in the image, given as rowcolumn. The upper left pixel of the image has the coordinate 11. Column values greater than 1 indicate the overlay plane origin is to the right of the image origin. "}},{"Overlay Plane Origin":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0052","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150435","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlay Planes":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0040","SuperCategory":"DICOM term","Id":"nlx_150436","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Indicates whether this overlay represents a region of interest or other graphics."}},{"Overlay Rows":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0010","SuperCategory":"DICOM term","Id":"nlx_150437","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Number of Rows in Overlay."}},{"Overlay Subtype":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0045","SuperCategory":"DICOM term","Id":"nlx_150438","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Defined term which identifies the intended purpose of the ROI Overlay Type."}},{"Overlay Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0034","SuperCategory":"DICOM term","Id":"nlx_150439","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"The time the Overlay was created."}},{"Overlay Type":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_0045","SuperCategory":"DICOM term","Id":"nlx_150440","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Defined term which identifies the intended purpose of the Overlay Type."}},{"Overlays - Blue":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1203","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150441","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlays - Gray":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1200","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150442","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlays - Green":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1202","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150443","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Overlays - Red":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:60xx_1201","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150444","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"TBD (retired)."}},{"Override Parameter Pointer":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_0062","SuperCategory":"DICOM term","Id":"nlx_150445","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"AT","Definition":"Contains the Data Element Tag of the attribute which was overridden. Required if Override Sequence (3008,0060) is sent."}},{"Override Reason":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_0066","SuperCategory":"DICOM term","Id":"nlx_150446","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"User-defined description of reason for override of parameter specified by Override Parameter Pointer (3008,0062)."}},{"Override Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_0060","SuperCategory":"DICOM term","Id":"nlx_150447","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of parameters which were overridden during the administration of the beam segment immediately prior to the current control point. The sequence may contain one or more items."}},{"Oversampling Phase":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9029","SuperCategory":"DICOM term","Id":"nlx_150448","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Oversampling Phase. Required if Image Type (0008,0008) Value 1 is ORIGINAL or MIXED. May be present otherwise."}},{"Ovis":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C0036945","SuperCategory":"Caprinae","Id":"birnlex_450"}},{"Ovis aries musimon":{"Synonym":["Ovis musimon","Ovis gmelini","Ovis orientalis musimon"],"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C0325321","SuperCategory":"Sheep","Id":"birnlex_462"}},{"OX1 receptor":{"Created":"2007-09-19","Synonym":["OX1","Ox1r"],"CurationStatus":"uncurated","SuperCategory":"Orexin (hypocretin) receptor","Id":"nifext_7174"}},{"OX2 receptor":{"Synonym":"OX2","Created":"2007-09-19","SuperCategory":"Orexin (hypocretin) receptor","Id":"nifext_7631"}},{"Oxacillin":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["Oxacillin Sodium"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7809","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00713","Definition":"An antibiotic similar to flucloxacillin used in resistant staphylococci infections. (PubChem) Pharmacology: Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \"penicillin\" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Mechanism of action: By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Penicillins"}},{"Oxaliplatin":{"RelatedTo":"DNA","Synonym":["Oxalatoplatin","Oxalatoplatinum","Oxaliplatin (Usan:Inn:Ban)","Oxaliplatino (Spanish)","Oxaliplatinum (Latin)","Oxaloplatine (French)","Oxaloplatino (Spanish)","oxaliplatin","DACPLAT","Eloxatin","Elplat","Foloxatine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:31941","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00526","Definition":"Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin. Pharmacology: Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mechanism of action: After activation oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents"}},{"Oxamniquine":{"RelatedTo":"DNA","Synonym":[", Mansil"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01096","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01096","Definition":"An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Extra Pharmacopoeia, 31st ed, p121) Pharmacology: Oxamniquine is an anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release egg. Mechanism of action: Oxamniquine may associates with an irreversible inhibition of the nucleic acid metabolism of the parasites. A hypothesis has been put forth that the drug is activated by a single step, in which a schistosome enzyme converts oxamniquine into an ester (probably acetate, phosphate, or sulfate). Subsequently, the ester spontaneously dissociates, the resulting electrophilic reactant is capable of alkylation of schistosome DNA. Drug type: Approved. Small Molecule. Drug category: Schistosomicides"}},{"Oxandrolone":{"RelatedTo":"Androgen receptor","Synonym":["Ossandrolone (DCIT)","Oxandrolona (INN-Spanish)","Oxandrolonum (INN-Latin)","oxandrolone","Anavar","Lonavar","Oxandrin","Protivar","Provitar"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7820","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00621","Definition":"A synthetic hormone with anabolic and androgenic properties. (PubChem) Pharmacology: Oxandrolone is an anabolic steroids indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis. Anabolic steroids are synthetic derivatives of testosterone. Mechanism of action: Oxandrolones interact with androgen receptors in target tissues. Drug type: Approved. Investigational. Small Molecule. Drug category: Anabolic Agents. Androgens"}},{"Oxaprozin":{"RelatedTo":"Prostaglandin G/H synthase 2","Synonym":["Oxaprozina (INN-Spanish)","Oxaprozine (INN-French)","Oxaprozinum (INN-Latin)","Alvo","Daypro","Daypro Alta","Deflam"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00991","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00991","Definition":"Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Pharmacology: Oxaprozin is a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain. Mechanism of action: Antiinflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Drug type: Approved. Small Molecule. Drug category: Anti-Inflammatory Agents, Non-Steroidal. Anti-inflammatory Agents. Nonsteroidal Antiinflammatory Agents (NSAIDs)"}},{"Oxazepam":{"RelatedTo":["Serum albumin"],"Synonym":["Oxazipam","Oxozepam","d-Oxazepam hemisuccinate","Adumbran","Ansioxacepam","Anxiolit","Aplakil","Astress","Azutranquil","Bonare","Drimuel","Droxacepam","Durazepam","Enidrel","Hi-Long","Isodin","Lederpam","Limbial","Murelax","Nesontil","Noctazepam","Notaral","Oxa-puren","Oxanid","Pacienx","Praxiten","Propax","Psiquiwas","QUEN","Quilibrex","Rondar","Sedigoa","Serax","Serenal","Serenid","Serenid-D","Serepax","Seresta","Serpax","Sigacalm","Sobril","Tacepam","Tazepam","Uskan","Vaben","Wy-3498 stic"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7823","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00842","Definition":"A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia. (PubChem) Pharmacology: Oxazepam is a drug which is a benzodiazepine derivative. It possesses relatively weak anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Mechanism of action: Oxazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation. Drug type: Approved. Small Molecule. Drug category: Anti-anxiety Agents. GABA Modulators. Hypnotics and Sedatives"}},{"Oxcarbazepine":{"RelatedTo":"Sodium channel protein type 5 subunit alpha","Synonym":["Oxcarbamazepine"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00776","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00776","Definition":"Oxcarbazepine is structurally a derivative of carbamazepine, adding an extra oxygen atom to the benzylcarboxamide group. This difference helps reduce the impact on the liver of metabolizing the drug, and also prevents the serious forms of anemia occasionally associated with carbamazepine. Aside from this reduction in side effects, it is thought to have the same mechanism as carbamazepine - sodium channel inhibition - and is generally used to treat partial seizures in epileptic children and adults. Pharmacology: Oxcarbazepine is structurally a derivative of carbamazepine, adding an extra oxygen atom to the benzylcarboxamide group. This difference helps reduce the impact on the liver of metabolizing the drug, and also prevents the serious forms of anemia occasionally associated with carbamazepine. Aside from this reduction in side effects, it is thought to have the same mechanism as carbamazepine - sodium channel inhibition - and is generally used to treat the same conditions. Mechanism of action: The exact mechanism by which oxcarbazepine exerts its anticonvulsant effect is unknown. It is known that the pharmacological activity of oxcarbazepine occurs primarily through its 10-monohydroxy metabolite (MHD). In vitro studies indicate an MHD-induced blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neuronal membranes, inhibition of repetitive neuronal discharges, and diminution of propagation of synaptic impulses. Drug type: Approved. Small Molecule. Drug category: Anticonvulsants"}},{"OXE receptor":{"Synonym":"OXE","Created":"2007-09-19","SuperCategory":"Leukotriene and lipoxin receptor","Id":"nifext_5286"}},{"Oxiconazole":{"RelatedTo":"Ergosterol biosynthetic protein 28","Synonym":["Oxiconazol (INN-Spanish)","Oxiconazole Nitrate","Oxiconazolum (INN-Latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00239","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00239","Definition":"Oxiconazole nitrate (U.S.: Oxistat, Canada: Oxizole) is an antifungal medication typically administered in a cream or lotion to treat skin infections such as athlete's foot, jock itch and ringworm. (Wikipedia) Pharmacology: Oxiconazole is a broad-spectrum imidazole derivative whose antifungal activity is derived primarily from the inhibition of ergosterol biosynthesis, which is critical for cellular membrane integrity. It has fungicidal or fungistatic activity in vitro against a number of pathogenic fungi including the following dermatophytes, and yeasts: T. rubrum, T. mentagrophytes, T. tonsurans, T. violaceum, E. floccosum, M. canis, M. audouini, M. gypseum, C. albicans, and M. furfur. Mechanism of action: Oxiconazole inhibits ergosterol biosynthesis, which is required for cytoplasmic membrane integrity of fungi. Drug type: Approved. Small Molecule. Drug category: Antifungal Agents"}},{"Oxidized Molecular Quality":{"CurationStatus":"uncurated","SuperCategory":"Molecular Quality","Id":"nlx_qual_090901"}},{"Oxprenolol":{"RelatedTo":["Beta-1 adrenergic receptor"],"Synonym":["(+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol","(+-)-oxprenolol","(1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol","1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane","1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol","1-(2-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol","DL-oxprenolol","Osprenololo (dcit)","Oxprenololum (inn-latin)","Coretal","Laracor","Slow-pren","Trasacor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01580","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01580","Definition":"A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. (PubChem) Pharmacology: Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. Oxprenolol is a lipophilic beta blocker which passes the blood-brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol. Oxprenolol is an potent beta-blocker and should not be administered to asthmatics because it can cause irreversible airway failure and inflammation. Mechanism of action: Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Oxprenolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Antagonists. Anti-Arrhythmia Agents. Anti-anxiety Agents. Antihypertensive Agents. Sympatholytics. Vasodilator Agents"}},{"Oxybenzone":{"Synonym":["(2-Hydroxy-4-methoxyphenyl)phenylmethanone","2-Benzoyl-5-methoxyphenol","2-Hydroxy-4-methoxybenzophenone","4-Methoxy-2-hydroxybenzophenone","4-Methoxy-2-hydroxybenzophenone butyric acid","Oxibenzona (inn-spanish)","Oxybenzonum (inn-latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01428","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01428","Definition":"Oxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents. It is used as an ingredient in sunscreen and other cosmetics because it absorbs UV-A ultraviolet rays. Pharmacology: Oxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. Mechanism of action: Oxybenzone absorbs UV-A ultraviolet rays, preventing them from reaching the skin. Drug type: Approved. Small Molecule. Drug category: Sunscreening Agents"}},{"Oxybuprocaine":{"RelatedTo":"Sodium channel protein type 10 subunit alpha","Synonym":["Benoxinate","Benoxinate HCL","Benoxinate hydrochloride","Dorsacaine hydrochloride","Oxbarukain","Oxibuprocainum","Oxibuprokain","Oxybucaine","Oxybuprocaine HCL","Oxybuprocaine hydrochloride","Oxyriprocaine","Benoxil","Cebesine","Conjucain","Conjuncain","Dorsacain","Dorsacaine","Fluress","Lacrimin","Minims Benoxinate","Novesin","Novesina","Novesine","Novesinol","Opulets Benoxinate"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00892","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00892","Definition":"Oxybuprocaine is the name of a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Pharmacology: Oxybuprocaine is a local anaesthetic. It may be less irritating than tetracaine, and the onset and duration of action are similar to tetracaine. Mechanism of action: Oxybuprocaine binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses. Drug type: Approved. Small Molecule. Drug category: Anesthetics, Local"}},{"Oxybutynin":{"RelatedTo":["Cholinergic system","Muscarinic acetylcholine receptor M3","Muscarinic acetylcholine receptor M1"],"Synonym":["Oxibutinina (INN-Spanish)","Oxibutyninum","Oxybutinin","Oxybutynin Base","Oxybutynin Chloride","Oxybutynin Hydrochloride","Oxybutynine (INN-French)","Oxybutyninum (INN-Latin)","oxybutynin","oxybutynin topical gel","transdermal patch","Ditropan","Ditropan Xl"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7856","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01062","Definition":"Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor. Pharmacology: Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer. Mechanism of action: Oxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). Drug type: Approved. Investigational. Small Molecule. Drug category: Anticholinergic Agents. Antispasmodics. Genitourinary Smooth Muscle Relaxants. Muscarinic Antagonists. Parasympatholytics"}},{"Oxycodone":{"RelatedTo":["Delta-type opioid receptor","Kappa-type opioid receptor"],"Synonym":["Dihydrohydroxycodeinone","Dihydrohydroxycondeinone","Dihydrone","Oxicodona (INN-Spanish)","Oxycodone Hcl","Oxycodone Hydrochloride","Oxycodonum (INN-Latin)","PTI-821","oxycodone","Combunox","Dihydroxycodeinone","Dinarkon","Diphydrone","Endocet","Endodan","Endone","Eubine","Eucodal","Eucodalum","Eukodal","Eutagen","Oxanest","Oxicon","Oxicone","Oxikon","OxyFAST","OxyIR","OxyNorm","Oxycodeinone","Oxycodon","Oxycon","Oxycontin","Pancodine","Percobarb","Percodan","Percolone","Remoxy","Roxicodone","Supendol","Supeudol","Tecodin","Tekodin","Thecodine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7852","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00497","Definition":"Semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. (PubChem) Pharmacology: Oxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes. Mechanism of action: Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Drug type: Approved. Illicit. Investigational. Small Molecule. Drug category: Analgesics, Opioid. Antitussives. Narcotics. Opiate Agonists"}},{"Oxycodone hydrochloride":{"Synonym":["oxycodone HCL","Oxycontin"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"CHEBI_7859","Has role":["Drug of abuse role"],"Definition":"A hydrochloride that has formula C18H22ClNO4."}},{"Oxygen Sensor":{"CurationStatus":"uncurated","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","SuperCategory":"Chemical quantification instrument","Id":"nlx_152767","Has role":"Instrument role","Definition":"usually amperometric or optical detection methods used for sensing oxygen concentration."}},{"Oxymetazoline":{"RelatedTo":["Alpha-2A adrenergic receptor"],"Synonym":["Oximetazolinum","Oxymethazoline","Oxymetozoline","oxymetazoline hydrochloride crystalline","Afrin","Afrin Cherry 12 Hour Nasal Spray","Afrin Extra Moisturizing 12 Hour Nasal Spray","Afrin Original 12 Hour Nasal Spray","Afrin Original 12 Hour Nose Drops","Afrin Original 12 Hour Pump Mist","Afrin Sinus 12 Hour Nasal Spray","Dristan Long Lasting Mentholated Nasal Spray","Dristan Long Lasting Nasal Mist","Drixoral Nasal Solution","Duramist Plus Up To 12 Hour Nasal Decongestant Spray","Duration 12 Hour Nasal Spray","Genasal Nasal Spray Up to 12 Hour Relief","Hazol","Iliadin","Nafrine","Nasal Relief 12 Hour Nasal Spray","Nasivine","Navasin","Navisin","Neo-Synephrine 12 Hour Spray","Nezeril","Nostrilla 12 Hour Nasal Decongestant","OcuClear","Oxylazine","Rhinofrenol","Rhinolitan","Sinerol","Vicks Sinex 12 Hour Nasal Spray","Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief","Visine L,R"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00935","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00935","Definition":"A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251) Pharmacology: Oxymetazoline a adrenergic alpha-agonists, direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis. Mechanism of action: Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion. Drug type: Approved. Small Molecule. Drug category: Adrenergic alpha-Agonists. Nasal Decongestants. Sympathomimetics"}},{"Oxymetholone":{"Synonym":["Anadrol"],"CurationStatus":"uncurated","Id":"nlx_chem_100310","Has role":["Drug of abuse role","Drug"],"Definition":"A synthetic anabolic steroid developed by Zoltan 'Anadrol Z' F. in 1960. Its primary clinical applications include treatment of osteoporosis and anaemia, as well as stimulating muscle growth in undernourished or underdeveloped patients. (Wikipedia)"}},{"Oxymorphone":{"RelatedTo":"Mu-type opioid receptor","Synonym":["14-Hydroxydihydromorphinone","Dihydrohydroxymorphinone","Dihydroxymorphinone","EN3202","Oximorphonum","Oxymorphine","oxymorphone","Numorphan","OPANA ER"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01192","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01192","Definition":"An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092) Pharmacology: Oxymorphone is a semi-synthetic opioid substitute for morphine. It is a potent analgesic. Opioid analgesics exert their principal pharmacologic effects on the CNS and the gastrointestinal tract. The principal actions of therapeutic value are analgesia and sedation. Opioids produce respiratory depression by direct action on brain stem respiratory centers. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation. Mechanism of action: Oxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. Drug type: Approved. Investigational. Small Molecule. Drug category: Adjuvants. Adjuvants, Anesthesia. Analgesics. Analgesics, Opioid. Narcotics. Opiate Agonists"}},{"Oxyphencyclimine":{"RelatedTo":["Cholinergic system","Muscarinic acetylcholine receptor M3","Muscarinic acetylcholine receptor M1"],"Synonym":["Oxifencicliminum (INN-Spanish)","Oxiphencycliminum","Oxyphencyclimine Hydrochloride","Oxyphencycliminum (INN-Latin)","Antulcus","Caridan","Cycmin","Daricol","Daricon","Dominil","Enterex","Gastrix","Manir","Naridan","Oximin","Setrol","Spazamin","Syklifen","Ulcociclinina","Vio-Thene","W-T Anticholinergic"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00383","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00383","Definition":"Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers. Pharmacology: Oxyphencyclimine is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Oxyphencyclimine is an antimuscarinic, anticholinergic drug. Mechanism of action: Oxyphencyclimine binds the muscarinic acetylcholine receptor. It may block all three types of muscarinic receptors including M-1 receptors in the CNS and ganglia, M-2 receptors in the heart (vagus) and M-3 receptors at the parasympathetic NEJ system. The muscarinic acetylcholine receptors mediate various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Oxphencyclimine inhibits vagally mediated reflexes by antagonizing the action of acetylcholine. This in turn reduces the secretion of gastric acids in the stomach. Drug type: Approved. Small Molecule. Drug category: Anticholinergic Agents. Antispasmodics"}},{"Oxyphenonium":{"RelatedTo":["Cholinergic system"],"Synonym":["DCF","Hydroxymethylgramicidin","Methocidin (Dcf:Inn)","Methocidine (INN-French)","Methocidinum (INN-Latin)","Metocidina (INN-Spanish)","Oxiphenonum","Oxyphenonium Bromide","Antrenyl","Argicillin","Methacin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00219","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00219","Definition":"A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. (PubChem) Pharmacology: Oxyphenonium is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Oxyphenonium is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Oxyphenonium inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions. Mechanism of action: Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic). Drug type: Approved. Small Molecule. Drug category: Muscarinic Antagonists. Mydriatics. Parasympatholytics"}},{"Oxytetracycline":{"RelatedTo":["30S ribosomal protein S4","30S ribosomal protein S9"],"Synonym":[", Oxytetracycline HCl","Oxytetracycline anhydrous"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:27701","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00595","Definition":"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. (PubChem) Pharmacology: Oxytetracycline is known as a broad-spectrum antibiotic due to its activity against such a wide range of infections. It was the second of the tetracyclines to be discovered. Oxytetracycline, like other tetracyclines, is used to treat many infections common and rare. Its better absorption profile makes it preferable to tetracycline for moderately severe acne, but alternatives sould be sought if no improvement occurs by 3 months. Mechanism of action: Oxytetracycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Oxytetracycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Tetracyclines"}},{"Oxytocin":{"RelatedTo":["Oxytocin-neurophysin 1"],"Synonym":["Pitocin","Syntocinon","Oxytocin (BAM Biotech)","Pitocin (Parke-Davis)"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Peptide","Curator":"ab","Id":"CHEBI:7872","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00107","Definition":"Synthetic 9 residue cyclic peptide. The hormone is prepared synthetically to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity. Pharmacology: Used to induce labor or to enhance uterine contractions during labor. Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+-dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+, which in turn activates myosins light chain kinase.. Oxytocin has specific receptors in the muscle llining of the uterus and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term. Mechanism of action: Binds the oxytocin receptor which leads to an increase in intracellular calcium levels. Drug type: Approved. Biotech. Drug category: Anti-tocolytic Agents. Labor Induction Agents. Oxytocics"}},{"P2x1":{"RelatedTo":"Adenosine triphosphate","CurationStatus":"uncurated","SuperCategory":"ATP-gated ion channel","Id":"nlx_85283","DefiningCitation":["http://omim.org/entry/600845"]}},{"P2x2":{"RelatedTo":"Adenosine triphosphate","CurationStatus":"uncurated","SuperCategory":"ATP-gated ion channel","Id":"nlx_45283","DefiningCitation":["http://omim.org/entry/600844"]}},{"P2x3":{"RelatedTo":"Adenosine triphosphate","CurationStatus":"uncurated","SuperCategory":"ATP-gated ion channel","Id":"nlx_69493","DefiningCitation":["http://omim.org/entry/600843"]}},{"P2x4":{"RelatedTo":"Adenosine triphosphate","CurationStatus":"uncurated","SuperCategory":"ATP-gated ion channel","Id":"nlx_87482","DefiningCitation":["http://omim.org/entry/600846"]}},{"P2x5":{"RelatedTo":"Adenosine triphosphate","CurationStatus":"uncurated","SuperCategory":"ATP-gated ion channel","Id":"nlx_65730","DefiningCitation":["http://omim.org/entry/602836"]}},{"P2x6":{"RelatedTo":"Adenosine triphosphate","CurationStatus":"uncurated","SuperCategory":"ATP-gated ion channel","Id":"nlx_19899","DefiningCitation":["http://omim.org/entry/608077"]}},{"P2x7":{"RelatedTo":"Adenosine triphosphate","CurationStatus":"uncurated","SuperCategory":"ATP-gated ion channel","Id":"nlx_89955","DefiningCitation":["http://omim.org/entry/602566"]}},{"P2Y receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5311"}},{"P2Y receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"P2Y receptor","Id":"nifext_7477"}},{"P2Y1 receptor":{"EditorialNote":"Additional agonists from V Ralevic and G Burnstock, Pharm. Rev., v50:n3, p413 (BB).","Synonym":"P2Y1","Created":"2007-09-19","SuperCategory":"P2Y receptor","Id":"nifext_6522"}},{"P2Y11 receptor":{"Synonym":"P2Y11","Created":"2007-09-19","SuperCategory":"P2Y receptor","Id":"nifext_5312"}},{"P2Y12 receptor":{"Created":"2007-09-19","Synonym":"P2Y12; ADP-glucose receptor; ADPG-R; P2T(AC); P2Y(AC); P2Y(ADP); P2Y(cyc); P2Y12 platelet ADP receptor; SP1999; P2Y purinoceptor 12","CurationStatus":"uncurated","SuperCategory":"P2Y receptor","Id":"nifext_6707"}},{"P2Y13 receptor":{"Synonym":"P2Y13","Created":"2007-09-19","SuperCategory":"P2Y receptor","Id":"nifext_7840"}},{"P2Y2 receptor":{"Created":"2007-09-19","EditorialNote":"Additional agonists from V Ralevic and G Burnstock, Pharm. Rev., v50:n3, p413 (BB).","Synonym":"P2Y2; ATP receptor; P2U purinoceptor 1; P2U1; Purinergic receptor; P2Y purinoceptor 2","CurationStatus":"uncurated","SuperCategory":"P2Y receptor","Id":"nifext_6695"}},{"P2Y4 receptor":{"Synonym":"P2Y4","Created":"2007-09-19","SuperCategory":"P2Y receptor","Id":"nifext_7886"}},{"P2Y6 receptor":{"Synonym":"P2Y6","Created":"2007-09-19","SuperCategory":"P2Y receptor","Id":"nifext_7488"}},{"Paced auditory serial addition test":{"Created":"4/15/2011 10:26","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00930","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Paced_auditory_serial_addition_test","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146154","Definition":"No definition submitted yet."}},{"Pacemaker neuron":{"Has_role":"Fly_Anatomy_Ontology","CurationStatus":"uncurated","Comment":["Molecular oscillation of Period (FBgn0003068) and Timeless (FBgn0014396) expression considered to be central to molecular mechanism of pacemaking"],"SuperCategory":"Neuron","Id":"nlx_147931","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00006048","Definition":"Neuron that supports clock-gene oscillations under light:dark cycles or constant conditions, and participates in control of the diurnal rhythm of the organism."}},{"Pacifastacus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998237","SuperCategory":"Astacidae","Id":"birnlex_328"}},{"Pacinian corpuscle":{"CurationStatus":"uncurated","SuperCategory":"Encapsulated nerve ending","Id":"FMA:83604","Has role":["Mechanoreceptor"],"DefiningCitation":"Foundational Model of Anatomy","Definition":"Encapsulated nerve ending located in skin composed of nerve ending of a dorsal root ganglion neuron wrapped in 20-60 concentric lamellae composed of fibrous tissue and fibroblasts. They function as mechanoreceptors for pressure (adapted from Wikipedia)"}},{"Paclitaxel":{"RelatedTo":["Tubulin beta-1 chain"],"Synonym":["7-Epipaclitaxel","7-Epitaxol","7-epi-Paclitaxel","7-epi-Taxol","Epitaxol","LipoPac","Onxol","Paxceed","Paxene","Taxol","Taxol A","Vascular Wrap"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01229","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01229","Definition":"A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS brevifolia. It stabilizes microtubules in their polymerized form leading to cell death. (PubChem) Pharmacology: Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or \"bundles\" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Mechanism of action: Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the  subunit of tubulin. Tubulin is the \"building block\" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Phytogenic. Tubulin Modulators"}},{"Paedomorphic growth":{"Synonym":["pedomorphic growth"],"SuperCategory":"Heterochronic growth","Id":"PATO_0001749","Definition":"A heterochronic growth quality in which the growth of an organism, structure, or group of organisms has a reduced outcome."}},{"PAF receptor":{"Synonym":"PAF","Created":"2007-09-19","SuperCategory":"Platelet-activating factor receptor","Id":"nifext_7523"}},{"Page Number Vector":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_2001","SuperCategory":"DICOM term","Id":"nlx_150449","Has role":"imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"An array which contains, for each of the image frames, the corresponding page numbers of the original document. Required if Frame Increment Pointer (0028,0009) points to Page Number Vector (0018,2001)."}},{"Paguridae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998257","SuperCategory":"Paguroidea","Id":"birnlex_559"}},{"Paguroidea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998256","SuperCategory":"Anomura","Id":"birnlex_645"}},{"Pagurus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1510492","SuperCategory":"Paguridae","Id":"birnlex_567"}},{"Pain disorder":{"Comment":"This should be an inferred class where any syndrome or disorder involving pain is classified","SuperCategory":"Nervous system disease","Id":"nlx_285"}},{"Pain monitor-discrimination task":{"Created":"4/27/2011 14:09","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00763","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Pain_monitor-discrimination_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145985","Definition":"Subjects experience thermal or electrical stimulation at a painful threshold."}},{"Paired associate learning":{"Created":"4/15/2011 11:10","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00938","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Paired_associate_learning","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146163","Definition":"was invented by Mary Whiton Calkins in 1894 and involves the pairing of two items (usually words)√É¬¢√¢\u201a¬¨√¢\u20ac?a stimulus and a response. For example, words such as calendar (stimulus) and shoe (response) may be paired, and when the learner is prompted with the stimulus, he responds with the appropriate word (shoe)."}},{"Paired associate recall":{"Created":"4/27/2011 14:08","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00764","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Paired_associate_recall","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145986","Definition":"Subjects are shown paired stimuli prior to the task.  During the task, subjects are shown a single stimuli and are asked to recall the associated pair.  Stimuli may be words, faces, objects, etc."}},{"Paired Helical Filament":{"Synonym":"PHF","SuperCategory":"Filament","Id":"sao6603990120","Definition":"Two threads of tau protein that are wound around each other."}},{"Palate":{"CurationStatus":"uncurated","SuperCategory":"Regional part of body","Id":"nlx_151721","Is part of":"Oral cavity","Definition":"The roof of the oral cavity. It separates the oral cavity from the nasal cavity.(NCI Thesaurus:C12229)"}},{"Pale pink":{"SuperCategory":"Pink","Id":"PATO_0002020","Definition":"Pink color having high brightness and low saturation."}},{"Paleocortex":{"DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated","ChemoDefiningCriteria":"Three to five cytoarchitectural layers","NeuronamesID":"2336","SuperCategory":"Regional part of brain","Id":"nlx_143559","Is part of":"Allocortex","Definition":"Part of the allocortex defined on the basis of cytoarchitecture. The other two are archicortex and periallocortex. It consists of very thin, primitive cortex with few clearly defined layers. It is distinguished ontogenetically by the fact that it does not develop through a cortical plate. It includes the olfactory bulb, accessory olfactory bulb, olfactory tubercle, septum, prepyriform area and periamygdalar area ( Stephan-1975 ). (adapted from Brain Info)"}},{"Paleodentate of dentate nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-18","NeuronamesID":"682","CurationStatus":"uncurated","Umlscui":"C0175486","SuperCategory":"Regional part of brain","Id":"birnlex_1490","Is part of":"Dentate nucleus","Abbrev":"Pdt"}},{"Paleopolyploid":{"SuperCategory":"Polyploid","Id":"PATO_0001380","Definition":"A polyploidy quality inhering in a bearer by virtue of having an ancient polyploid ancestor."}},{"Palette Color Lookup Table UID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1199","SuperCategory":"DICOM term","Id":"nlx_150450","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"UI","Definition":"Palette Color Lookup Table UID. This data element uniquely identifies a palette color lookup table set (red, green, blue)."}},{"Palifermin":{"RelatedTo":["Collagen alpha-1(I) chain","Fibroblast growth factor receptor 2","Basement membrane-specific heparan sulfate proteoglycan core protein","Fibroblast growth factor receptor 4","Neuropilin-1","Collagen alpha-1(III) chain","Basic fibroblast growth factor receptor 1","Collagen alpha-1(VI) chain"],"Synonym":["FGF-7","Fibroblast growth factor- 7","HBGF-7","KGF","Keratinocyte growth factor precursor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00039","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00039","Definition":"Human keratinocyte growth factor (KGF), 140 residues long, expressed in E. coli. First 23 residues removed to improve stability. Pharmacology: Used in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs. Mechanism of action: Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival. Drug type: Approved. Biotech. Drug category: Antimucositis Agents"}},{"Palinura":{"Synonym":"Palinuridea","Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998244","SuperCategory":"Pleocyemata","Id":"birnlex_198"}},{"Palinuridae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0446343","SuperCategory":"Palinuroidea","Id":"birnlex_133"}},{"Palinuroidea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1055043","SuperCategory":"Palinura","Id":"birnlex_208"}},{"Palinurus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998245","SuperCategory":"Palinuridae","Id":"birnlex_137"}},{"Paliperidone":{"RelatedTo":["5-hydroxytryptamine 2A receptor"],"Synonym":["9-Hydroxyrisperidone"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01267","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01267","Definition":"Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not the same, pathways. It has been proposed that the drug's therapeutic activity in schizophrenia ismediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. Pharmacology: Paliperidone is an atypical antipsychotic developed by Janssen Pharmaceutica. Chemically, paliperidone is primary active metabolite of the older antipsychotic risperidone (paliperidone is 9-hydroxyrisperidone, i.e. risperidone with an extra hydroxyl group). While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not the same, pathways. Mechanism of action: Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia ismediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Drug type: Approved. Small Molecule. Drug category: Antipsychotic Agents"}},{"Palivizumab":{"RelatedTo":["Fusion glycoprotein F0","High affinity immunoglobulin gamma Fc receptor I","Low affinity immunoglobulin gamma Fc region receptor III-B","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["Synagis","anti-RSV","palivizumab"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00110","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00110","Definition":"Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF) Pharmacology: Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients. Mechanism of action: Binds to the outer coat or Fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors. Drug type: Approved. Biotech. Investigational. Drug category: Antiviral Agents"}},{"Pallid Bat":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C0324754","SuperCategory":"Antrozous","Id":"birnlex_100"}},{"Pallidotegmental fasciculus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"521","CurationStatus":"uncurated","Umlscui":"C0175407","SuperCategory":"Regional part of brain","Id":"birnlex_1331","Is part of":["Midbrain tegmentum"],"Abbrev":"ptf"}},{"Pallidum caudal region of ABA 2009":{"PartiallyOverlapsWith":"Pallidum  caudal region","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153705","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Pallidum dorsal region of ABA 2009":{"PartiallyOverlapsWith":"Pallidum  dorsal region","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153735","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Pallidum medial region of ABA 2009":{"PartiallyOverlapsWith":"Pallidum  medial region","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153528","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Pallidum of ABA 2009":{"PartiallyOverlapsWith":"Pallidum","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153494","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Pallidum of CIVM postnatal rat brain atlas":{"AtlasImage":["pallidum p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151536","Is part of":"Subpallium of CIVM postnatal rat brain atlas","Definition":"The pallidum is fairly easy to segment on coronal diffusion-weighted images (DWI). The entire medial border of the globus pallidus is defined by the internal capsule, which appears as a dark (high diffusivity) vertical band. The entire lateral border is with the caudate/putamen. This border is somewhat more subtle and may be indistinguishable on T2 MRI. On DWI, the pallidum is somewhat darker (higher diffusivity) than the caudate/putamen and is more densely striated. By narrowing the contrast window, this difference can be accentuated enough to make the border apparent. The ventral pallidum is also quite easy to segment on DWI. It appears as a dark horizontal band just ventral to the pale, circular accumbens nucleus and dorsal to the very bright olfactory tubercle. Caudal to the posterior limbs of the anterior commissure, the ventral pallidum moves dorsal and merges with the globus pallidus."}},{"Pallidum ventral region of ABA 2009":{"PartiallyOverlapsWith":"Pallidum  ventral region","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152904","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Pallium":{"Synonym":"Cerebral Cortex","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_158478","Definition":"The commonly used synonym of the cerebral cortex. Used first by Burdach for macrodissected adult humans (1822), and by many others since, including His (1895), and Nauta & Feirtag (1986). In Latin pallium means a mantle, cloak, or blanket"}},{"Pallium of CIVM postnatal rat brain atlas":{"AtlasImage":["pallium p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151527","Is part of":"Telencephalon of CIVM postnatal rat brain atlas","Definition":"The pallium is a superparcellation consisting of the hippocampal formation, the isocortex and the olfactory structures."}},{"Palonosetron":{"RelatedTo":"5-hydroxytryptamine 3 receptor","Synonym":["palonosetron","Aloxi"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00377","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00377","Definition":"Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2007, it is the most recent 5-HT3 antagonist to enter clinical use. (Wikipedia) Pharmacology: Palonosetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Palonosetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. Mechanism of action: Palonosetron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Palonosetron works by blocking the reception of serotonin at these 5-HT3 receptors. Drug type: Approved. Investigational. Small Molecule. Drug category: Antiemetics. Serotonin Antagonists"}},{"Paludicola":{"Created":"2007-11-30","CurationStatus":"pending_final_vetting","Umlscui":"C1083764","SuperCategory":"Tricladida","Id":"birnlex_7207"}},{"Pamidronate":{"RelatedTo":"Farnesyl pyrophosphate synthetase","Synonym":["APD","Acide pamidronique (INN-French)","Acido pamidronico (INN-Spanish)","Acidum pamidronicum (INN-Latin)","Pamidronate Disodium","Pamidronic acid","Amidronate","Aminomux"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00282","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00282","Definition":"Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. (Wikipedia) Pharmacology: Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma. Mechanism of action: The mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. Drug type: Approved. Small Molecule. Drug category: Anti-inflammatory Agents. Antineoplastic Agents. Bisphosphonates. Bone Density Conservation Agents"}},{"Pan":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2007-08-03","CurationStatus":"raw_import","Umlscui":"C0085999","SuperCategory":"Homo Pan Gorilla group","Id":"birnlex_290"}},{"Panarthropoda":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1039396","SuperCategory":"Coelomata","Id":"birnlex_527"}},{"Pancreatic polypeptide":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5091"}},{"Pancrelipase":{"Synonym":["1,4-alpha-D- glucan glucanohydrolase","PA","Pancreatic alpha-amylase precursor","pancrelipase","Cotazym (Organon)","Creon","Ku-Zyme (Koichi)","Pancrease (Ortho-McNeil)","Ultrase (Axcan Scandipharm)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00085","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00085","Definition":"Protein mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. Contains 3 enzymes, amylase, lipase and a protease (chymotrypsin). Pharmacology: Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool. Mechanism of action: The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Drug type: Approved. Biotech. Investigational. Drug category: Enzyme Replacement Agents"}},{"Pancrustacea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1218615","SuperCategory":"Mandibulata","Id":"birnlex_555"}},{"Panic Disorder":{"Synonym":"Panic Attack","Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Anxiety Disorder","Id":"birnlex_12676","Definition":"A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait (MeSH)."}},{"Panitumumab":{"RelatedTo":"Epidermal growth factor receptor","Synonym":["ABX-EGF","panitumumab","Vectibix"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01269","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01269","Definition":"Panitumumab (ABX-EGF) is a fully human monoclonal antibody specific to the EGF receptor. Pharmacology: Panitumumab is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human Epidermal Growth Factor Receptor (EGFR). Overexpression of EGFR is detected in many human cancers, including those of the colon and rectum. When Panitumumab binds to EGFR it competitively inhibits the binding of ligands for EGFR. This results in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production. Mechanism of action: Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents"}},{"Pantomime task":{"Created":"2/28/2011 12:42","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00848","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Pantomime_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146071","Definition":"is when a subject is asked to explain an emotion or how an object is used by only gesturing with their hands and not using speech."}},{"Pantoprazole":{"RelatedTo":["Potassium-transporting ATPase alpha chain 1","Sodium/potassium-transporting ATPase alpha-1 chain"],"Synonym":["Pantoprazol (INN-Spanish)","Pantoprazole Na","Pantoprazole Sodium","Pantoprazolum (INN-Latin)","Pantoprozole","Astropan","Pantoloc","Pantopan","Pantor","Pantozol","Protium","Protonix","Protonix I,V,"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7915","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00213","Definition":"Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. Pharmacology: Pantoprazole is a substituted benzimidazole indicated for the short-term treatment (up to 16 weeks) in the healing and symptomatic relief of erosive esophagitis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production. Mechanism of action: Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H+,K+ )- ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect is dose- related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. Drug type: Approved. Small Molecule. Drug category: Anti-Ulcer Agents. Proton-pump Inhibitors"}},{"Panulirus":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998247","SuperCategory":"Palinuridae","Id":"birnlex_138"}},{"Papaverine":{"RelatedTo":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","Synonym":["Chlorhydrate de Papaverine","Papavarine Chlorhydrate","Papaverin","Papaverine Chlorohydrate","Papaverine Hcl","Papaverine Hydrochloride","Papaverine Monohydrochloride","Papaverinium Chloride","Alapav","Artegodan","Cardiospan","Cardoverina","Cepaverin","Cerebid","Cerespan","Delapav","Dilaves","Dispamil","Drapavel","Durapav","Dynovas","Forpavin","Genabid","Myobid","Optenyl","Pameion","Pamelon","Panergon","Pap H","Papacon","Papalease","Papanerin","Papanerin-Hcl","Papanerine","Papaversan","Papital T,R,","Paptial T,R,","Pavabid","Pavabid Hp","Pavacap","Pavacels","Pavacen","Pavacot","Pavadel","Pavagen","Pavakey","Pavarine","Pavased","Pavatest","Pavatine","Pavatym","Paverolan","Paveron","Pavnell","Qua Bid","Ro-Papav","Robaxapap","Spasmo-Nit","Therapav","Vasal"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:28241","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01113","Definition":"An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. (PubChem) Pharmacology: Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries. Mechanism of action: Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy. Drug type: Approved. Small Molecule. Drug category: Phosphodiesterase Inhibitors. Vasodilator Agents"}},{"Paper chromotography instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Planar liquid chromotography instrument","Id":"birnlex_2414"}},{"Papillary Craniopharyngioma":{"Synonym":["Craniopharyngioma"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Craniopharyngioma","Id":"birnlex_12615","Definition":"Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations (MeSH)."}},{"Papio hamadryas":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":["sacred baboon"],"Created":"2007-07-28","CurationStatus":"raw_import","Umlscui":"C0324820","SuperCategory":"Baboon","Id":"birnlex_122"}},{"Papio ursinus":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Synonym":"Papio hamadryas ursinus","Created":"2007-07-28","CurationStatus":"raw_import","Umlscui":"C0324817","SuperCategory":"Baboon","Id":"birnlex_7300"}},{"PAR1 receptor":{"Synonym":"PAR1","Created":"2007-09-19","SuperCategory":"Protease-activated receptor","Id":"nifext_7123"}},{"PAR2 receptor":{"Synonym":"PAR2","Created":"2007-09-19","SuperCategory":"Protease-activated receptor","Id":"nifext_6622"}},{"PAR3 receptor":{"Synonym":"PAR3","Created":"2007-09-19","SuperCategory":"Protease-activated receptor","Id":"nifext_6664"}},{"PAR4 receptor":{"Synonym":"PAR4","Created":"2007-09-19","SuperCategory":"Protease-activated receptor","Id":"nifext_6267"}},{"Parabigeminal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","ConnDefiningCriteriaPMID":"3708316","Synonym":["Nucleus parabigeminous"],"ChemoDefiningCriteriaPMID":"3708316","CurationStatus":"uncurated","EfferentProjections":"Superior colliculus","Abbrev":"PBG","CytoDefiningCriteria":"A compact cell group that lies along the lateral margin of the mesopontine region just ventral to the brachium of the inferior colliculus.","CytoDefiningCriteriaPMID":"3708316","Created":"2006-07-15","SynonymPMID":"3708316","DefiningCriteria":["cyto-architecture"],"ChemoDefiningCriteria":["Majority of cells are cholinergic.  ChAT-positive cell bodies of the parabigeminal nucleus are oval in shape and 10-20/um in diameter"],"NeuronamesID":"473","Umlscui":"C0262301","SuperCategory":"Regional part of brain","Id":"birnlex_1007","Is part of":"Midbrain tectum","Species":"Mammal","EfferentProjectionsPMID":"3708316","Definition":"Cholinergic cell group that is located ventral to the brachium of the inferior colliculus (in rat) and has reciprocal connectivity with the superior colliculus (Adapted from Paxinos, The rat central nervous system, 2nd ed, 1995, pg 865"}},{"Parabigeminal nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parabigeminal nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153322","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus":{"CurationStatus":"graph position temporary","SuperCategory":"Regional part of brain","Curator":"Maryann Martone,","Id":"nlx_23647","Is part of":["Pontine tegmentum"]}},{"Parabrachial nucleus lateral division central lateral part of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  lateral division  central lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153594","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus lateral division dorsal lateral part of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  lateral division  dorsal lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153634","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus lateral division external lateral part of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  lateral division  external lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153666","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus lateral division of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  lateral division","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153380","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus lateral division superior lateral part of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  lateral division  superior lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153078","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus lateral division ventral lateral part of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  lateral division  ventral lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153802","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus medial division external medial part of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  medial division  external medial part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153706","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus medial division medial medial part of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  medial division  medial medial part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153447","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus medial division of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  medial division","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153292","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus medial division ventral medial part of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus  medial division  ventral medial part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153740","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parabrachial nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153345","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parabrachial pigmented nucleus":{"CurationStatus":"uncurated","Abbrev":"PBP","CytoDefiningCriteria":["Contains mostly fusiform shaped cells that are oriented medolaterally or around the fiber bundles of the third nerve","as seen in coronal sections.  Cells are generally larger than other cells in the VTA.  In a comparative analysis of rat","cat","monkey and human"],"CytoDefiningCriteriaPMID":"3782510","DefiningCriteria":"cyto-architecture","NeuronamesID":"2264","SuperCategory":"Regional part of brain","Id":"nlx_144307","Is part of":"Ventral tegmental area","OrganismPMID":"3782510","Species":"Mammal,","Definition":"Nucleus identified in the medial ventral tegmental area that borders the red nucleus and superior cerebellar peduncle dorsally, the medial lemniscus laterally, the subtantia nigra pars compacta and paranigral nucleus ventrally and the rostral linear nucleus and interfascicular nucleus medially.  Generally, the largest nucleus in the ventral tegmental area, occupying an average of 50% of the total volume as measured in rat, cat, monkey and human.","DefinitionPMID":"3782510"}},{"Parabrachial pigmented nucleus of PHT00":{"Synonym":"parabrachial pigmented nucleus","CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"PBP","PartiallyOverlapsWith":"parabrachial pigmented nucleus","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_596","Is part of":"#N/A","Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Paracentral nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["paracentral nucleus thalamus (Gurdjian 1927)","paracentral thalamic nucleus","nucleus paracentral thalami","paracentral nucleus of thalamus","nucleus paracentral","nucleus centralis lateralis superior (Kusama"],"CurationStatus":"uncurated","NeuronamesID":"305","Umlscui":"C0228354","SuperCategory":"Nucleus of CNS","Id":"birnlex_981","Is part of":"Rostral intralaminar nuclei","Abbrev":"PC"}},{"Paracentral nucleus of ABA 2009":{"PartiallyOverlapsWith":"Paracentral nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153595","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paracentral sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":"Sulcus subcentralis medialis","CurationStatus":"uncurated","NeuronamesID":"51","Umlscui":"C0228204","SuperCategory":"Sulcus","Id":"birnlex_1121","Is part of":"Frontal lobe","Species":"Human","Abbrev":"pcs","Definition":"Component of the frontal lobe.  The rostral boundary of the paracentral lobule is the posterior extent of the superior frontal gyrus whereas the caudal boundary is the rostral extent of the precuneus cortex. The medial and lateral boundaries are the medial aspect of the cortex and the superior frontal gyrus (or pre- and postcentral gyri when visible) respectively (Christine Fennema-Notestine)."}},{"Parafascicular nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["parafascicular nucleus (Vogt)","nucleus parafascicularis (Hassler)","parafascicular thalamic nucleus","parafascicular nucleus of the thalamus","nucleus parafascicularis thalami","nuclei parafasciculares thalami"],"CurationStatus":"uncurated","EfferentProjections":"Striatum,","Abbrev":"PF","AfferentProjections":["Primary Motor Cortex Lamina V","Primary motor cortex lamina VI","Primary somatosensory cortex lamina VI","Thalamic reticular nucleus","Zona incerta","Striatum","Entopeduncular nucleus","Midbrain reticular formation","Pretectum"],"Created":"2007-03-05","AfferentProjectionsPMID":["2836036"],"NeuronamesID":"307","Umlscui":"C0228352","SuperCategory":"Nucleus of CNS","Id":"birnlex_952","Is part of":"Intralaminar nuclear group,","EfferentProjectionsPMID":"16814420"}},{"Parafascicular nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parafascicular nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153215","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraflocculus of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Paraflocculus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153520","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Hemispheric regions of ABA 2009","Species":"Mouse"}},{"Paragigantocellular reticular nucleus dorsal part of ABA 2009":{"PartiallyOverlapsWith":"Paragigantocellular reticular nucleus  dorsal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153241","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paragigantocellular reticular nucleus lateral part of ABA 2009":{"PartiallyOverlapsWith":"Paragigantocellular reticular nucleus  lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153267","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paragigantocellular reticular nucleus of ABA 2009":{"PartiallyOverlapsWith":"Paragigantocellular reticular nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153147","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parahippocampal area":{"Synonym":"Region of the piriform lobe that includes the entorhinal cortex","SynonymPMID":"7240454","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_144076","Is part of":"Cerebral cortex","Species":["Mammal"]}},{"Parahippocampal cortex of RHA11":{"CurationStatus":"uncurated","SuperCategory":"\tRHA11 hippocampal parcellation scheme region","PublicationLink":"http://cmbn-approd01.uio.no/zoomgen/hippocampus/structureindexB.do","Id":"nlx_156081","ParcellationScheme":"RHA11 hippocampal parcellation scheme","ParcellationSchemePMID":"21519393","Species":["Long Evans Rat"],"DefinitionPMID":"21519393","Definition":"Supraparcellation from the Rat Hippocampal Atlas comprising the entorhinal cortex, parasubiculum, perirhinal cortex, postrhinal cortex and presubiculum"}},{"Parahippocampal gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":"hippocampal gyrus","CurationStatus":"uncurated","NeuronamesID":"146","Umlscui":"C0228249","SuperCategory":"Regional part of brain","Id":"birnlex_807","Is part of":"Limbic lobe","Abbrev":"PaI","Definition":"Component of the temporal lobe on the mesial surface, posterior to the entorhinal cortex. The rostral and caudal boundaries are the posterior end of the netorhinal cortex and the caudal portion of the hippocampus, respectively.  The medial boudnary is designated as the medial aspect off the temporal lobe and the lateral boundary is the collateral sulcus (Christine Fennema-Notestine)."}},{"Paralaminar amygdaloid nucleus of PHT00":{"Synonym":"paralaminar amygdaloid nucleus","CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"PaL","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_607","Is part of":"Amygdala of PHT00","Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Paralaminar part of medial dorsal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["pars multiformis","nucleus medialis dorsalis","nucleus medialis dorsalis thalami","paralaminar part of dorsomedial nucleus","nucleus medialis dorsalis caudalis (Hassler)","pars paralaminaris","mediodorsal thalamic nucleus","paralaminar part","ventral mediodorsal nucleus"],"NeuronamesID":"296","CurationStatus":"uncurated","Umlscui":"C0228332","SuperCategory":"Regional part of brain","Id":"birnlex_1276","Is part of":"Medial dorsal nucleus","Abbrev":"MDPL"}},{"Parallel Acquisition":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9077","SuperCategory":"DICOM term","Id":"nlx_150451","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Parallel acquisition has been used to reduce measurement time. Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL. May be present otherwise."}},{"Parallel Acquisition Technique":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9078","SuperCategory":"DICOM term","Id":"nlx_150452","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Parallel acquisition characteristics. Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL and Parallel Acquisition (0018,9077) equals YES. "}},{"Parallel fiber":{"LocationOfAxonArborization":"Molecular layer of cerebellar cortex","CurationStatus":"pending final vetting","SuperCategory":"Axon","Id":"nlx_330","Is part of":["Cerebellum granule cell axon"],"Definition":"Regional part of a cerebellar granule cell axon referring to the bifurcation of the granule cell axon in the molecular layer into two diametrically opposed branches that are oriented parallel to the long axis of the folium.  (adapted from Shepherd, G. M. The synaptic organization of the brain, 5th ed.  New York:  Oxford University Press, 2004."}},{"Parallel processing":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001180","Definition":"deployment of several parallel neuronal pathways to convey similar information or to process different components of a common sensory modality, eg., processing of form and motion in vision."}},{"Parallel Reduction Factor In-plane":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9069","SuperCategory":"DICOM term","Id":"nlx_150453","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FD","Definition":"Measurement time reduction factor expressed as ratio of original and reduced measurement time for the inplane direction. Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL and Parallel Acquisition (0018,9077) equals YES.  "}},{"Parallel Reduction Factor out-of-plane":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9155","SuperCategory":"DICOM term","Id":"nlx_150454","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FD","Definition":"Measurement time reduction factor expressed as ratio of original and reduced measurement time for the out-ofplane direction Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL and Parallel Acquisition (0018,9077) equals YES. "}},{"Parallel Reduction Factor Second In-plane":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9168","SuperCategory":"DICOM term","Id":"nlx_150455","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FD","Definition":"Measurement time reduction factor expressed as ratio of original and reduced measurement time for the second in-plane direction. Only required for MR Spectroscopy SOP Instances. Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL."}},{"Parallelodromous":{"SuperCategory":"Branched (PATO 0000402)","Id":"PATO_0001968","Definition":"A shape inhering in a bearer by virtue of having two or more parallel primary branches originate beside each other and converge apically."}},{"Paralysed":{"SuperCategory":"Behavioral quality","Id":"PATO_0000763","Definition":"A behavioral quality inhering in a bearer by virtue of beign affected by paralysis."}},{"Paralysis":{"EditorialNote":"Note BIRNLex seeks to evolve a core subsumptive disease hierarchy based first on the effected function, then the effected structure, the latter for those categories of nervous system disease that have typically been associated with structural abnormalities or trauma (e.g., Motor neuron diseases, cerebrovascular trauma, etc.). Disease causation is in fact the ultimate goal of much biomedical research, and our recognitition of ALL the driving causes of a particular disease - and the ways in which these causes inter-relate with each other and with effected structures to cause a change in normal function is a critical representational task BIRNlex will increasingly take on to provide an evolving, nuanced functional reconstruction of disease as a process and an outcome.  These relations will be represented using OWL ObjectProperties.  Function is the most sensible context to drive the asserted subsumptive hierarchy for representing nervous system disease, since it is with the clinical description of altered, impaired, decreased, or lost function that the diagnosis - and the research - of disease is rooted.  Much has already been described regarding both the effected biomaterial entities and the causes of disease.  However, it is because understanding of such relations still is far from comprehensive, that biomedical investigation into nervous system disease continues.  Finally, given the \"realist\" ontology design approach being used to construct BIRNLex, function must be represented as inhering in some biomaterial entity from molecules and their controlling elements on up through gross anatomical structures.  Over time, BIRNLex will provide the required relations to depict these functionally-related structures for both the normal and pathological function of the nervous system.  This will be true both for the causes and for the outcomes of nervous system disease.  Initial work to extend this expressive representation will focus on the neurodegenerative diseases being studied by BIRN researchers.  Though this will be te case, BIRNLex still needs to provide a core asserted hierarchy for a broad swarth of nervous system disease, so as to enable BIRN researchers to link to the breadth of disorders that may impact or relate to those directly under study.","Synonym":["Plegia"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Nervous system disease","Id":"birnlex_12641","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"Severe loss of motor function as compared with PARESIS, a slight loss; GENERAL PARALYSIS see NEUROSYPHILIS does not mean \"generalized paralysis\" ( "}},{"Paramedian lobule of ABA 2009":{"PartiallyOverlapsWith":"Paramedian lobule","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153602","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paramedian reticular nucleus":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_151902","Has role":"Precerebellar nucleus","Is part of":"Medullary reticular formation"}},{"Paramedian reticular nucleus of ABA 2009":{"PartiallyOverlapsWith":"Paramedian reticular nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153085","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paramedian reticular nucleus of PHT00":{"Synonym":"paramedian reticular nucleus","CurationStatus":"uncurated","PartiallyOverlapsWith":"paramedian reticular nucleus","ISBN":"123582555","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Curator":"CoCoMac{{PONS brain region","Id":"nlx_br_610","Authors":["George Paxinos","Xu-Feng Huang"],"Species":"Macaque","Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","DefiningCitation":"ISBN 0123582555","Abbrev":"PMn"}},{"Parameter Fitting":{"CurationStatus":"uncurated","SuperCategory":"Neural coding","Id":"oen_0001054","Has role":"Electrophysiology concept","DefiningCitation":"ModelDB:3637"}},{"Parameter sensitivity":{"EditorialNote":"determining robustness of model","CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001053","DefiningCitation":"ModelDB:116962","Definition":"In neural modeling, refers to how model results vary as model parameters are changed."}},{"Paramethadione":{"RelatedTo":"Voltage-dependent T-type calcium channel subunit alpha-1I","Synonym":[", Isoethadione","Paradione","Paradione (TN)","Parametadiona (INN-Spanish)","Parametadione","Parametadione (DCIT)","Paramethadione (BAN:INN)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00617","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00617","Definition":"Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome. Pharmacology: Paramethadione is an oxazolidinedione anticonvulsant similar to trimethadione that acts on the central nervous system (CNS) to reduce the number of absence seizures (often seen in epileptics). Absence seizures involve an interruption to consciousness where the person experiencing the seizure seems to become vacant and unresponsive for a short period of time (usually up to 30 seconds). Paramethadione acts on thalamic neurons in the thalamic reticular nucleus (which studies have shown to be associated with absence seizures, von Krosigk et al., 1993). Mechanism of action: Dione anticonvulsants such as paramethadione reduce T-type calcium currents in thalamic neurons (including thalamic relay neurons). This inhibits corticothalamic transmission and raises the threshold for repetitive activity in the thalamus. This results in a dampening of the abnormal thalamocortical rhythmicity proposed to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram (EEG) during absence seizures. Drug type: Approved. Small Molecule. Drug category: Anticonvulsants"}},{"Paramethasone":{"RelatedTo":"Corticosteroid-binding globulin","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7922","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01384","Definition":"A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737) Pharmacology: Paramethasone is a glucocorticoid with the general properties of corticosteroids. Mechanism of action: Glucocorticoids such as paramethasone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Paramethasone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression. Drug type: Approved. Small Molecule. Drug category: Anti-inflammatory Agents. Glucocorticoids"}},{"Paraneoplastic Cerebellar Degeneration":{"Synonym":"Paraneoplastic Cerebellar Syndrome","Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Nervous System Paraneoplastic Syndrome","Id":"birnlex_12645","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"Cerebellar degeneration associated with a remote neoplasm. Clinical manifestations include progressive limb and GAIT ATAXIA; DYSARTHRIA; and NYSTAGMUS, PATHOLOGIC. The histologic type of the associated neoplasm is usually carcinoma or lymphoma. Pathologically the cerebellar cortex and subcortical nuclei demonstrate diffuse degenerative changes. Anti-Purkinje cell antibodies (anti-Yo) are found in the serum of approximately 50% of affected individuals (MeSH)."}},{"Paraneoplastic Myelitis":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Transverse Myelitis","Id":"birnlex_12523","Definition":"A form of Transverse Myelitis associated with a neoplastic condition.(MeSH)."}},{"Paraneoplastic Polyneuropathy":{"Synonym":["Paraneoplastic Peripheral Neuropathy"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Nervous System Paraneoplastic Syndrome","Id":"birnlex_12646","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A diffuse or multifocal peripheral neuropathy related to the remote effects of a neoplasm, most often carcinoma or lymphoma. Pathologically, there are inflammatory changes in peripheral nerves. The most common clinical presentation is a symmetric distal mixed sensorimotor polyneuropathy (MeSH)."}},{"Paranode":{"SuperCategory":"Node Related Site","Id":"sao-234066064","Definition":"Region of nodal complex adjacent to the nodal region"}},{"Paranode Axon":{"CurationStatus":"uncurated","SuperCategory":"Regional Part Of Cell","Id":"sao936144858"}},{"Paranoid Disorder":{"Synonym":["Psychosis","Paranoia"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Psychotic Disorder","Id":"birnlex_12763"}},{"Paranoid Schizophrenia":{"Synonym":"Delusional Disorder","Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Schizophrenia","Id":"birnlex_12766"}},{"Parapyramidal nucleus deep part of ABA 2009":{"PartiallyOverlapsWith":"Parapyramidal nucleus  deep part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153344","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parapyramidal nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parapyramidal nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153044","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parapyramidal nucleus superficial part of ABA 2009":{"PartiallyOverlapsWith":"Parapyramidal nucleus  superficial part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153685","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parasolitary nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["nucleus juxtasolitarius"],"CurationStatus":"uncurated","NeuronamesID":"-1639234958","SuperCategory":"Regional part of brain","Id":"birnlex_2653","Is part of":"Medulla oblongata","Abbrev":"PSol"}},{"Parasolitary nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parasolitary nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153067","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parastacidae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1007112","SuperCategory":"Parastacoidea","Id":"birnlex_381"}},{"Parastacoidea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1002934","SuperCategory":"Astacidea","Id":"birnlex_372"}},{"Parastrial nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parastrial nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153143","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parasubiculum":{"AtlasImage":"Brainmaps parasubiculum.jpg,","Synonym":"parasubicular area","DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated","NeuronamesID":"2304","SuperCategory":"Regional part of brain","Id":"nlx_anat_091002","OrganismPMID":"21599693","Is part of":"Hippocampal formation,","Species":"Mammal,","Abbrev":"PaS","Definition":"A transitional zone between the presubiculum and the entorhinal area in the mouse (Paxinos-2001), the rat (Swanson-1998) and the primate (Zilles-1990). Defined on the basis of cytoarchitecture, it is more similar to the presubiculum than to the entorhinal area (Zilles-1990). (from Brain Info)"}},{"Parasubiculum of ABA 2009":{"AtlasImage":["Parasubiculum of ABA 2009.jpg"],"CurationStatus":"uncurated","PartiallyOverlapsWith":"Parasubiculum","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_151333","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Retrohippocampal region of ABA 2009","Species":"Mouse"}},{"Parasubthalamic nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parasubthalamic nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153733","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parasympathetic Nervous System Disease":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Autonomic Nervous System Disease","Id":"birnlex_12580"}},{"Parasympathetic nervous system function":{"Created":"2007-08-25","CurationStatus":"uncurated","SuperCategory":"Autonomic nervous system function","Id":"birnlex_2508"}},{"Parataenial nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parataenial nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153229","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paratenial nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["Paratenial thalamic nucleus"],"CurationStatus":"uncurated","NeuronamesID":"290","Umlscui":"C0175252","SuperCategory":"Regional part of brain","Id":"birnlex_860","Is part of":"Midline nuclear group,","Abbrev":"PT"}},{"Paraterminal gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-04","CurationStatus":"uncurated","NeuronamesID":"153","Umlscui":"C0175231","SuperCategory":"Regional part of brain","Id":"birnlex_1138","Is part of":"Limbic lobe"}},{"Parathyroid hormone":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5147"}},{"Paraventricular hypothalamic nucleus descending division dorsal parvicellular part of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  descending division  dorsal parvicellular part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153210","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus descending division forniceal part of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  descending division  forniceal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153672","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus descending division lateral parvicellular part of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  descending division  lateral parvicellular part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152981","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus descending division medial parvicellular part ventral zone of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  descending division  medial parvicellular part  ventral zone","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152953","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus descending division of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  descending division","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153606","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus magnocellular division anterior magnocellular part of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  magnocellular division  anterior magnocellular part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153691","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus magnocellular division medial magnocellular part of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  magnocellular division  medial magnocellular part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153291","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus magnocellular division of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  magnocellular division","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153453","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus magnocellular division posterior magnocellular part of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  magnocellular division  posterior magnocellular part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153033","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153219","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus parvicellular division anterior parvicellular part of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  parvicellular division  anterior parvicellular part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153471","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus parvicellular division medial parvicellular part dorsal zone of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  parvicellular division  medial parvicellular part  dorsal zone","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152988","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus parvicellular division of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  parvicellular division","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153168","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic nucleus parvicellular division periventricular part of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular hypothalamic nucleus  parvicellular division  periventricular part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153396","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paraventricular hypothalamic region":{"Synonym":"Paraventricular Hypothalamus","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_144080","Is part of":"Hypothalamus"}},{"Paraventricular nucleus of hypothalamus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","CurationStatus":"uncurated","NeuronamesID":"370","Umlscui":"C0030532","SuperCategory":"Nucleus of CNS","Id":"birnlex_1407","Is part of":"Anterior hypothalamic region","Abbrev":"Pa","Definition":"Nucleus in the anterior part of the hypothalamus. (MSH) * one of the magnocellular hypothalamic nuclei, an elongated plate of large, deeply staining cells located close to the third ventricle in the anterior hypothalamic area; major source of oxytocin and to a lesser extent, of antidiuretic hormone, neurohormones, which are carried to the neurohypophysis along the paraventriculohypophysial tract. (CSP)]] (definition from UMLS)"}},{"Paraventricular nucleus of thalamus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":"Paraventricular thalamic nucleus","CurationStatus":"uncurated","NeuronamesID":"291","Umlscui":"C0175253","SuperCategory":"Regional part of brain","Id":"birnlex_764","Is part of":"Midline nuclear group,","Abbrev":"PV"}},{"Paraventricular nucleus of the hypothalamus descending division":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1413","Is part of":"Anterior hypothalamic region","Abbrev":"PVHd"}},{"Paraventricular nucleus of the hypothalamus descending division - forniceal part":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1374","Is part of":"Paraventricular nucleus of the hypothalamus descending division","Abbrev":"PVHf"}},{"Paraventricular nucleus of the hypothalamus descending division - lateral parvicellular part":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1354","Is part of":"Paraventricular nucleus of the hypothalamus descending division","Abbrev":"PVHlp"}},{"Paraventricular nucleus of the hypothalamus descending division - medial parvicellular part, ventral zone":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1342","Is part of":"Paraventricular nucleus of the hypothalamus descending division","Abbrev":"PVHmpv"}},{"Paraventricular nucleus of the hypothalamus magnocellular division":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1419","Is part of":"Paraventricular nucleus of hypothalamus","Abbrev":"PVHm"}},{"Paraventricular nucleus of the hypothalamus magnocellular division - anterior magnocellular part":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1384","Is part of":"Paraventricular nucleus of the hypothalamus magnocellular division","Abbrev":["PVHam"]}},{"Paraventricular nucleus of the hypothalamus magnocellular division - medial magnocellular part":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1388","Is part of":"Paraventricular nucleus of the hypothalamus magnocellular division","Abbrev":"PVHmm"}},{"Paraventricular nucleus of the hypothalamus magnocellular division - posterior magnocellular part":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1394","Is part of":"Paraventricular nucleus of the hypothalamus magnocellular division","Abbrev":"PVHpm"}},{"Paraventricular nucleus of the hypothalamus magnocellular division - posterior magnocellular part lateral zone":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1320","Is part of":"Paraventricular nucleus of the hypothalamus magnocellular division - posterior magnocellular part","Abbrev":"PVHpml"}},{"Paraventricular nucleus of the hypothalamus magnocellular division - posterior magnocellular part medial zone":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1312","Is part of":"\tParaventricular nucleus of the hypothalamus magnocellular division - posterior magnocellular part","Abbrev":"PVHpmm"}},{"Paraventricular nucleus of the hypothalamus parvicellular division":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1426","Is part of":"Paraventricular nucleus of hypothalamus","Abbrev":"PVHp"}},{"Paraventricular nucleus of the thalamus of ABA 2009":{"PartiallyOverlapsWith":"Paraventricular nucleus of the thalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153212","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Paravermic Lobule II":{"SuperCategory":"Regional Parts of the Paravermal Lobules","Id":"nlx_anat_20081215"}},{"Paravermic Lobule III":{"SuperCategory":"Regional Parts of the Paravermal Lobules","Id":"nlx_anat_20081216"}},{"Paravermic Lobule IV":{"SuperCategory":"Regional Parts of the Paravermal Lobules","Id":"nlx_anat_20081217"}},{"Paravermic Lobule IX":{"SuperCategory":"Regional Parts of the Paravermal Lobules","Id":"nlx_anat_20081218"}},{"Paravermic Lobule V":{"SuperCategory":"Regional Parts of the Paravermal Lobules","Id":"nlx_anat_20081219"}},{"Paravermic Lobule VI":{"SuperCategory":"Regional Parts of the Paravermal Lobules","Id":"nlx_anat_20081220"}},{"Paravermic Lobule VII":{"SuperCategory":"Regional Parts of the Paravermal Lobules","Id":"nlx_anat_20081221"}},{"Paravermic Lobule VIII":{"SuperCategory":"Regional Parts of the Paravermal Lobules","Id":"nlx_anat_20081222"}},{"Paravermis of the anterior lobe of the cerebellum":{"SuperCategory":"Paravermis parts of the cerebellar cortex","Id":"nlx_anat_20081239"}},{"Paravermis of the posterior lobe of the cerebellum":{"SuperCategory":"Paravermis parts of the cerebellar cortex","Id":"nlx_anat_20081238"}},{"Paravermis parts of the cerebellar cortex":{"SuperCategory":"Regional part of a lobe of the cerebellum","Id":"nlx_anat_20081237"}},{"Parcellation scheme":{"EditorialNote":"Should this definition be modified to include a Gaussian distribution to represent distribution of cells or other features?  I changed the definition to include all anatomical entities and not just brain, as we also have parcellation schemes for spinal cord and other parts of the nervous system","Synonym":"Partition scheme","CurationStatus":"graph position temporary","SuperCategory":"Role","Curator":["Maryann Martone"],"Id":"nlx_144019","Definition":"Set  of parcels occupying part or all of an anatomical entity that has been delineated using a common approach or set of criteria, often in a single study.  A parcellation scheme for any given individual entity may include gaps, transitional zones, or regions of uncertainty.  A parcellation scheme derived from a set of individuals registered to a common target (atlas) may be probabilistic and include overlap of parcels in regions that reflect individual variability or imperfections in alignment."}},{"Parcellation scheme parcel":{"Synonym":"partition","CurationStatus":"uncurated","SuperCategory":"Anatomical entity","Id":"nlx_143757","Has role":"CUMBO term","Is part of":"Parcellation scheme","Definition":"Regions delineated in a particular parcellation scheme by either manual or automated tracing."}},{"Parencephalon":{"Synonym":"Thalamus","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_158506","Definition":"Synonym for thalamus (Nebenhirn in German, originally; His, 1893)."}},{"Parental behavior":{"CurationStatus":"uncurated","Comment":"A reproductive behavior in which a parent cares for and rears offspring.","SuperCategory":"Reproductive process","Id":"GO:0060746"}},{"Paresis":{"EditorialNote":"Note BIRNLex seeks to evolve a core subsumptive disease hierarchy based first on the effected function, then the effected structure, the latter for those categories of nervous system disease that have typically been associated with structural abnormalities or trauma (e.g., Motor neuron diseases, cerebrovascular trauma, etc.). Disease causation is in fact the ultimate goal of much biomedical research, and our recognitition of ALL the driving causes of a particular disease - and the ways in which these causes inter-relate with each other and with effected structures to cause a change in normal function is a critical representational task BIRNlex will increasingly take on to provide an evolving, nuanced functional reconstruction of disease as a process and an outcome.  These relations will be represented using OWL ObjectProperties.  Function is the most sensible context to drive the asserted subsumptive hierarchy for representing nervous system disease, since it is with the clinical description of altered, impaired, decreased, or lost function that the diagnosis - and the research - of disease is rooted.  Much has already been described regarding both the effected biomaterial entities and the causes of disease.  However, it is because understanding of such relations still is far from comprehensive, that biomedical investigation into nervous system disease continues.  Finally, given the \"realist\" ontology design approach being used to construct BIRNLex, function must be represented as inhering in some biomaterial entity from molecules and their controlling elements on up through gross anatomical structures.  Over time, BIRNLex will provide the required relations to depict these functionally-related structures for both the normal and pathological function of the nervous system.  This will be true both for the causes and for the outcomes of nervous system disease.  Initial work to extend this expressive representation will focus on the neurodegenerative diseases being studied by BIRN researchers.  Though this will be te case, BIRNLex still needs to provide a core asserted hierarchy for a broad swarth of nervous system disease, so as to enable BIRN researchers to link to the breadth of disorders that may impact or relate to those directly under study.","Created":"2007-11-18","CurationStatus":"uncurated","SuperCategory":"Nervous system disease","Id":"birnlex_12640","Definition":"A general term referring to a mild to moderate degree of muscular weakness, occasionally used as a synonym for PARALYSIS (severe or complete loss of motor function). In the older literature, paresis often referred specifically to paretic neurosyphilis (see NEUROSYPHILIS). \"General paresis\" and \"general paralysis\" may still carry that connotation. Bilateral lower extremity paresis is referred to as PARAPARESIS (MeSH)."}},{"Pargyline":{"Synonym":["Benzyl-methyl-2-propinylamin","Methylbenzylpropynylamine","Methylbenzylpropynylamine hydrochloride","N-Benzyl-N-methyl-2-propyn-1-amine","N-Benzyl-N-methyl-2-propynylamine","N-Benzyl-N-methyl-2-propynylamine hydrochloride","N-Methyl-N-2-propynylbenzylamine","Paragyline","Pargylamine","Pargylin","Pargyline chloride","Pargyline hydrochloride","Eudatin","Eutonyl","Eutonyl-ten","Lopac-P-8013"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01626","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01626","Definition":"A monoamine oxidase inhibitor with antihypertensive properties. (PubChem) Pharmacology: Pargyline is a monoamine oxidase B (MAO-B) inhibitor with antihypertensive properties. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as bleu cheese and beer, as this can lead to a hypertensive crisis. Mechanism of action: Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Drug type: Approved. Small Molecule. Drug category: Antihypertensive Agents. Monoamine Oxidase Inhibitors"}},{"Paricalcitol":{"RelatedTo":"Vitamin D3 receptor","Synonym":["paricalcitol"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7931","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00910","Definition":"Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. Pharmacology: Secondary hyperparathyroidism is characterized by an elevation in parathyroid hormone (PTH) associated with inadequate levels of active vitamin D hormone. The source of vitamin D in the body is from synthesis in the skin and from dietary intake. Vitamin D requires two sequential hydroxylations in the liver and the kidney to bind to and to activate the vitamin D receptor (VDR). The endogenous VDR activator, calcitriol (1,25(OH)2 D3), is a hormone that binds to VDRs that are present in the parathyroid gland, intestine, kidney, and bone to maintain parathyroid function and calcium and phosphorus homeostasis, and to VDRs found in many other tissues, including prostate, endothelium and immune cells. VDR activation is essential for the proper formation and maintenance of normal bone. In the diseased kidney, the activation of vitamin D is diminished, resulting in a rise of PTH, subsequently leading to secondary hyperparathyroidism and disturbances in the calcium and phosphorus homeostasis.1 Decreased levels of 1,25(OH)2 D3 have been observed in early stages of chronic kidney disease. The decreased levels of 1,25(OH)2 D3 and resultant elevated PTH levels, both of which often precede abnormalities in serum calcium and phosphorus, affect bone turnover rate and may result in renal osteodystrophy. An in vitro study indicates that paricalcitol is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A at concentrations up to 50 nM (21 ng/mL). Mechanism of action: Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion. Drug type: Approved. Investigational. Small Molecule. Drug category:"}},{"Parietal cortex":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_79282","Is part of":["Neocortex"],"Definition":"Gray matter of the parietal region of the neocortex, located in the parietal lobe of gyrencephalic animals.  It is continuous anteriorly with the frontal cortex, posteriorly with the occipital cortex and medially with the insular cortex and with the temporal cortex on the posterior/inferior border."}},{"Parietal lobe":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-04","CurationStatus":"uncurated","NeuronamesID":"77","Umlscui":"C0030560","SuperCategory":"Lobe of cerebral cortex","Id":"birnlex_1148","Definition":"Upper central part of the cerebral hemisphere. (MSH)"}},{"Parietal operculum":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":"Operculum parietale","NeuronamesID":"78","CurationStatus":"uncurated","Umlscui":["C1284612"],"SuperCategory":"Superficial feature part of parietal cortex","Id":"birnlex_4029","Abbrev":"pao"}},{"Parieto-occipital sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":["parieto-occipital incisure","Fissura parieto-occipitalis","Sulcus parietoccipitalis","Sulcus parietooccipitalis","Sulcus parieto-occipitalis","parietooccipital sulcus","parieto-occipital fissure"],"DefiningCriteria":"topography","CurationStatus":"uncurated","NeuronamesID":"33","Umlscui":"C0228191","SuperCategory":"Sulcus","Id":"birnlex_1428","Is part of":"Cerebral cortex"}},{"Parkin":{"SuperCategory":"Protein","Id":"sao6339175133","Definition":"A cytoplasmic neuronal protein containing two ring-finger domains and a ubiquitin-like dmain at its amino terminus."}},{"Parkin Mutant Drosophila":{"PMID":"15073152","CurationStatus":"uncurated","Pages":"2183-2194","PublicationDate":"04/08/04","JournalVolume":"131","PublicationName":"Development","Id":"nlx_organ_090706","Table":"1","Authors":["Yakov Pesah","Tuan Pham","Heather Burgess","Brooke Middlebrooks","Patrik Verstreken","Yi Zhou","Mark Harding","Hugo Bellen"],"Title":"Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress","Figure":["3, 4","5"],"Definition":"These flies exhibit a mutation in the protein parkin.  Loss of function in parkin results in the accumulation of toxic substrates. This causes locomotive defects, dopaminergic neuron degeneration, mitochondrial dysfunction, and sensitivity to oxidative stress.  Physically, Parkin mutants are smaller, show locomotive dysfunction, sterile, and have a decreased lifespan.  Parkin mutant drosophila exhibit many of the same symptoms as Parkinson's disease and are used in the laboratory to study the disease."}},{"Parkinsons disease":{"Synonym":["Idiopathic PD","Parkinsonian disorder","Parkinson syndrome","Paralysis Agitans","Parkinson","Parkinson's disease","Parkinsons","Parkinson's","Parkinson disease"],"Created":"2007-03-05","CurationStatus":"uncurated","Umlscui":"C0030567","SuperCategory":"Neurodegenerative disease","Id":"birnlex_2098","Curator":"Bill Bug","Xref":"ModelDB:65417","Definition":"* A disease characterized as a progressive motor disability manifested by tremors, shaking, muscular rigidity, and lack of postural reflexes. (PSY)       * A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) (MSH)       * progressive, degenerative disorder of the nervous system characterized by tremors, rigidity, bradykinesia, postural instability, and gait abnormalities; caused by a loss of neurons and a decrease of dopamine in the basal ganglia. (CSP)","Abbrev":"PD"}},{"Parnell's mustached bat":{"Synonym":"mustached bat","Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1021555","SuperCategory":"Pteronotus","Id":"birnlex_303"}},{"Paromomycin":{"RelatedTo":"16S rRNA","Synonym":["Aminosidin","Aminosidine","Paramomycin sulfate","paromomycin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7934","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01421","Definition":"An oligosaccharide antibiotic produced by various streptomyces. (PubChem) Pharmacology: Paromomycin is a broad spectrum antibiotic produced by Streptomyces rimosus var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin. Mechanism of action: Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Drug type: Approved. Investigational. Small Molecule. Drug category: Amebicides. Anti-Bacterial Agents. Antibacterial Agents"}},{"Paroxetine":{"RelatedTo":["5-hydroxytryptamine 2A receptor","Sodium-dependent noradrenaline transporter"],"Synonym":["Paroxetina (INN-Spanish)","Paroxetine Hcl","Paroxetinum (INN-Latin)","paroxetine","Aropax","Paxil","Paxil CR","Pexeva","Seroxat"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:7936","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00715","Definition":"A serotonin uptake inhibitor that is effective in the treatment of depression. (PubChem) Pharmacology: Paroxetine, an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) type, has no active metabolites and has the highest specificity for serotonin receptors of all the SSRIs. It is used to treat depression resistant to other antidepressants, depression complicated by anxiety, panic disorder, social and general anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder, premature ejaculation, and hot flashes of menopause in women with breast cancer. Mechanism of action: Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. Drug type: Approved. Investigational. Small Molecule. Drug category: Antidepressants. Antidepressive Agents, Second-Generation. Selective Serotonin Reuptake Inhibitors (SSRIs). Serotonin Uptake Inhibitors"}},{"Parrott scale":{"Created":"7/10/2009 14:06","CurationStatus":"uncurated","Contributor":"System Administrator","CAO_Id":"CAO_00849","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Parrott_scale","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146072","Definition":"No definition submitted yet"}},{"Pars nervosa of hypophysis":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","Synonym":["Pars nervosa pituitary gland","Pars nervosa of posterior lobe of pituitary gland","Pars nervosa of hypophysis"],"NeuronamesID":"385","CurationStatus":"uncurated","Umlscui":"C0447640","SuperCategory":"Regional part of brain","Id":"birnlex_941","Is part of":"Neurohypophysis","Abbrev":"PNHP"}},{"Pars postrema of ventral lateral nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-03","EditorialNote":"Synonyms derived both from UMLS and from NN, with NN given precedence (BB: 2007-03-03).","Synonym":["ventral lateral nucleus (pars postrema)","pars postrema","nucleus ventralis lateralis thalami","nucleus lateralis intermedius mediodorsalis situs postremus","posterodorsal part of ventral lateral posterior nucleus (Jones)"],"NeuronamesID":"324","CurationStatus":"uncurated","Umlscui":"C0262304","SuperCategory":"Regional part of brain","Id":"birnlex_1170","Is part of":"Ventral lateral nucleus","Abbrev":"VLP"}},{"Part-of-speech tagging algorithm":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Natural language processing algorithm","Id":"birnlex_2332","Value_Representation":"CS","Definition":"Part-of-speech tagging (POS tagging or POST), also called grammatical tagging, is the process of marking up the words in a text as corresponding to a particular part of speech, based on both its definition, as well as its context, i.e., relationship with adjacent and related words in a phrase, sentence, or paragraph. A simplified form of this is commonly taught school-age children, in the identification of words as nouns, verbs, adjectives, adverbs, etc. Once performed by hand, POS tagging is now done in the context of computational linguistics, using algorithms which associate discrete terms, as well as hidden parts of speech, in accordance with a set of descriptive tags."}},{"Partial Epilepsy":{"Synonym":["Focal Epilepsy","Simple Partial Epilepsy","Simple Partial Seizure","Consciousness Preserved","Partial Seizure Disorder","Localization-Related Epilepsy"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Epilepsy","Id":"birnlex_12726","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely (MeSH)."}},{"Partial Fourier":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9081","SuperCategory":"DICOM term","Id":"nlx_150456","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Partial Fourier. Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL. May be present otherwise."}},{"Partial Fourier Direction":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9036","SuperCategory":"DICOM term","Id":"nlx_150457","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Direction of Partial Fourier. Required if Frame Type (0008,9007) Value 1 of this frame is ORIGINAL and Partial Fourier (0018,9081) equals YES. Otherwise may be present if Frame Type (0008,9007) Value 1 is DERIVED and Partial Fourier (0018,9081) equals YES"}},{"Partial trisomy":{"SuperCategory":"Trisomy","Id":"PATO_0001390","Definition":"A trisomy quality inhering in a bearer where part of an extra chromosome is attached to one of the other chromosomes, or if one of the chromosomes has two copies of parts of its chromosomes."}},{"Partial View":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1350","SuperCategory":"DICOM term","Id":"nlx_150458","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Indicates whether this image is a partial view, that is a subset of a single view of the breast. If this Attribute is absent, then the image may or may not be a partial view. Note: This may occur when a breast is larger than the active area of the detector."}},{"Partial View Description":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_1351","SuperCategory":"DICOM term","Id":"nlx_150459","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"ST","Definition":"Free text description of the portion of the breast captured in a partial view image."}},{"Partially dislocated":{"Synonym":"subluxation","CurationStatus":"uncurated","SuperCategory":"Dislocated","Id":"PATO_0002157","Definition":"A positional quality inhering in a bearer by virtue of the bearer's being slightly out of its usual or proper place, or position."}},{"Partially paralysed":{"SuperCategory":"Paralysed","Id":"PATO_0001858","Definition":"A functionality quality inhering in a bearer by virtue of not being completely paralysed."}},{"Participant":{"RelatedTo":"BIRN-INCF Derived Data Project","CurationStatus":"uncurated","SuperCategory":"XCEDE term","Id":"nlx_151396","DefiningCitation":"http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Participant","Definition":"Someone who takes part in an activity."}},{"Participant Group":{"RelatedTo":"BIRN-INCF Derived Data Project","CurationStatus":"uncurated","SuperCategory":"XCEDE term","Id":"nlx_151449","Definition":"The group a participant belongs to for a given project."}},{"Parts of general white matter of PHT00":{"Synonym":"parts of general white matter","CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"[WM]","EditorialNote":"I don't see this structure in the Scalable Brain Atlas?  How was it generated?","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_3","Is part of":"Brain of PHT00","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Parvalbumin":{"Created":"2007-09-05","CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"nifext_6","Has role":["Calcium Binding Protein"]}},{"Parvicellular part of medial dorsal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["parvicellular part","lateral mediodorsal nucleus","parvicellular part of medial dorsal nucleus","nucleus medialis dorsalis","parvicellular part of dorsomedial nucleus","mediodorsal thalamic nucleus","nucleus medialis dorsalis fasciculosis (Hassler)","pars fasciculosa","pars parvicellularis","nucleus medialis dorsalis nucleus fasciculosis (Hassler)"],"NeuronamesID":"298","CurationStatus":"uncurated","Umlscui":"C0228330","SuperCategory":"Regional part of brain","Id":"birnlex_1283","Is part of":"Medial dorsal nucleus","Abbrev":"MDPC"}},{"Parvicellular part of ventral anterior nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-04","Synonym":["parvicellular part","nucleus ventralis anterior (DeWulf)","nucleus ventralis anterior","ventral anterior thalamic nucleus","ventralis anterior (Jones)"],"NeuronamesID":"318","CurationStatus":"uncurated","Umlscui":"C0228334","SuperCategory":"Regional part of brain","Id":"birnlex_722","Is part of":"Ventral anterior nucleus","Abbrev":"VAPC"}},{"Parvicellular part of ventral posteromedial nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-04","Synonym":["parvicellular part","gustatory thalamic nucleus","gustatory nucleus (thalamus)","ventral posteromedial nucleus of thalamus","ventroposteromedial nucleus of the thalamus","nucleus ventralis posterior medialis thalami","ventral posteromedial thalamic nucleus"],"NeuronamesID":"332","CurationStatus":"uncurated","Umlscui":"C0175290","SuperCategory":"Regional part of brain","Id":"birnlex_917","Is part of":"Ventral posteromedial nucleus","Abbrev":"VPMPC"}},{"Parvicellular reticular nucleus of ABA 2009":{"PartiallyOverlapsWith":"Parvicellular reticular nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153540","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Parvocellular oculomotor nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","EditorialNote":"Neuronames has the parvocellular oculomotor nucleus as the preferred label but I think Edinger Westphal is more common.","Synonym":"Edinger-Westphal nucleus","CurationStatus":"uncurated","NeuronamesID":"489","Umlscui":"C0228416","EfferentProjections":"Ciliary ganglion","SuperCategory":"Nucleus of CNS","Id":"birnlex_822","Is part of":"Oculomotor nuclear complex","Abbrev":["PC3"],"Definition":"Nucleus that is part of the oculomotor nerve complex consisting of preganglionic parasympathetic neurons situated close to the midline at the level of the superior colliculus (Heimer, the Human Brain and Spinal Cord, 1994, pg 244)"}},{"Parvocellular part of red nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","Synonym":"Parvocellular red nucleus","CurationStatus":"uncurated","NeuronamesID":"497","Umlscui":"C0175401","SuperCategory":"Regional part of brain","Id":"birnlex_725","Is part of":"Red nucleus,","Abbrev":"RPC","DefinitionPMID":"21927901","Definition":"Rostral portion of the red nucleus, located in the midbrain but originated from the diencephalon. Contains both large and small cells."}},{"Pass band":{"CurationStatus":"uncurated","SuperCategory":"Device parameter","Id":"oen_0001235","Has role":"Electrophysiology concept","Definition":"Frequency region below the 3DB frequency (adapted from the Axon Guide)"}},{"Passeridae":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C0326937","SuperCategory":"Passeroidea","Id":"birnlex_467"}},{"Passeriformes":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C0600537","SuperCategory":"Neognathae","Id":"birnlex_413"}},{"Passeroidea":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1201267","SuperCategory":"Passeriformes","Id":"birnlex_289"}},{"Passive":{"SuperCategory":"Behavioral quality","Id":"PATO_0000764","Definition":"Receiving or subjected to an action without responding or initiating action in turn."}},{"Passive attention":{"Created":"4/12/2011 9:38","CurationStatus":"uncurated","Contributor":"Natalie Picchetti","CAO_Id":"CAO_00433","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Passive_attention","SuperCategory":"Attention","Id":"nlx_145646","Definition":"refers to the involuntary process directed by external events that stand out from their environment, such as a bright flash, a strong odor, or a sudden loud noise."}},{"Passive Current":{"CurationStatus":"uncurated","SuperCategory":"Non-selective current","Id":"oen_0001288"}},{"Passive listening":{"Created":"4/27/2011 14:06","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00765","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Passive_listening","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145987","Definition":"Subjects listen to various auditory stimuli and make no response.  Stimuli include speech (words, sentences), noise, tones, etc.  If the stimulus is tones, then the experiment is co-coded with Tone Monitor-Discrimination."}},{"Passive viewing":{"Created":"4/27/2011 14:05","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00766","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Passive_viewing","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_145988","Definition":"Subjects view various visual stimuli and make no response.  Stimuli include houses, faces, objects, fractals, letter strings, line drawings, complex scenes, etc. If the presented stimuli were faces, the experiments are co-coded with Face Monitor-Discrimination.  But if the presented stimuli are words, the experiments are NOT coded as Passive Viewing but rather as Reading (Covert)."}},{"Patch clamp technique":{"Synonym":["Patching"],"CurationStatus":"uncurated","SuperCategory":"Electrical recording protocol","Id":"oen_0001179","Has role":"Electrophysiology concept","Xref":["D018408"],"Definition":"A method for recording the electrical activity of neurons or small pathes of membrane by forming a tight seal between electrode and membrane"}},{"Patchy":{"SuperCategory":"Irregular spatial pattern","Id":"PATO_0001608","Definition":"Marked by, consisting of, or diversified with patches."}},{"Patent":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Narrative resource","Id":"birnlex_2364","Definition":"A set of exclusive rights granted by the national government to an inventor for a limited period of time in exchange for public disclosure of an invention. "}},{"Paternal assessment":{"Created":"2008-03-14","CurationStatus":"graph_position_temporary","SuperCategory":"Familial member assessment","Id":"birnlex_3019","Definition":"Assessment of status of the father of patient under study."}},{"Paternal behavior":{"CurationStatus":"uncurated","SuperCategory":"Parental behavior","Id":"GO:0042712","Definition":"Male behaviors associated with the care and rearing offspring."}},{"Pathological":{"SuperCategory":"Abnormal","Id":"PATO_0001869","Definition":"Abnormal and having a destructive effect on living tissue."}},{"Pathology":{"Synonym":"General pathology","CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100659","Abbrev":"Pathol","Definition":"From BRO: (from Greek œÄŒ¨Œ∏ŒøœÇ, pathos, \"fate, harm\"; and -ŒªŒøŒ≥ŒØŒ±, -logia) is the study and diagnosis of disease through examination of organs, tissues, bodily fluids, and whole bodies (autopsies). The term also encompasses the related scientific study of disease processes, called General pathology.Medical pathology is divided in two main branches, Anatomical pathology and Clinical pathology. Veterinary pathology is concerned with animal disease whereas Phytopathology is the study of plant diseases. - definition adapted from Wikipedia"}},{"Pathophysiology":{"CurationStatus":"uncurated","SuperCategory":"Specimen preparation","Id":"oen_0001051","Has role":"Electrophysiology concept","Xref":["Q000503"],"Definition":"Used with organs and diseases for disordered function in disease states."}},{"Pathway":{"Synonym":["network","module","cascade","Examples: glycolysis","valine biosynthesis"],"CurationStatus":"uncurated","SuperCategory":"Entity","Id":"Pathway","DefiningCitation":"http://www.biopax.org/release/biopax-level3.owl#Pathway","Definition":"A set or series of interactions, often forming a network, which biologists have found useful to group together for organizational, historic, biophysical or other reasons. Usage: Pathways can be used for demarcating any subnetwork of a BioPAX model. It is also possible to define a pathway without specifying the interactions within the pathway. In this case, the pathway instance could consist simply of a name and could be treated as a 'black box'. Pathways can overlap, i.e. a single interaction might belong to multiple pathways. Pathways can also contain sub-pathways. Taken from BioPAX"}},{"Pathway model":{"Synonym":["signaling pathway model","regulatory network model"],"Created":"2007-10-10","CurationStatus":"uncurated","SuperCategory":"Network interaction model","Id":"birnlex_2307"}},{"Patient Additional Position":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0184","SuperCategory":"DICOM term","Id":"nlx_150460","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"User-defined additional description of patient position. Required if Patient Position (0018,5100) is not present."}},{"Patient attribute":{"SuperCategory":"Attribute entity role","Id":"nlx_153870 ","Definition":"TBD"}},{"Patient Comments":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_4000","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150461","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"User-defined comments about the patient."}},{"Patient Eye Movement Command Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0006","SuperCategory":"DICOM term","Id":"nlx_150462","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Coded value for patient movement or orientation, which is the intent, and not necessarily the result, based on what the patient is capable of. Required if the value of Patient Eye Movement Commanded (0022,0005) is YES. "}},{"Patient Eye Movement Commanded":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0005","SuperCategory":"DICOM term","Id":"nlx_150463","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"A code string representing whether or not patient eye movement was commanded."}},{"Patient Gantry Relationship Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0414","SuperCategory":"DICOM term","Id":"nlx_150464","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence which describes the orientation of the patient with respect to the gantry."}},{"Patient ID":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_0020","SuperCategory":"DICOM term","Id":"nlx_150465","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Primary hospital identification number or code for the patient."}},{"Patient Orientation":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0020","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150466","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Patient direction of the rows and columns of the image. Required if image does not require Image Orientation (Patient) (0020,0037) and Image Position (Patient) (0020,0032). See C.7.6.1.1.1 of the DICOM standard for further explanation."}},{"Patient Orientation Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0410","SuperCategory":"DICOM term","Id":"nlx_150467","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence that describes the orientation of the patient with respect to gravity."}},{"Patient Orientation Modifier Code Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0412","SuperCategory":"DICOM term","Id":"nlx_150468","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Patient Orientation Modifier. Required if needed to fully specify the orientation of the patient with respect to gravity."}},{"Patient Position":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_5100","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150469","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Patient position descriptor relative to the equipment. Required for CT and MR images; shall not be present if Patient Orientation Code Sequence (0054,0410) is present; may be present otherwise. "}},{"Patient registry":{" limit":"1000","CurationStatus":"uncurated","SuperCategory":"People resource"," format":"CSV","Id":"nlx_94095","Definition":"A list of people that are afflicted with some disease and can potentially be recruited for clinical research into the condition."}},{"Patient role":{"Synonym":"patient","CurationStatus":"uncurated","SuperCategory":"Organism role","Id":"nlx_33832","Definition":"The role of patient;  i.e., a person who is or has been treated for a disease or disorder"}},{"Patient Setup Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0182","SuperCategory":"DICOM term","Id":"nlx_150470","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Identification number of the Patient Setup. The value of Patient Setup Number (300A,0182) shall be unique within the RT Plan in which it is created."}},{"Patient Setup Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0180","SuperCategory":"DICOM term","Id":"nlx_150471","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of patient setup data for current plan. One or more items may be included in this sequence."}},{"Patient State":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0038_0500","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150472","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Description of patient state (comatose, disoriented, vision impaired, etc.)."}},{"Patient Support Angle":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0122","SuperCategory":"DICOM term","Id":"nlx_150473","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Patient Support angle, i.e. orientation of IEC PATIENT SUPPORT coordinate system with respect to IEC FIXED REFERENCE coordinate system (degrees)."}},{"Patient Support Angle Tolerance":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_004C","SuperCategory":"DICOM term","Id":"nlx_150474","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Maximum permitted difference (in degrees) between planned and delivered Patient Support Angle."}},{"Patient Support Rotation Direction":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0123","SuperCategory":"DICOM term","Id":"nlx_150475","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Direction of Patient Support Rotation when viewing table from above, for segment following Control Point. Required for first item of Control Point Sequence, or if Patient Support Rotation Direction changes during Beam."}},{"Patient Transport Arrangements":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_1004","SuperCategory":"DICOM term","Id":"nlx_150476","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Mode of transportation of the patient to the location of examination."}},{"Patient-support portal":{" limit":"1000","Created":"2007-10-11","Synonym":"Patient-advocate portal","CurationStatus":"uncurated","SuperCategory":"Disease-related portal"," format":"CSV","Id":"birnlex_2373","Definition":"A portal where the aggregated resources are restricted to those describing or related to a particular disease and are specifically targeted to provide information to the community of patients and the families of patients diagnosed with that disease."}},{"Patients Address":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_1040","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150477","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Legal address of the named patient."}},{"Patients Age":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_1010","SuperCategory":"DICOM term","Id":"nlx_150478","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"AS","Definition":"Age of the Patient."}},{"Patients Birth Date":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_0030","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_150479","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"Date of birth of the named patient."}}]}